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Abstract. 
Vancomycin is a member of an important antibiotic group known as the glycopeptide 
antibiotics, which mainly act as bactericidal agents against Gram positive bacteria. 
Vancomycin acts by destroying the integrity of the bacterial cell wall and thereby 
exerts its detrimental effect on the most virulent gram-positive bacteria such as 
MRSA. Emergence of resistant strains against vancomycin has drawn scientists’ 
curiosity to find new analogues to restore its powerful activity or to avoid loss of its 
efficiency against infectious bacteria. One of the routes that has been followed to find 
a novel vancomycin analogue is via chemical modification to its structure relying on 
its well-known mechanism of action. Our approach was to synthesise the constituent 
amino acids of the backbone of vancomycin in Fmoc-protected form to be suitable for 
conjugation using solid phase peptide chemistry (SPPS). The SPPS procedure 
potentially ensures rapid synthesis and modification of a peptide through concise and 
less demanding chemistry.  
The central amino acid of vancomycin was synthesised in Fmoc-protected form at the 
α-amine terminal with a free carboxylic acid group. The synthesis proceeded through 
chemistry modification of the route developed by Nicoloau and co-workers and 
involved a series of reactions such as Sharpless AD reaction, Mitsunobu reaction and 
a TEMPO oxidation reaction. The Fmoc protected amino acid was successfully 
obtained and was potentially suitable for the conjugation with other amino acids using 
Fmoc chemistry and SPPS. Several trials were performed for the conjugation of the 
central unit on SPPS. Although different coupling reagents and solid supports were 
used, the results were unsuccessful. To confirm that peptide coupling with this amino 
acid was possible, it was demonstrated that solution phase coupling led to the   
successful generation of a tripeptide containing this unit. The suggestion here is that 
the triazene unit on the central amino acid is too unstable for incorporation into the 
SPPS protocol. 
Finally, the successful synthesis of the Fmoc-protected ethyl ester analogues of the 
two tyrosine isomers, amino acid 2 and amino acid 6, in the vancomycin structure 
was completed. Several trials were attempted to hydrolyse the ethyl ester to release 
the carboxylic acid but were unsuccessful. Due to the time constrains, further efforts 
for hydrolysis reaction attempts were halted. 1H NMR, 13C NMR, IR, and mass-
spectrometry were used throughout for assignments and characterisation of all the 
products and intermediates of the chemical reactions. 
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Abreviations. 
Alloc Allyloxycarbonyl 
D-Ala Dextro-alanine 
AMR 
Asn 
Antimicrobial resistance 
Asparagine 
BnBr Benzyl bromide 
Boc tert-Butyloxycarbonyl 
Boc2O Di-tert-butyl dicarbonate 
B(OMe)3 Trimethylborate 
BOP Benzotriazol-1-yloxy) tris(dimethylamino)phosphonium 
hexafluorophosphate 
Bu Butyl 
n-BuLi n-Butyllithium 
Bz Benzoyl 
C Carbon  
Cbz Carboxybenzyl 
COMU 1-[(1-(Cyano-2-ethoxy-2-oxoethylideneaminooxy) 
dimethylaminomorpholino)] uronium hexafluorophosphate 
Cr Chromium 
4-CBP 4-Chlorobiphenyl 
COSY Correlation spectroscopy 
DIBAL-H Diisobutylaluminium hydride 
DBU 1, 8-Diazabicyclo [5.4.0] undec-7-ene 
DCM Dichloromethane 
D-Lac dextro-Lactic acid 
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DIC Diisopropylcarbodiimide 
DCC N, N'-Dicyclohexylcarbodiimide 
(DHQ)2 Dihydroquinine 
(DHQD)2 Dihydroquinidine 
 DEAD Diethyl azodicarboxylate 
DIAD Diisopropyl azodicarboxylate 
DIPEA N, N-Diisopropylethylamine 
DMAP 4-Dimethylaminopyridine 
DNA Deoxyribonucleic acid 
DMF N, N-dimethylformamide 
DMSO 
DPPA 
Dimethylsulfoxide 
Diphenylphosphoryl azide 
D-Ser dextro-Serine 
EDCI 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
Et3N Triethylamine 
ee Enantiomeric excess 
equiv Equivalents 
Et Ethyl 
Fmoc Fluorenylmethyloxycarbonyl 
Fmoc-Cl Fluorenylmethyloxycarbonyl chloride 
g Gram 
GlcNAc N-Acetylglucosamine 
Gln Glycine 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b] pyridinium 
3-oxid hexafluorophosphate 
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HBTU O-(Benzotriazol-1-yl)-N, N, N′, N′-tetramethyluronium 
hexafluorophosphate 
HCl Hydrochloric acid 
HF Hydrogenfluoride 
Hpg Hydroxyphenylglycine 
HOAt 1-Hydroxy-7-azabenzotriazole 
HOBt 1-Hydroxybenzotriazole 
HPLC High performance liquid chromatography 
K Potassium 
KI  Potassium iodide 
LiAlH4 Lithium aluminium hydride 
LC-MS Liquid chromatography–mass spectrometry 
Lys Lysine 
M Molar 
Me Methyl 
MeSO2NH2 Methanesulfonamide 
MeOH Methanol 
min Minute 
MTS 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium 
Ms Mesylate 
MIC Minimum inhibitory concentration 
MRSA Methicillin resistant S. aureus 
Mtt N-Methyltrityl 
MurNAc N-Acetylmuramic acid  
MDR Multiple drug resistance 
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NaH Sodium hydride 
NBP N-Bromophthalimide 
NMR nuclear magnetic resonance spectroscopy 
oC Degrees Celsius 
PBP Penicillin binding protein 
PEG Polyethylene glycol 
Pd(PPh3)4 Palladium-tetrakis(triphenylphosphine) 
Ph3P Triphenylphosphine 
Ph Phenyl 
pH Log hydrogen cation concentration 
PHAL Phthalazine 
PhSiH3 Phenylsilane 
PyBop (Benzotriazol-1-yloxy) tripyrrolidinophosphonium 
Hexafluorophosphate 
PCC Pyridinium chlorochromate 
RNA Ribonucleic acid 
rt Room temperature 
SAD Sharpless asymmetric dihydroxylation 
SAR Structure activity relationship 
SCF Supercritical fluid 
Ser Serine 
SO2Cl2 Thionyl chloride 
SN Nucleophilic substitution 
SNAr Nucleophilic aromatic substitution 
SM Starting material 
SnCl2 Tin (II) chloride 
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SPPS  Solid phase peptide synthesis 
TFAA Trifluoroacetic anhydride 
TMS Trimethylsilane 
TBAF tetra-Butylammonium fluoride solution 
TBS tert-Butyldimethylsilane 
TBSOTf tert-Butyldimethylsilyl Trifluoromethanesulfonate 
t-BuOH tert-Butanol 
t-butyl tert-butyl 
TEMPO (2,2,6,6-Tetramethylpiperidin-1-yl) oxyl or (2,2,6,6-
tetramethylpiperidin-1-yl) oxidanyl 
TFA Trifluoroacetic acid 
Tfa Trifluoroacetamide 
THF tetra-hydrofuran 
TIPS Triisopropylsilane 
TLC Thin-layer chromatography 
Tyr Tyrosine 
UV Ultraviolet 
VOF3 Vanadium(V)oxytrifluoride 
VRE Vancomycin resistant Enterococci 
VSSA Vancomycin sensitive resistance S. aureus 
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1.1. Antibiotics. 
The discovery of penicillin in 1928 represented the starting point for the discovery and 
development of other active antimicrobials via the study of the interactions between 
the drug and its targets and/or manipulating the chemical structures of existing 
effective medicines.(1, 2) Antibiotics are defined as chemical entities produced by living 
organisms, whether they are microorganisms such as fungi and bacteria or animals 
or plants. They are used for the treatment and prevention of infectious diseases and 
exert their mode of activity suppressing bacterial growth and/or survival.(3) In general, 
the classification of antibiotics is divided into two main categories depending on the 
cellular target site they affect; 1) bactericidal, which cause microbial cell death, 2) 
bacteriostatic, which causes cell growth inhibition.(3, 4) The main cellular targets of 
bactericidal antibiotics are the cell wall, DNA, RNA, or proteins (Figure 1.1).(5) β-
lactam antibiotics such as penicillin, and cephalosporins, are bactericidal antibiotics 
that inhibit cell wall synthesis by binding to penicillin binding proteins (PBP) destroying 
the mechanical supporting layer, peptidoglycan, of the cell wall,(6) so rendering 
bacteria susceptible to the surrounding changes in osmotic pressure causing their 
lysis and death.(7) 
Other examples of bactericidal antibiotics include vancomycin and teicoplanin, which 
are glycopeptidic antibiotics that act on the integrity of the Gram positive bacterial cell 
wall via prevention of cross-linking of the peptidoglycan layer components to each 
other.(8) The quinolone antibiotics such as ciprofloxacin and levofloxacin, inhibit DNA 
synthesis via interference with the action of the enzymes, topoisomerase II and 
topoisomerase IV, that act to rejoin DNA strands during the chromosomal supercoiling 
process.(5) There are other three classes of bactericidal antibiotics that act by 
inhibiting ribosomal protein synthesis; macrolides such as erythromycin, tetracyclines 
such as doxycycline, and aminoglycomycins such as streptomycin.(9) Rifampicin is 
one of the most important antibiotics used for serious infections such as tuberculosis, 
and acts via inhibition of protein synthesis in bacteria.(10)  
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Figure 1.1: Mechanism of action of commonly used bactericidal antibiotics. a) Quinolone 
antibiotics cause a defect in DNA supercoiling via binding to topoisomerase. b) β-lactams 
inhibit integration process of the peptidoglycan strands by binding to PBPs. c) 
Aminoglycosides bind to the ribosomal units and inhibit elongation process of peptides. (Taken 
from reference(5)). 
1.1.2. Antibiotic resistance. 
Antibiotic resistance is defined as an adaptive ability of bacteria to resist and survive 
the use of antibiotics reducing their susceptibility of treatment and leading to 
aggravation of the infective diseases.(11) Evolutionary changes, called mutations, are 
behind the development of such bacterial ability, and are responsible for generating 
resistance genes. Mutations can be transferred horizontally, between species, or 
vertically, to the new offspring.(8) The ability of bacteria to pick up and pass on 
information between each other is the main route to the development of resistance 
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against the activity of many antibiotics.(12) The transferable information is 
disseminated by circular DNA structures called plasmids, which enable bacteria to 
encode drug resistance and spread it over different bacterial species.(13) Antibiotic 
resistance has had a great impact on human and animal health and as a 
consequence has influenced the economic sector.(14) Gene transfer is not restricted 
to virulent species. Antibiotic resistance can be gained by normal living microflora in 
the human body as well.(15) The prevalence of antibiotic resistance is related to 
several factors including geographic locations and poor hygiene. Overuse and misuse 
of antibiotics is the most important factor relevant to the emergence of antibiotic 
resistance.(16) Emergence of multiple-drug resistant bacteria represents the most 
detrimental consequence of misuse of antibiotics.(8)  
1.1.3. Causes of antibiotic resistance.  
As was noted above, the irrational use and increase in the amount of prescribed  
antibiotics has been the main contributor to the spread of multidrug resistance (MDR) 
and emergence of virulent resistant bacteria.(17) Overprescribed and/or 
inappropriately-prescribed antibiotics, especially broad-spectrum ones for even 
unindicated infections as viral infections, has been a main contributor in the dispertion 
of antibiotic resistance.(18) Increase in medical admissions to hospitals, and morbidity 
and mortality of patients as a consequence of inappropriate antibiotic prescription, 
leads to a proportional increase in medical cost and economic impact.(19) The 
appearance of Methicillin Resistant S. aureus (MRSA)  is one of the consequences 
of misuse of antibiotics and is a main cause of many serious infections particularly for 
immune compromised people, such as those with HIV infection.(20) Norway has 
introduced restrictions to prevent dissemination of MRSA, which involve intensive 
screening of the patient before admission, during the stay, and after discharge from 
hospitals.(21) Other factors that have a direct and/or indirect role in antibiotic resistance 
can be listed as follows: 1) poor hand hygiene of medical staff and hospital equipment 
has been recognised as an important factor in distribution of MRSA in medical 
sectors; 2) contaminated food with resistant antibiotics and their role in increased 
human infections may have  an important contribution in a rising antibiotic resistance 
level;(22) 3) human migration has increased the concerns of distribution of antibiotic 
resistance over a large area of the world.(23) Recent investigations of refugees that 
are coming from countries at war such as Syria, Afghanistan, and Iraq, display they 
are carrying dfferent kinds of MDR;(24) 4) excretion of incomplete metabolised 
antibiotics from humans and animals to sewage increases the possibility of resistant 
genes being transferred between bacterial cells and leads to elevation in the toxicity 
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to the environment and public health;(25, 26) 5) Use of antibiotics as a means for 
promotion of animal growth in their food and as a preventive and therapeutic 
procedure for infections, has led to rising levels of antibiotic resistance and adaptive 
ability of microorganisms.(27),(28) In addition, formation of bacterial biofilms is 
considered a very important mechanism of resistance by which even susceptible 
strains of bacteria can survive.(29) When bacteria attach to a surface such as an 
inflamed tissue or implanted organ or medical device, they can aggregate and 
encapsulate themselves in a sheet of polysaccharides and proteins.(30, 31) Bacteria in 
biofilms obtain an obvious resistance as the antibiotic penetration is greatly 
retarded.(29, 30) Therefore, bacterial biofilms are a cause of several chronic infections 
such as periodontitis and lung infections.(29, 32) 
1.1.4. Measurements to tackle antibiotic resistance. 
The increasing number of resistant pathogens has been a challenging problem to 
scientific research and the pharmaceutical industry as the number of novel antibiotics 
has declined.(33, 34) The main reason for the diminishing amount of innovative 
antibiotics is that their production or discovery is costly and time consuming.(35, 36) 
Most of the novel synthetic antimicrobials are structurally simple, so the bacteria 
easily develop resistance against them. This differs from previously discovered 
natural product antibiotics, which consist of complex structures, often acting by more 
than one mechanism so the possibility of resistance is diminished.(36) The structure 
simplicity of recent antibiotics is important for oral active antibiotic according to the 
Lipinski rule. Lipiniski and co-workers in 1997,(37) had set four properties of a 
candidate compound to be orally active. These properties are; the molecular weight, 
no more than 500 daltons, the octanol-water partion coeffiecient (logP), no more than 
5, number of hydrogen bond donors, no more than 5, and number of hydrogen bond 
acceptors, no more than 10.(38) It is crucial to know the applicable measures by which 
antimicrobial resistance (AMR) could be controlled. There are several steps for 
controlling the dissemination and progression of antibiotic resistance: 1) Appropriate 
use of antibiotics and restricting their use to evidence-based infections and illnesses 
caused by bacteria, is the key effective procedure to tackle the AMR problem. 
Therefore, keeping antibiotics for only bacterial-caused infection and mostly for 
treatment protocol other than preventive procedures, and improving the diagnostic 
procedures to avoid prescribing antibiotics for viral infections, can lead to a reduction 
in the serious consequence of infections.(39) Moreover, optimisation of antibiotic 
prescriptions, which relates to using the most efficient antibiotic in a certain bacterial 
infection with optimised dose and concentration, can contribute to a large extent  in 
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AMR control.(40) 2) Minimisation of antibiotic use in animal food could lead to a 
considerable decline in the growth of AMR.(28) 
3) Establish an efficient protocol to keep sewage bacteria isolated and avoid their 
contact with other microorganisms and hence the genes that responsible on antibiotic 
resistance can be prevented from conveying the AMR to new bacteria.(25) 4) Another 
approach to avoid progression of AMR is the synthesis of new and efficient antibiotics 
and/or chemical modifications to the existing drugs. That is, to find new antimicrobial 
drugs working with  unfamiliar mechanisms to the resistant bacteria, which should not 
be liable to cross-resistance with other antimicrobial agents.(41) An example of 
antimicrobial agent that has been produced via chemical modification is the second 
and third generation of β-lactam containing antibiotics, penicillin and cephalosporin. 
Example of the semi-synthesised antimicrobial agents is the second generation of 
erythromycins such as azithromycin.(9) 
1.1.5. Mechanisms of antibiotic resistance in bacteria. 
Generally, there are two types of mechanisms by which bacteria exhibit their 
resistance against antibiotics; intrinsic resistance, which is a natural capability of 
bacteria to avoid antibiotic effects, and acquired resistance, which is described as the 
ability of bacteria to develop mutations responsible for their resistance property or 
acquire genetic information from other species.(8) Bacteria can obtain antibiotic 
resistance via four basic types of mechanisms (Figure 1.2).(42)  
1) Enzymatic inactivation or modification. Antibiotic modification, is a characteristic of 
bacteria to keep their sensitive targets unmodified as those of antibiotic sensitive 
species but block the access of drugs to them. Some bacteria produce enzymes that 
destroy the chemical structure of some antibiotics.(12) For example, many Gram-
positive and Gram-negative bacteria produce a β-lactamase enzyme that hydrolyses 
the structural β-lactam ring of some antibiotics, such as first generation penicillin 
rendering them ineffective (Scheme 1.1).(8, 43, 44) The main difference between Gram 
negative and Gram positive bacteria relys on the cell wall components. The lipid 
content of the cell wall of Gram negative is much higher than that of Gram positive. 
Therefore, the resistance of Gram negative bacteria to various chemicals is attributed 
to their cell wall lipid content.(45) The Gram terminology is reffered to Hans Christian 
Gram who developed a staining technique in 1884 by which the two types of bacteria 
can be differentiated.(46) 
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Figure 1.2: Four main resistance mechanisms of antibiotics. 1) Enzymatic inactivation or 
modification. 2) Decreased uptake or reduced antibiotic intake into the bacterial cell. 3) 
Alteration or inactivation of enzymes. 4) Bypass pathways. (Taken from reference(44)). 
A single base change in the gene for a β-lactamase can change the substrate 
specificity of the enzyme. 
 
Scheme 1.1: Chemical alteration to the β-lactam ring by β-lactamase developed by resistance 
bacteria. (Taken from reference(9)). 
2) Decreased uptake: drug efflux mechanisms which involve prevention of the 
antibiotic from entering the bacterial cell or removing them at a rate faster than it is 
entering. It is an active transport process, energy-dependent mechanism, mediated 
by proteins located in the cytoplasmic membrane.(47) 
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For example, imipenem gains its access to the sensitive bacteria through the cell 
membrane via a transporting protein called porin. In Pseudomonas aeruginosa 
bacteria, which is imipenem resistant, the lack of porin protein gives it resistance as 
imipenem cannot enter the bacterial cell (Scheme 1.2).(44) This mechanism is also 
found to a lesser extent in resistance to fluoroquinolones and aminoglycosides. 
Pumping of tetracyclines out by a positive transport method in Enterobacteriaceae, 
which is encoded by a specific gene called tet (A), is considered an efficient strategy 
of resistance for this type of bacteria.(48) 
 
Scheme 1. 2: Diagram shows the natural resistance of Gram negative bacteria, Pseudomonas 
aeruginosa, to β-lactam antibiotics. (Taken from reference (44)). 
3) Altered target site: in which the antibiotic may reach its target inside the bacterial 
cell but because of structural changes it would not affect any of the cellular 
components function. Cephalosporins, broad-spectrum antibiotics, introduce their 
bactericidal effect by the inhibition of cell wall synthesis. Binding to the penicillin 
binding proteins, responsible for the formation of integrating structures in the cell wall, 
peptidoglycan, leads to bacterial lysis and death. Enterococci bacteria exhibit 
resistance against cephalosporins by producing lower affinity proteins to 
cephalosporin than that of sensitive strains and therefore the formation of the 
peptidoglycan layer is not suppressed.(49, 50) The modified enzymes still function 
properly although they have a different structure.(51)  
4) Bypass pathways: Production of an alternative target alongside the original one is 
considered one of the important mechanisms by which bacteria avoid antibiotic 
action. Methicillin resistant Staphylococcus aureus (MRSA) produce an alternative 
penicillin binding protein (PBP2a) that differs in structure to the normal one and 
thereby MRSA develops its resistance against penicillin-based antibiotics.(52) 
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1.1.6. Bacterial cell wall biosynthesis. 
The biosynthesis process of the bacterial cell wall is a target of action of the most 
efficient antimicrobials.(53) The cell wall is defined as the peripheral layer that protects 
the bacterial cell from harmful environmental influences and changes in osmotic 
pressure, maintaining its integrity, shape and functionality.(54) The main function of the 
cell wall is mechanical support, therefore it is composed of supportive components, 
sugars and peptides, which are integrated together forming what is called 
peptidoglycan.(55) The sugar part is a thread of polysaccharides consisting of two 
alternating sugars, N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid 
(MurNAc) units.(56) Both the latter units are cross-linked via covalent bonds to 
segments of peptide forming a stable polymer structure.(56) The core structure of the 
cell wall is synthesized inside the cytoplasm. The synthesis process starts with 
formation of what is called lipid II, which is transported to the outer surface (Scheme 
1.3). At the  outer surface, two type of enzymes exert their action on lipid II, 
transglycosylase and transpeptidase.(57) The former polymerises lipid II and the later 
enzyme connects peptide segments to each other via peptide linkages.(58) There are 
five amino acid units constituting the peptide part in the peptidoglycan layer, L-Ala, 
D-Glu, L-Lys, D-Ala and D-Ala, which are attached to the sugar units in a sequential 
manner.(58, 59) 
1.1.7. Glycopeptide antibiotic resistance. 
Two important examples of glycopeptide antibiotics are vancomycin and teicoplanin. 
They are bactericidal antibiotics that prevent cell wall synthesis. They are used for 
the treatment of Gram positive infections, such as skin infections and septicaemia.(60) 
They act specifically on the prevention of formation of the peptidoglycan through 
forming complexes with their precursors preventing their transfer to the cell wall. 
Hence, their integration into the cell wall would be prevented. Glycopeptides form a 
complex with the enzyme substrates rather than the enzymes themselves.(61),(60) 
Consequently, the substrate specificity of glycopeptide antibiotics is considered as a 
detriment to their activity rather than their enzyme affinity.(61, 62) 
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Scheme 1.3: The basic processes for cell wall biosynthesis in vivo. UMP=uridine-5’ 
monophosphate. (Taken from reference(63)). 
Glycopeptide antibiotics complex with the peptidic part in the cell wall via hydrogen 
bonding with the carboxylic acid terminal of the D-Ala residue. This complexation 
occurs at the outer surface and no penetration of these antibiotics happens into the 
cytoplasm.(61) This leads to accumulation of the complexes out of the cytoplasm rather 
than their incorporation to the growing cell wall.(64) The resistant strain produces lower 
affinity substrates than those produced by the sensitive bacteria to the glycopeptide 
antibiotics. The genetic factors that are responsible for such changes are obtained 
from external sources.(61) 
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Figure 1. 3: Chemical interpretation of vancomycin inhibition to the peptidoglycan precursors 
via forming of five hydrogen bonds between vancomycin and carboxy-terminal D-alanine (D-
AIa) residues of peptidoglycan precursors.  
1.1.8. Vancomycin resistance. 
Vancomycin is one of the most important members of the family of glycopeptide 
antibiotics. It acts mainly on Gram positive bacteria including MRSA. Its importance 
is derived from the fact that it is clinically the last antibiotic of resort acting against 
Gram positive including MRSA bacteria.(65) Recognition of a resistant strain of 
Enterococci to vancomycin in 1987 has increased concern that this resistance could 
be transferred to S. aureus bacteria.(60) Vancomycin exerts its action via binding to 
the terminal D-Ala-D-Ala residue in the peptide strand through five hydrogen bonds 
(Figure 1.3). Moreover, its bulky size and high molecular weight blocks further cross-
linking between peptide segments that are necessary for the integrity of the 
peptidoglycan layer.(66) Enterococci acquired its resistance via acquisition of two types 
of genes, VanA and VanB. These genes have given the bacterial chromosomal 
system the ability to replace the terminal D-Ala residue with D-Lac. Thus, vancomycin 
would complex to the terminal peptide residue, D-Ala-D-Lac in resistant bacteria via 
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four hydrogen bonds instead of five to D-Ala-D-Ala in the susceptible strains. This 
change reduces vancomycin’s affinity to its substrate by 1000-fold, which in turn 
results in a sharp decline in its efficiency.(67) The more the substrates carry the 
modified unit, the greater degree of resistance the bacteria gain.(65) 
It is noteworthy that another genetic modification can also occur and contribute to 
antibiotic resistance: This involves changing the terminal dipeptide D-Ala-D-Ala to D-
Ala-D-Ser. This change leads to a 7-fold reduction in the affinity of vancomycin to its 
substrates.(66) 
1.2. The chemical structure of vancomycin. 
The structure of vancomycin (Figure 1.4) consists of a sugar part and a peptide part. 
The peptide part involves seven amino acids, a heptapeptide backbone, and  the 
sugar part consists of two sugar moieties glucose and vancosamine.(68) There are 
three macrocyles formed as a result of connections of the side chains of the 
heptapeptide backbone to each other. Two are 16-membered rings, C-O-D and D-O-
E, formed as a result of linking the aromatic side chain of the amino acid-6 and amino 
acid-4, and between amino acid-2 and amino acid-4 respectively. Both are connected 
through biaryl ether bonds.(68) The third macrocycle is a 12-membered ring formed 
through a lactam linkage between the side chains of amino acid-6 and amino acid-
7.(69) The disaccharide, is connected to the phenolic part of the central amino acid 4 
through a β-glycoside linkage.(70),(71)  
In addition, there are two chlorine atoms attached to the ortho positions of each of the 
aromatic ring side chains of amino acid-2 and amino acid-6.(72) These chlorine atoms 
are situated in opposite positions, one of them is affixed to the front of the compound, 
and the other is situated to the back.(68) It is noticeable that the glycopeptide antibiotics 
are structurally complex and affect their action on bacteria by more than one 
mechanism. Therefore, the study of the structure of this type of drug and the basic 
reasons behind its bacterial resistance is an attractive subject in the medicinal 
chemistry field.(73) 
One approach to establishing a structure activity relationship (SAR) for vancomycin 
is through synthesis. This requires a relatively easy synthesis that can rapidly 
generate analogues. In the following section, the approaches to the synthesis of 
vancomycin and of analogues that have been disclosed to date, will be discussed. 
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Figure 1. 4: The chemical structure of vancomycin. 
1.3. Review of the chemical synthesis of vancomycin; 
1.3.1. Solution phase synthesis of vancomycin. 
The earliest reports of the total synthesis of vancomycin aglycon 1 (Figure 1.5) were 
made by David A. Evans,(74) and K. C. Nicolaou,(75, 76) in 1998 which both culminated 
in successful approaches.  Although Nicolaou’s approach was carried out in a liquid 
phase synthesis, it forms the basis for our approach to synthesise vancomycin on the 
solid phase.  
In the Evans approach, the derivatives of the amino acid-4, amino acid-5, and amino 
acid-7 (Figure 1.6) were synthesised in a previous work.(74) The amino acid-6 was 
formed from reaction of (isothiocyanoacetyl)-oxazolidinone 2 with 3-chloro-4-flouro-
5-nitrobenzaldehyde 3 (scheme 1.4) in an aldol reaction utilising stannous fluoride. 
This generated 4 in a stereoselective manner. Following N-Boc protection, the chiral 
auxiliary (Xp) was removed to give 5.(77),(74) 
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Figure 1. 5: The chemical structure of the vancomycin aglycon 1.(74) 
The latter was attached to amino acid-7 through peptide coupling, using the 
EDCl.HCl/HOBt system, affording dipeptide 6. Cleavage of the endocyclic 
oxazolidinone of 6 could be performed using Li2CO3 in methanol to provide 7. After 
removal of the Boc group, tripeptide 8 was obtained via coupling dipeptide 7 to the 
amino acid 5.  The Boc group on amino acid 5 was exchanged with a 
trifluoroacetamide protecting group to give 9.(74) The cyclic tripeptide (5-7) 10 was 
obtained via an oxidative reaction using VOF3. After removal of the trifluoroacetamide 
protecting group using NaHCO3 in MeOH/H2O generating amine compound 11, 
incorporation of amino acid-4 to the latter  was achieved via peptide coupling affording 
the tetrapeptide 12.(74) Silyl de-protection of the phenol group of the ring 4 was 
affected under fluoride (HF· pyridine) to give 13. 
 
 
Figure 1. 6: Derivatives of amino acids 4, 5, and 7 in vancomycin. 
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Scheme 1. 4: Synthesis of the cyclic tetrapeptide (5-7). a) Sn(OTf)2 , N-ethylpiperidine, THF, 
-78 oC, then 3; b) Boc2O, DMAP, CH2Cl2 , then 1:1 HCO2H/30% H2O2 ; c) 3.1 equiv LiOOH, -
5 oC, 1.2 equiv LiOOH, -10 oC; d) amino acid 7, TFA, DMS, CH2Cl2 , 0 oC, then 5, EDCl.HCl, 
HOBt, CH2Cl2/DMF, 0 oC; e) Li2CO3 , MeOH, rt; f) LiOH, MeOH/H2O; g) TFA, DMS, CH2Cl2 , 
0 oC, then amino acid-5, EDCI.HCl, HOBt, THF, 0 oC; h) TFA, DMS, CH2Cl2 , 0 oC, then TFAA, 
2,6-lutidine, CH2Cl2 , rt; i) VOF3, BF3.Et2O, AgBF4, TFA/CH2Cl2 , 0 oC, then NaHB(78)3; j) 
NaHCO3 , MeOH, H2O, rt, 6 d; k) amino acid-4, HATU, HOAt, collidine, CH2Cl2/DMF, -20 oC, 
16 h; l) Isobutyl chloroformate, N-methylmorpholine, EtOAc, -10  -5 oC, 30 min, then 
amino acid-4 in EtOAc/DMF, -20 oC rt, 2 h; m) HF. pyridine, THF, rt, 1 h. 
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Cyclisation of the 6-4 ring was carried out using Na2CO3, (DMSO, rt) to give the 
bicyclic peptide 14 in a relatively rapid reaction (1.5 h) (Scheme 1.5). The authors 
argued that the presence of the chloride substituent enhances the electrophilicity to 
get such fast cyclisation. Also, the dissolution of compound 13 in the aprotic solvent, 
DMSO, has an impact on the rate of the reaction without added base (Scheme 1.5).(74)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
Submission of the bicyclic 14 to a palladium catalysed reduction deprotected both the 
aryl triflate and the phenolic allyl group on ring-5 and on ring-4 respectively giving 
phenol 15. Bicyclic peptide 16 was obtained after replacement of the Boc group with 
Tfa and protection of the phenol group of ring-4 with pivaloyl chloride. The bicyclic 
peptide 17 with required S configuration (95:5) was given via deprotection of the 
methyl ether groups on rings 5 and 7 followed by 5-7 ring atropisomerisation (MeOH, 
55 oC, 24 h). To prepare the bicyclic tetrapeptide 17 for the final peptide coupling in 
Evan’s approach, hydroxyl groups on rings 7 and 5 were benzylated. Protection of 
the phenolic hydroxyl group of the amino acid-4 with allyl protecting group and 
removal of mesylate and trifluoroacetamide afforded the free amine bicyclic 
tetrapeptide 18.(74) 
Coupling of 18 (EDCI.HCl, HOAt, THF, 0 oC) with the prepared tripeptide 19, 
previously described by Evans(79) (Scheme 1.6), afforded heptapeptide 20 without 
apparent epimerisation. The tricyclic core of vancomycin 21 was obtained via 
intramolecular SNAr cyclisation with excess of desired R configuration of 2-4 ring by 
5:1. By reduction and purification of the nitro atropisomers mixture, followed by 
Sandmeyer transformation, a single atropisomer of the protected vancomycin aglycon 
22 was obtained. Compound 23 with the free carboxylic terminal group was afforded 
by selective removal of the N-methyl amide function through nitrosation and treatment 
with lithium hydrogen peroxide. Finally, vancomycin aglycon 1 was obtained through 
deprotection of 23.(74) 
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Scheme 1. 5:  Synthesis of the bicyclic tetrapeptide. Synthesis of the M (4-6) (5-7) bicyclic 
tetrapeptide. a) Na2CO3, DMSO, rt, 1.5 h, then Tf2NPh, 1 h; b) Zn0, HOAc, EtOH, 40 oC; c) 
NaNO2, H3PO2, cat. Cu2O, THF/H2O, 0 oC, 1 h; d) [Pd(dppf)Cl2] ´CH2Cl2 , Et3N, HCO2H, DMF, 
75 °C; e) PivCl, Et3N, THF, rt; f) TFA, DMS, CH2Cl2, 0 oC, then TFAA, 2,6-lutidine, CH2Cl2 , 0 
oC to rt; g) AlBr3 , then EtSH, 0 oC; h) MeOH, 55 oC; i) BnBr, Cs2CO3, Bu4NI, DMF, 0 oC; j) 
LiSEt, THF, 0 oC; k) allyl-Br, Cs2CO3 , DMF, 0 oC; l) LDA, THF, -78 oC; m) LiOH, 
THF/H2O/MeOH, 0 oC. 
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Scheme 1. 6: Assemblage of the vancomycin aglycon 1. a) EDCI, HOAt, THF, 0 °C; b) CsF, 
DMSO, rt; c) Zn0, HOAc, EtOH, 40 °C; d) HBF4, t-BuONO, MeCN, then CuCl, CuCl2, H2O; e) 
N2O4, NaOAc, CH2Cl2/CH3CN, 0 °C; f) H2O2, LiOH, THF/H2O. 
In the same year, Nicolaou and co-workers synthesised the vancomycin aglycon 
adopting a triazene-driven method for cyclisation of the C-O-D and D-O-E rings.(75) 
As it has been argued in the literature, its facile formation and removal, and its lability 
to chemical manipulation were the reasons behind choosing the triazene moiety. The 
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possibility of triazene conversion to the required aromatic phenol to be the acceptor 
for the sugar part of the vancomycin addressed one of the targeted steps in the 
synthesis. Herein, all the synthesis strategies of the seven vancomycin amino acids 
that were conducted by Nicolaou et al, will be discussed. As noted earlier, Nicolaou’s 
approach for the synthesis of vancomycin building units in solution phase represents 
the starting point for the current work towards the solid phase synthesis of 
vancomycin. 
The synthesis of the amino acid-6, started with commercially available 4-hydroxy 
benzaldehyde 24, which was benzylated to afford 25 (Scheme 1.7). Using a Horner-
Wadsworth-Emmons reaction with (EtO)2P(O)CH2COOEt, styrene 26 was 
obtained.(75) The latter was subjected to the Sharpless asymmetric 
aminohydroxylation reaction that afforded directly the required Cbz-protected amino 
alcohol 27 in 87% ee. The hydroxyl group in 27 was then protected using TBSOTf, 
and the resulting compound 28 was subjected to hydrogenolysis, which caused 
cleavage of both the benzyl and Cbz groups, affording phenol 29. Finally, chlorination 
of 29 at the ortho position was carried out with SO2Cl2, resulting in the production of 
the desired  building unit 30.(75) 
 
 
Scheme 1. 7: Synthetic route of the compound 30. Reagents and conditions: a) K2CO3 (1.5 
equiv), BnBr (1.0 equiv), KI (0.1 equiv), DMF, 25 °C, 12 h, 98%; b) (EtO)2(O)PCH2-COOEt 
(1.1 equiv), KOH (1.5 equiv), THF, 25 oC, 12 h, 95%; c) NaOH (3.0 equiv), BnOCONH2 (3.1 
equiv), t-BuOCl (3.0 equiv), (DHQD)2AQN (0.05 equiv), K2[OsO2(OH)4] (0.04 equiv), n-
PrOH:H2O (1:1), 25 oC, 12 h,45% (87% ee); d) TBSOTf (1.1 equiv), 2,6-lutidine (1.5 equiv), 
CH2Cl2, 0 oC, 0.5 h, 98%; e) H2 , Pd(OH)2/C (0.01 equiv), MeOH, 0.5 h, 95%; f) SO2Cl2 (1.0 
equiv), Et2O (3.0 equiv), CH2Cl2 , 0 °C, 1 h, 80%. 
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For the synthesis of the central amino acid-4, 4-aminobenzoic acid 31 was used as 
the SM (Scheme 1.8). Thus, after methylation and bromination, dibromide 33 was 
formed through methyl ester 32. Reduction of the methyl ester using LiAlH4 afforded 
alcohol 34. Triazene compound 35 was synthesised via a two step-reaction. The first 
step is the diazotization of the amino group by NaNO2 furnishing the diazonium salt, 
which was then treated with pyrrolidine to give triazene 35. Using PCC, oxidation of 
the alcohol to the aldehyde 36 was carried out. The latter was converted to a terminal 
olefin 37 by Wittig olefination. Asymmetric dihydroxylation using AD-mix-α, was 
performed affording diol 38 in 95% ee. Reaction of the primary alcohol in 38 with 
TBSCl afforded TBS-protected 39. Conversion of the alcohol 39 to the azide 
compound 40 was conducted with DPPA via a Mitsunobu reaction. The azide 
compound was then reduced to the desired amine 41 using Ph3P. After Boc protection 
of the amino group to give 42, desilylation of the primary alcohol with TBAF afforded 
43. The latter was oxidised with TEMPO to give the required building unit 44.(75)  
The synthesis of amino acid-5, which is equivalent to compound 49 was 
accomplished using 4-hydroxyphenyl glycine 45 as SM (Scheme 1.9). Methylation of 
45 in methanol and TMSCl gave the methyl ester 46, followed by Boc protection to 
the amino group affording 47. Methylation of the phenol group with MeI gave the fully 
protected compound 48. 
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Scheme 1. 8: Synthesis of the central amino acid-4 derivative. Reagents and conditions: a) 
SOCl2 (1.0 equiv), MeOH, reflux, 2 h, 100%; b) Br2 (2.0 equiv), AcOH, 25 oC, 0.5 h, 98%; c) 
LiAlH4 (1.5 equiv), THF, 0 oC, 2 h, 95%; d) 6 M HCl (5.0 equiv), NaNO2 (1.2 equiv), AcOH:H2O 
(1:2), 0 oC, 0.5 h, then KOH (8.0 equiv), pyrrolidine (1.5 equiv), 0 oC, 0.5 h, 75%; e) PCC (1.5 
equiv), CH2Cl2 , 25 oC, 2 h, 88%; f) n-BuLi (1.4 equiv), CH3PPh3Br (1.5 equiv), THF, -20 oC, 2 
h, 92%; g) AD-Mix-α (1.4 gmmol-1), t-BuOH/H2O (1:1), 6 h, 95%, (95% ee); h) TBSCl (1.1 
equiv), imidazole (1.5 equiv), DMF, 0 oC, 5 h, 88%; i) Ph3P (2.5 equiv), DEAD (2.5 equiv), 
DPPA (2.5 equiv), THF, 0 oC, 2 h, 79%; j) Ph3P (3.0 equiv), H2O (10.0 equiv), THF, 60 oC, 3 
h, 78%; k) (80)2O, Et3N,CH2Cl2 , 25 oC , 4 h, 95%; l) TBAF (1.2 equiv), THF, 0 oC, 2 h, 93%; 
m) TEMPO (1.0 equiv), 5% aq. NaOCl (3.0 equiv), 5% NaHCO3 , KBr (0.05 equiv), Me2CO, 0 
oC, 1 h, 75%. 
The final step involved a regioselective iodination using I2 and trifluoroacetate, which 
produced the desired amino acid 5 (49).(75)  
The boronic acid derivative 54, which is equivalent to amino acid-7 was synthesised 
from 3,5-dimethoxy benzaldehyde 50 (Scheme 1.9). Thus, Wittig olefination was 
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performed to give styrene compound 51. Via Sharpless asymmetric dihydroxylation, 
the diol 52 was afforded. Selective monobenzylation to the terminal hydroxyl group 
was carried out giving 53. Finally, the desired building block 54 was obtained by 
lithiation with n-BuLi followed by quenching with B(OMe)3. 
 
 
Scheme 1. 9: Synthetic route of the amino acid-5 and amino acid-7. Reagents and conditions: 
a) TMSCl (2.1 equiv), MeOH, 25 oC,15 h, 98%; b) (80)2O (1.1 equiv), K2CO3 (4.0 equiv), 
dioxane: H2O (1:1), 25 oC, 4 h, 95%; c) MeI (2.0 equiv), K2CO3 (4.0 equiv), DMF, 25 oC, 6 
h,93%; d) I2 (1.2 equiv), CF3COOAg (2.2 equiv), CHCl3, 25 oC, 12 h, 90%; e) n-BuLi (1.3 
equiv), CH3PPh3Br (1.5 equiv), THF, -20 oC, 10 h, 91%; f) AD-β (1.4 gmmol-1), t-BuOH/H2O 
(1:1), 25 oC, 8 h, 92% (96% ee); g) n-Bu2SnO (1.0 equiv), toluene, reflux, 1 h, then BnBr (1.5 
equiv), n-Bu4NI (0.5 equiv), 70 oC, 2 h, 89%; h) n-BuLi (2.2 equiv), benzene, 0 25 oC, 2 
h, then B(OMe)3 , THF, -78 oC 25 oC, 6 h, dilute HCl, 55%. 
The amino acid-5 and amino acid-7, compounds 49 and 54 respectively, were 
coupled to each other using a Suzuki coupling reaction (Pd(Ph3P)4, Na2CO3, 90 oC) 
giving the desired atropisomer 55 in an excess ratio (2:1) (Scheme 1.10). After 
chromatographic separation, the latter was converted to azide 56 using a Mitsunobu 
reaction. To prepare this biaryl compound 56 for the peptide coupling with amino acid-
6, it was hydrolysed with LiOH to its carboxylic acid form 57 (Scheme 1.10).(75) 
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Scheme 1. 10: Synthesis of the compound 57, carboxylic acid form. Reagents and conditions. 
a) DPPA (2.5 equiv), DEAD (2.5 equiv), Ph3P (2.5 equiv), THF, -20 oC, 2 h, 95%, b) LiOH (1.5 
equiv), THF/H2O (1:1), 0 oC, 0.5 h, 99%.(75) 
The coupling of biaryl compound 57 to compound 30 was accomplished using 
(EDC/HOAt) and afforded tripeptide 58 (Scheme 1.11).(81) The Boc group was 
deprotected using excess of TMSOTf to prepare the amine tripeptide 59 for the 
subsequent coupling reaction to compound 44 (amino acid-4). Thus, the amine 
tripeptide was coupled to compound 44 using EDC/HOAt affording tetrapeptide 60 
(Scheme 1.11). Then, C-O-D ring closure of 60 was accomplished using CuBr· SMe2, 
K2CO3, and pyridine in CH3CN with reflux and resulted in equal ratios (1:1) of the two 
atropisomers 61a and 61b.  
Both atropisomers were taken through three steps of reactions; TBS deprotection 
affording 62a and 62b, reduction of azide giving 63a and 63b, and hydrolysis of the 
ethyl ester furnishing 64a and 64b. For the AB ring closure, the latter two 
atropisomers were exposed to macrolactamisation reaction using FDPP and iPr2NEt 
in DMF giving the two atropisomers 65a and 65b of AB/COD ring system (Scheme 
1.12).(75, 81)  
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Scheme 1. 11: Synthetic route of compound 60 and closure of C-O-D ring. Reagents and 
conditions. a) 3.3 equiv of TMSOTf, 3.0 equiv of 2,6-lutidine, CH2Cl2 , 0 °C, 3 h, 90%; b) EDC 
(3.0 equiv), HOAt (3.3 equiv), THF, -5 °C, 12 h, 76%; c) CuBr .SMe2 (3.0 equiv), K2CO3 (3.0 
equiv), pyridine (3.0 equiv), MeCN, reflux, 20 min, ca. 1:1 ratio of atropisomers, 60% combined 
yield.(75)  
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Scheme 1. 12: Construction of AB/C-O-D bicyclic systems 65a and 65b from natural biaryl 
system. a) 1.1 equiv of n-Bu4NF, THF, -25 → -15 °C, 3 h, 95% of 62a, 98% of 62b; b) 2.0 
equiv of Et3P, MeCN/H2O (4:1), 25 °C, 20 h, 78% of 63a, 79% of 63b; c) 5.0 equiv of LiOH, 
THF/H2O (1:1), -5 → 0 °C, 10 min, 92% of 64a, 90% of 64b, crude yields; d) 3.0 equiv of 
FDPP, 5.0 equiv of iPr2NEt, DMF, 0 → 25 °C, 12 h, 86% of 65a, 60% of 65b.(81) 
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In order to complete the synthesis of the whole AB-COD-DOE complex, Nicolaou and 
co-workers needed to synthesise the rest of the molecule, amino acids-1, amino acid-
2 and amino acid-3.(76) Thus, the derivative of the amino acid-2 was prepared using 
the previously synthesised intermediate, ethyl cinnamate 26 (Scheme 1.13), via the 
following four-step sequence: 1) Sharpless asymmetric dihydroxylation of the double 
bond to give 66, 2) protection of the hydroxyl group with nosyl protecting group 
afforded 67, 3) production of azide 68 using NaN3, 4) finally, reduction of the azide 
with SnCl2 furnished the desired amino acid-2 derivative, compound 69.(76)  
For the synthesis of the amino acid-3 derivative, compound 72, asparagine was used 
as the SM (Scheme 1.14). After protection of both nitrogen with Cbz, and Ddm to 
afford compound 70, the carboxylic acid group was methylated using MeI giving 
compound 71. Then, the Cbz was removed via hydrogenolysis to afford the required 
asparagine derivative 72. For the amino acid-1 unit, the commercially available N-
methyl leucine Boc derivative 73 was used (Figure 1.7). 
 
 
Scheme 1. 13: Synthesis pathway of amino acid-2 derivative, compound 69. Reagents and 
conditions: a) AD-β, (1.4 gmmol-1), MeSO2NH2 (1.0 equiv), t-BuOH/H2O (1:1), 25 oC, 12 h, 
79% (92% ee); b) NsCl (1.0 equiv), Et3N (2.0 equiv), DMF, 0 oC, 5 h, 60%; c) NaN3 (1.5 equiv), 
DMF, 55 oC, 12 h, 90%; d) SnCl2.H2O (2.0 equiv), MeOH, 25 oC, 2 h, 90%. 
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Scheme 1. 14: Synthestic route of the amino acid-3 derivative. Reagents and conditions: a) 
MeI (2.0 equiv), K2CO3 (2.0 equiv), DMF, 25 oC, 12 h, 70%; b) H2, 20 wt% Pd(OH)2/C, MeOH, 
25 oC, 1 h, 99%.(76) 
 
Figure 1. 7: N-methyl leucine Boc derivative. 
These three amino acids, -1, -2 and -3, were assembled to form the desired tripeptide 
80 of the vancomycin heptapeptide backbone (Scheme 1.15). Thus, by coupling 69 
to 73 using EDC/HOBt the dipeptide 74 was formed. To have it ready for the 
subsequent coupling to 72, amino acid-3, the dipeptide ethyl ester was hydrolysed to 
its carboxylic form 75 using LiOH. The third amino acid was attached using 
EDC/HOAt leading to formation of the tripeptide 76. Protection of the hydroxy group 
of the latter with TBSOTf giving 77, cleavage of the benzyl group by hydrogenolysis 
to give 78, chlorination at ortho position using SO2Cl2 to furnish 78,  and hydrolysis of 
the methyl ester using LiOH, in consequent reactions afforded the requisite tripeptide 
80.(82)  
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Scheme 1. 15: Synthesis of tripeptide 80.(82) a) 3.0 equiv of EDC, 3.3 equiv of HOBt, THF, 
0 °C, 12 h, 93%; b) 2.0 equiv of LiOH, THF/H2O (1:1), 0 °C, 1 h, 99%; c) 3.0 equiv of EDC, 
3.3 equiv of HOAt, THF, 0 °C, 12 h, 82%; d) 1.3 equiv of TBSOTf, 2.2 equiv of 2,6-lutidine, 
CH2Cl2, 0 °C, 2 h, 81%; e) H2 , 20% Pd(OH)2/C, MeOH, 25 °C, 1 h, 99%; f) 1.1 equiv of SO2Cl2 
, Et2O, 0 °C, 75%; g) 4.0 equiv of LiOH, t-BuOH/H2O (2:1), 0 °C, 0.5 h, 95%. 
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Before the coupling process between the two synthesised parts of vancomycin, the 
tetrapeptide and the tripeptide, the natural atropisomer of the tetrapeptide 65a was 
Boc-deprotected using an excess of TMSOTf. The resulting natural amino form of the 
tetrapeptide 81a was taken through the coupling process with the tripeptide part 80.(81) 
The coupling was performed using the EDC/HOAt system furnishing the uncyclised-
D-O-E ring heptapeptide 82. The cyclisation process to the D-O-E ring was carried 
out using (CuBr·Me2S, K2CO3, pyr·CH3CN ∆), furnishing the targeted polycyclic 
intermediate in a good yield as a mixture of the two atropisomers 83a and 83b 
(Scheme 1.16).(81) Nicolaou and co-workers then converted the triazene into the 
required phenol group for the glycosidation reaction and universally deprotected the 
polycyclic intermediate in preparation for the synthesis of vancomycin itself. In the 
following work,(83) he was able to end up with the synthesis of the whole vancomycin 
structure after attachment of the two sugar moieties. 
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Scheme 1. 16: Construction of AB/C-O-D/D-O-E tricyclic systems 83a and 83b. a) 2.0 equiv 
of TMSOTf, 3.0 equiv of 2,6-lutidine, CH2Cl2 , -10 °C, 0.5 h, 96%; b) 2.0 equiv of EDC, 10.0 
equiv of HOAt, THF, -15 → 0 °C, 12 h, 86%; c) 5.0 equiv of CuBr ´Me2S, 5.0 equiv of K2CO3, 
5.0 equiv of pyr., MeCN, reflux, 2 h, 83a: 83b ca. 1:3 ratio of atroipisomers, 74% combined 
yield.(81) 
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1.3.1.1. Summary. 
Both the Evans and Nicolaou syntheses gave the vancomycin aglycon, and ultimately 
vancomycin, through an extended solution phase synthesis, with protection of 
intermediates at each step. Solid phase synthesis offers, potentially, a more rapid 
approach to develop vancomycin analogues. In addition, the purification process to 
obtain the required peptide in SPPS involves mainly filteration, which makes the 
synthesis process rapid and facile. In contrary, with the solution phase, the purification 
process requires for crude after each reaction step, which is time consuming and 
costly. The following section will focus on some literatures that considered the solid 
phase synthesis of vancomycin. 
1.3.2. The solid phase synthesis of vancomycin. 
Given the key goal of the research in this thesis is the synthesis of vancomycin on 
solid phase, the literature that has dealt with such chemistry is reviewed here. In 1999 
Ernst Freund and John A. Robinson synthesised a heptapeptide using solid phase 
methods relying on Alloc protecting group chemistry for the N-terminal elongation,(84) 
(Scheme 1.17). 2-Chlorotrityl chloride resin was used as a solid support and the 
benzyl ether protecting group for aromatic side chain protection.(84) (S)-Alloc-
Dhpg(OBn)2-OH was first attached to 2-chlorotrityl chloride resin using DCM as a 
solvent to give 84. The elongation of the peptide chain was accomplished using 
HATU/HOAt (4 equiv). DMF was used as a solvent for the required amino acids 
alongside the coupling agents. Alloc removal after each coupling process was carried 
out with Pd(PPh3)4 and PhSiH3. 
Upon completion of the synthesis of the protected form of heptapeptide 85 on the 
solid phase, deprotection of the side chains was carried out universally and the 
heptapeptide was cleaved from the resin giving the desired linear heptapeptide 86. 
Noteworthy, the final attached amino acid was protected with Boc at the N-terminus, 
therefore it was removed in a separate step.(84) The researchers argued that the use 
of Alloc protecting groups for chain elongation was to avoid epimerisation of several 
amino acids through the use of Fmoc/Boc system in solid phase. Alloc deprotection 
proceeded under neutral conditions rather than basic or acidic conditions with Fmoc 
and Boc respectively.(84) The desired linear heptapeptide 86 was produced in 16% 
yield. As it is noticeable, this protocol proceeded with non-chlorinated tyrosine 
derivatives. 
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Scheme 1. 17: Synthesis of the linear heptapeptide 86 by Ernst Freund and John A. Robinson. 
Reagents and conditions: a) for coupling (R)-Alloc-Hpg(OBn)-OH, (R)- and (S)-Alloc-
Tyr(OBn)-OH, L-Alloc-Asn(Mtt)-OH, or D-Boc-Leu-OH (4 equiv), HATU and HOAt (each 4 
equiv.), NMM, DMF, and for Alloc deprotection Pd(PPh3)4 (0.5 equiv) and PhSiH3 (30 equiv.) 
in CH2Cl2; b) CF3CH2OH–AcOH–CH2Cl2 (1:1:3); c) TFA–CH2Cl2 (1:1) + 5% Pri3SiH, 0 °C, 2 h; 
d) TFA, thioanisole (3:1), 20 °C, 3 h.(84) 
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One year later, Robinson and co-workers described the synthesis of the linear 
heptapeptide intermediate with m-chlorinated tyrosine derivatives 87 using the Alloc 
strategy (Figure 1.9).(85) The required amino acid residues 88-94 were synthesised in 
solution phase using detailed literature methods (Figure 1.8). All of them were 
protected with the Alloc protecting group at the N-terminus. The amino acid 95 was 
commercially available.(85) 
 
 
Figure 1. 8: The chemical structure of the amino acid-building blocks required for synthesis 
of the chlorinated variant of linear heptapeptide.(85) 
The solid-phase synthesis was carried out using the same protocol that was used in 
the previous work regarding the type of the solid support and peptide elongation 
process. The monitoring of the coupling process was performed using reversed-
phase HPLC. After coupling of the hydroxyphenyl glycine residue (Hpg) 91, two 
compounds were obtained in a 4:1 ratio. This was due to epimerization, which 
persisted to the end of the synthesis.(85) Upon completion of the sequence, the 
heptapeptide was cleaved from the resin in its side-chain protected form, using a 
mixture of CH2Cl2/CF3CH2OH/AcOH. The deprotection of all side chain protecting 
groups was carried out with CF3COOH/thioanisole (i-Pr)3 SiH, and the purification of 
the product by reversed-phase HPLC.(85) The overall yield of the product was 13%. 
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Figure 1. 9: The chlorinated form of the linear heptapeptide made by Robinson.(85) 
In 2001 K. C. Nicolaou et al,(71) showed the  solid phase semisynthesis of vancomycin 
based on their previous work on the total synthesis of vancomycin.(75, 76) They chose 
vancomycin to be attached at its C-terminus and protected at its functional moieties 
with silicon protecting groups. Therefore, choosing a convenient linker that would be 
stable under acidic and basic conditions and suitable with protecting groups was of 
significant importance in this work. Already prepared and protected vancomycin was 
set to be loaded on a solid support.(71)  
Initially, two photocleavable resins linkers, 96 and 97, (Figure 1.10) were employed 
because of their compatibility with the above requirements.(71, 86) The vancomycin 
loading on resin linker 96 proceeded smoothly but the removal from the resin could 
not be performed. On the other hand, vancomycin loading on resin linker 97 gave low 
yields, attributed to the steric hindrance.(71) 
 
 
Figure 1. 10: The chemical structures of the unsuccessful photolabile linkers.(71) 
After that, three allyl linkers, 98-100, were trialled (Figure 1.11). The loading and 
cleavage of vancomycin and its analogue proceeded with ease with these linkers. 
The glycosidation step to install the sugar part of vancomycin, required Lewis acidic 
conditions. The resin-loaded vancomycin variants, 101 and 102, which correspond to  
 
55 
 
the resins 98 and 99 respectively, underwent a diminished cleavage process, a fact 
that was attributed to a [3,3]-sigmatropic rearrangement.(71) Using an acrylate linker-
loaded vancomycin 103, led to a noticeable improvement in the cleavage process 
due to lack of the problematic [3,3]-sigmatropic rearrangement, but the analogues 
suffered from premature cleavage. This was attributed to the acrylate resin linkers 
susceptibility to nucleophilic attack (Scheme 1.18).(71) 
 
 
Figure 1. 11: The allyl linkers that were not appropriate for the solid-phase semisynthesis of 
vancomycin.(71) 
 
 
Scheme 1.18: Presumed side reactions of allyl linkers 101, 102, and 103.(71) 
Nicolaou et al(71)  used pro-allyl and pro-alloc selenium resins in which the allyl group 
is masked, 104 and 105 (Figure 1.12).(71, 87) The pro-allyl safety catch linker  would 
have the advantage of the C-terminus protection and the stability for the conditions 
involved in the synthesis of vancomycin.(71) With this successful linking strategy, 
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Nicolaou and co-workers were able to proceed with the solid phase semisynthesis of 
vancomycin as the loading and cleavage processes proceeded in a facile manner.(71) 
 
  
Figure 1. 12: The pro-allyl selenium resins.(71) 
Accordingly, several modifications of the two amino groups, the leucine amino acid, 
and deglycosidation/reglycosidation were performed, and all the derivatives were 
biologically examined and evaluated.(71) 
In 2014 Clara Brieke and Max J. Cryle, used an optimised Fmoc protocol for the solid 
phase synthesis of a vancomycin-type hexapeptide 106 (Figure 1.13). They argued 
that the Fmoc chemistry still has advantages over other solid phase methods. The 
main advantage is the facile synthesis of building blocks and therefore, there are a 
wide range of such available starting materials. In addition, the monitoring process is 
easy and simple. In contrast, the Alloc chemistry is characterised by  a tedious 
synthesis of the building blocks and use of palladium-mediated procedure for the 
peptide cleavage.(88) Therefore, they explored different conditions to optimise the 
Fmoc protocol. That is, to reduce the epimerization associated with the N-Fmoc 
deprotection with piperidine, especially in arylglycine derivatives, to the minimum. For 
the deprotection of the N-Fmoc group, a 1% solution of DBU in DMF gave the best 
outcome, which allows for deprotection of phenylglycine residues in as short a time 
as 30 s with a very small ratio of racemisation.(88) For an effective coupling reaction, 
COMU and Et3N reagents were used in four equiv each and did not produce 
racemisation. A TFA/TIPS/H2O mixture was used for the final cleavage of the peptide 
from the resin. Noteworthy, using any type of base whether for scavenging the side 
products as diphenylfulvene or as an activator in the coupling step leads to increased 
racemisation. Moreover, using 4-hydroxyphenylglycine (4-HPg) has less influence in 
increasing racemisation than HPg. Consequently, one major product was obtained 
without occurrence of racemisation as was revealed by analytical HPLC-MS 
analysis.(88) 
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Figure 1. 13: The hexapeptide of vancomycin synthesised on SPPS by Clara Brieke and Max 
J. Cryle.(88) 
1.3.3. The modification of vancomycin. 
 Several attempts have been carried out on the modification of vancomycin as 
endeavours to find new analogues to function effectively against vancomycin 
resistant species. The loss of vancomycin binding affinity, and subsequently its 
antimicrobial activity, is largely attributed to the repulsion between the lone pairs of 
the carbonyl oxygen of the central amino acid in vancomycin and the oxygen of the 
D-Ala-D-Lac terminus of the peptidoglycan precursor in the resistant bacteria (Figure 
1.14).(89) Based on this idea, Boger and co-workers replaced the carbonyl functional 
group of the central residue-4 with a methylene group producing the analogue of the 
vancomycin aglycon 107 (Figure 1.15).(90) 
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Figure 1. 14: Illustration of the repulsive lone pair interaction between the vancomycin 
central residue carbonyl and the D-Ala-D-Lac oxygen. 
 
Figure 1. 15: Replacement of carbonyl oxygen by a methylene group in vancomycin aglycon 
107. 
This modification exhibited a 40-fold increase in affinity for the ligand D-Ala-D-Lac, and 
showed a reduction in binding to the ligand D-Ala-D-Ala by 35-fold. Amidine and 
thioamide derivatives of the central residue were anticipated to have a significant activity 
against resistant bacteria with a D-Ala-D-Lac peptidoglycan cell wall precursor (e.g., 
VanD, which is one of the non-transferable genes responsible for the vancomycin 
resistance of E. faecium strains(67)). On the other hand, amidine and thioamide 
derivatives were inactive against sensitive and inducible resistant bacteria (VanA and 
VanB) that maintain or at least start with a D-Ala-D-Ala peptidoglycan cell wall 
precursor.(90) 
Restoration of H bonding between vancomycin and peptidoglycan in the bacterial cell 
wall was one of the targeting approaches that Boger and his team attempted. In 2009, 
Boger and co-workers introduced unnatural amino acids to the N-terminus of 
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vancomycin aglycon creating different analogues (Figure 1.16). The amino acids contain 
functional groups exhibiting H-bonding to the carbonyl group of two ligand models, 108 
and 109, mimicking the peptidoglycan layers present in susceptible and resistant 
bacterial species (Figure 1.17).(91)  
The analogues containing N-terminal D-serine (110), O-tert-butyl-D-serine (111), D-
threonine (112), mono- or bi-dentate analogues of 3-amino-D-phenylalanine (113-115), 
3-aminomethyl-D-phenylalanine (116) and their corresponding hydrazine counterparts 
117-119 were examined. Analogue 119 was the only compound that showed a 
noticeable antimicrobial activity against the VanA strain, although the reason for this was 
unclear.(91) 
 
 
Figure 1. 16: The vancomycin analogues with a modified N-terminus. 
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Figure 1. 17: The model ligands mimic the bacterial cell wall binding to vancomycin. 
In 2010, Boger and co-workers introduced new derivatives of the vancomycin aglycon 
via protection of each of the four phenols with methyl groups.(92) Six analogues of 
vancomycin aglycon 1 were made (Figure 1.18). Analogues 120 and 121 showed 
considerable antimicrobial activity against sensitive and resistant bacteria (VanB), 
with an increased activity against VanA, without a significant change in the binding 
affinity to the model ligands. The antimicrobial activity was attributed to the 
hydrophobicity of permethylated analogues of the vancomycin aglycon, which have 
the ability to penetrate into the bacterial cell membrane sufficiently to avoid induction 
of the route where switching between D-Ala-D-Ala, and D-Ala-D-Lac would 
happen.(92) 
 
Figure 1. 18: Analogues of vancomycin aglycon. 
Boger and co-workers also made a change in the vancomycin aglycon 1 structure, 
that was able to exhibit a dual activity against both resistant and susceptible strains.(93) 
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They replaced the amide of the central residue with an amidine and investigated its 
antimicrobial activity (Figure 1.19). Compound 126 exhibited activity 1000-fold more 
potent than vancomycin and vancomycin aglycon against VanA resistant bacteria, 
and approximately the same activity against sensitive bacteria. They proposed that 
the significantly enhanced activity of the amidine derivative against the most virulent 
VanA species is due to the stabilising electrostatic interactions and the H-bonding 
donor property of the protonated form of amidine (Figure 1.20a). Accordingly, that 
leads to a significant reduction in the destabilising lone pair repulsion of the ester 
oxygen of the model ligand D-Ala-D-Lac 109.(93)  
                                                                            
 
Figure 1. 19: The potential dual binding behaviour of the amidine derivative. 
 
 
Figure 1. 20: Illustration of the electronic interaction between amidine and protonated amidine 
derivatives and ester oxygen. 
On the other hand, the susceptibility of the sensitive bacteria was attributed to the re-
establishment of the stabilising H-bonding between the amidine nitrogen and the 
amide group in the model ligand 108, and thereby showed an equal antimicrobial 
activity as vancomycin (Figure 1.20b). Regarding the binding affinity, the central 
residue amidine derivative showed a significant binding for both models, D-Ala-D-Ala 
and D-Ala-D-Lac, within a level of 2-3-fold of that displayed by vancomycin for D-Ala-
D-Ala.  
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In the same work, Boger and co-workers prepared vancomycin derivatives in which 
the amide of the central residue was replaced by a methylene and thioamide groups, 
compounds 127 and 128 respectively (Figure 1.21).(93)  
 
Figure 1.21: The methylene and thioamide derivatives of vancomycin aglycon. 
Vancomycin aglycon with residue-4 methylene derivatives displayed a slightly 
improved antimicrobial activity against resistant bacteria as it exhibited a 40-fold 
higher affinity to D-Ala-D-Lac than vancomycin aglycon. On the other hand, its affinity 
for D-Ala-D-Ala was reduced by 35-fold. Thioamide derivatives displayed neither 
significant antimicrobial activity nor binding affinity to either of the models, ligand 108 
and 109. They attributed the failure of thioamide derivatives to the weak ability of the 
thioamide thiocarbonyl to form H-bonds, the long bond of the thiocarbonyl and the 
large van der Waals radii of sulfur.(93) 
In the same year, Miller and Pathk,(94) reported different bromination approaches for 
vancomycin based on the fact that is the activity of bioactive compounds can be 
further modified and tuned, especially in the case of aromatic compounds, to produce 
different products via introduction of bromine. By a reaction of unprotected 
vancomycin with N-bromophthalimide (NBP) in H2O, mixtures of brominated isomers 
in addition to the unreacted vancomycin were produced (Figure 1.22).(94)  
 
 
 
 
63 
 
 
Figure 1. 22: Illustration of the three presumed sites (in red) for site-selective bromination of 
vancomycin. 
Focussing on the fact that it is important to explore other analogues of vancomycin to 
retain its essential and potent activity against resistant bacteria, in 2012 Miller made 
these different variants of brominated vancomycin (Figure 1.22), through a selective 
method using peptide based ligands.(94) These ligands (Figure 1.23), were designed 
based on the mechanism of the vancomycin activity and its binding affinity to its 
target, D-Ala-D-Ala, of the bacterial cell wall. N-bromophthalimide (NBP) was used as 
a source of bromination of vancomycin and H2O as a solvent.  
Monobrominated compound 130 was produced predominately when ligand 134, Asn 
(Me2)-D-AlaD-Ala, was used. Dibromide compound 132 was the predominant product 
when ligand 135, Gln(Me2) residue instead of Asn(Me2), was added. Lowering and 
increasing in the concentration of the ligand 134 significantly affected the 
monobrominated isomers ratio (129,130). Moreover, changing the position of the 
Asn(Me2) group within the tripeptide had diminished both activity and selectivity of the 
ligand. On the other hand, using a limited quantity of NBP (0.5 equiv) preserved the 
selectivity to the monobromide compound 130 and reduced the yield of dibromide  
isomer 132.(94) 
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Figure 1. 23: The ligands used for bromination of vancomycin. 
Production of dibromide compound 132 in excellent yield was achieved by use of NBP 
with an excess quantity (3 equiv) with 100 mol% of ligand 134. The tribromide isomer 
133 was produced in a significant yield with use of peptide ligand 136. After 
production of 130, 132, and 133 preferentially, they sought a way to improve the 
reaction selectivity for monobromide isomer 129. They found that the use of guanidine 
as an additive to the reaction condition that had provided the isomer 129 with good 
selectivity. The efficiency of guanidine came from its ability to bind the proximal acid 
of vancomycin and direct the bromide ion to the specific site (Figure 1.22).(94) 
Building on the earlier achievements by Boger in 2012,(93) in 2015, he and co-workers 
examined the effect of the introduction of a 4-chlorobiphenyl (4-CBP) substitution to 
the different three vancomycin analogues (amidine, methylene, and thioamide) 
(Figure 1.24).(95) Thus, with the different aglycon analogues in hand from the previous 
work,(93) enzymatic glycosylations of the carbohydrate moieties had been carried out 
using GtfE and GtfD for the introduction of glucose and vancosamine respectively. 
After the introduction of the 4-CBP was performed, the investigation of the 
antimicrobial activity of the different analogues was explored. Attachment of the 4-
CBP to vancomycin 137, resulted in an improvement of the antimicrobial activity 
against VanA and VanB by 100-fold (MIC=2.5 µg/ml) and against VSSA and MRSA 
by 20-fold (MIC= 0.03 µg/ml).(95)  
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Figure 1. 24: The vancomycin analogues with 4-CBP substitution. 
The most striking outcome of this work was after the introduction of 4-CBP 
substitution to the amidine analogue 138, where the antimicrobial activity increased 
by 500 and 50000-fold against most virulent and resistant bacteria, in comparison to 
the amidine analogue of vancomycin and to vancomycin itself, respectively. 
Regarding the methylene analogue, introduction of 4-CBP 140 showed equal activity 
as for the amidine analogue against both sensitive and resistant strains, though the 
amidine analogue was still more active than the methylene analogue by 15-fold.(95) 
Although, the thioamide analogue 139 showed no activity against both sensitive and 
resistant bacteria, introduction of 4-CBP resulted in a great improvement in its 
antimicrobial activity against both resistant and sensitive strains (MIC= 2-4 µg/ml).  
Accordingly, it was suggested that such impressive activity may belong to another 
mechanism alongside the assigned mechanisms via which vancomycin produces its 
antibacterial effect. This mechanism may involve enhancing antibiotic dimerisation for 
cell membrane anchoring, and disruption of the integrity of bacterial cell membrane. 
In addition, the direct suppression of the enzymatic system, transglycosylase and 
transpeptidase, that maintains bacterial cell wall integrity was presumed as another 
potential mechanism.(95) 
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1.3.4. Summary. 
In summary, while the total synthesis of vancomycin has been achieved, it is a multi-
step process that is not readily amenable to the generation of analogues. However, 
the value in generating new methods based on the vancomycin scaffold has been 
made clear by the approach taken by Boger and co-workers. This has generated new 
compounds with potential against resistant bacteria through small and simple 
variation. This suggested to us that a solid phase synthesis of the vancomycin 
aglycon could have the potential to generate new analogues in a relatively rapid way, 
providing molecules could be developed to synthesise suitably protected monomers 
for Fmoc-chemistry and suitablely derivatised to aid the on-resin formation of the 
macrocyclic rings. This thesis describes the initial studies towards the goal of 
generating suitably protected monomers and initial studies of their application to the 
solid phase. 
 
 
 
 
 
 
 
 
 
 
 
67 
 
 
 
 
 
Chapter 2. 
Synthesis of an analogue of the vancomycin 
central amino acid suitably protected for Fmoc 
solid phase synthesis 
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2.1. The design of the central unit. 
This chapter focuses on the synthesis of the central amino acid (Figure 2.1) of the 
vancomycin structure as a first step towards the introduction of a solid phase 
synthesis method. The central amino acid is part of two important macrocycles, 
therefore, access to both of these structures can be gained. It also contributes directly 
to the mechanism by which vancomycin inhibits the synthesis of the bacterial cell wall 
via hydrogen bonding. 
 
  
 
Figure 2. 1: Heptapeptide part of vancomycin. Illustration of the position of the central amino 
acid as a connecting bridge between two macrocycles in the vancomycin structure. 
 
The central unit is the only residue that has five linkages within the structure of 
vancomycin (Figure 2.2), two amide linkages and two ether bridges to the 
neighbouring amino acids, and one glycosidic linkage. With all these observations in 
mind, the route for the synthesis of the central unit for solid phase synthesis had to 
be designed. There were some considerations before commencing with the synthesis 
of the central unit: 
1) Protection of the amine group with Fmoc to be consistent with the standard strategy 
followed in SPPS. 
 2) At the end of the synthesis, the carboxylic acid group must be unprotected so that 
it can be used for amide bond formation via a coupling step, (Figure 2.3). 
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Figure 2. 2: Illustrating of the five connections of the central amino acid to other parts of 
vancomycin. 
3) A suitable aromatic substitution was required on the ortho positions to allow the 
macrocyclisation on both sides of the aromatic ring to be facile and smooth. 
Dibromide substitution on the ortho positions of the central unit was found to have an 
important role in Ullman coupling and could be applied for cyclisation.(70, 96)  
4) A suitable capping procedure for a phenolic hydroxyl group was required. The 
triazene moiety is relatively stable to the basic conditions used in Fmoc-SPPS but is 
labile to acid under relatively mild conditions (50% TFA/ DCM).(97) 
The triazene group can be easily formed and modified,(70) so potentially can be 
converted to phenol, which is a good acceptor for the vancomycin sugar moiety.(82)  In 
addition, it has an ability to protect a reactive diazonium salt through several 
reactions.(98) For these  important reasons, the triazene was chosen as a protecting 
group throughout the synthesis process. Moreover, its ability to activate the ortho 
bromide for a facile macrocyclisation, triazene-driven cyclisation, added another 
factor for its importance.(70, 96) 
 
 
 
 
 
 
 
 
 
70 
 
 
Figure 2. 3: The design of the central unit C2 for solid phase synthesis compatibility. 
2.2. The synthesis of the central unit. 
The proposed route to synthesis of the target compound is shown in scheme 2.1. 
Although the route parallels Nicolaou’s approach,(99) several modifications had to be 
made to achieve the final Fmoc-protected target C14. The steps of the synthetic route 
will be discussed in detail in below. 
2.2.1. Synthesis of the methyl ester C2. 
The formation of the acid chloride intermediate is a key step in the reaction (Scheme 
2.2). Acid chlorides are more reactive than carboxylic acids when used in the 
generation of carboxylic acid derivatives. Due to their high reactivity they can react 
even with weak nucleophilic species.(100),(101) Thionyl chloride is regularly utilised in 
the preparation of  acid chloride intermediates.(102) 
The esterification of the carboxylic acid C1 was performed by dissolving the starting 
material in methanol and adding thionyl chloride followed by heating of the reaction 
mixture at reflux and 4-aminomethyl benzoate C2 was obtained in 97% yield without 
purification. 
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Scheme 2. 1: The route to synthesis of the central amino acid in vancomycin: Reagents and 
conditions: a) SOCl2 (1.0 equiv.), MeOH, reflux, 2 h; b) Br2 (2.0 equiv), AcOH, 25 oC, 1 h; c) 
LiAlH4 (2 equiv), anhydrous THF, 0 oC, 2 h; d) 6 M HCl (5.0 equiv), NaNO2 (1.2 equiv), 
AcOH:H2O (1:1), 0 oC, 1 h, then KOH (30 equiv), pyrrolidine (1.5 equiv), 0 oC, 0.5; e) PCC (1.5 
equiv), CH2Cl2, 25 oC, 2 h; f) n-BuLi (1.4 equiv), CH3Ph3P+Br- (1.5 equiv), anhydrous THF, 
under N2, -20 oC, 4 h; g) AD-Mix-α (1.4 g mmol-1), t-BuOH/H2O (1:1), 24 h; h) TBSCl (1.1 
equiv), DMAP (0.1 equiv), Et3N (1.5 equiv), DCM, 0 oC, 2 h; i) Ph3P (2.5 equiv), DIAD (2.5 
equiv), DPPA (2.5 equiv), anhydrous THF, 0 oC, 2 h; j) Ph3P (3.0 equiv), H2O (10.0 equiv), 
THF, 60 oC, 2 h; k) Fmoc-Cl (1.1 equiv), NaHCO3 (2 equiv), THF, H2O , 0 oC , 3 h; l) TBAF (1.2 
equiv), AcOH (3 equiv), THF, 0 oC, 6 h; m) TEMPO (1.0 equiv), 5% aq. NaOCl (3.0 equiv), 5% 
NaHCO3 , KBr (0.1 equiv), Me2CO, 0 oC, 2 h. 
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Scheme 2. 2: The atom numbering of the 4-aminomethyl benzoate C2. 
The reaction product was confirmed using 1H NMR spectroscopy (see scheme 2.4 for 
atom numbering). A singlet peak at 3.85 ppm corresponded to the newly formed ester 
methyl group. The position is downfield because the two oxygen atoms of the ester 
are so electronegative that electron density around the methyl protons decreases. 
The two protons of C-3 and C-5 give rise to a doublet at 7.85 ppm, with coupling 
constant of 8.8 Hz, characteristic of coupling to neighbouring C-2 and C-6. The reason 
for a downfield shift compared with unsubstituted benzene proton (usually at 7.2 ppm) 
is due to the proximity to the ester moiety, which is electron-withdrawing to the relative 
ortho and para positions through a conjugation effect (Scheme 2.5).  
 
Scheme 2. 3: Effect of the ester moiety on the ortho and para proton position through the 
conjugation influence. 
A second doublet can be seen at 6.64 ppm with 8.8 Hz coupling constant. This is due 
to the protons at positions C-2 and C-6 which are shielded from the field due to the 
electron-donating amino group.  
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2.2.2. Synthesis of the dibrominated compound C3. 
 
Scheme 2. 4: The synthesis reaction of the dibrominated compound C3 using bromine. 
Bromination of compound C2 was affected via dissolving it in ethanol and adding 
bromine dropwise at room temperature (Scheme 2.6). Within 30 minutes a yellow 
precipitate was formed and filtered by suction filtration affording the di-brominated C3 
compound in 97% without purification.  
This reaction is an electrophilic aromatic substitution reaction (Scheme 2.7).(103), (104) 
The two  substituents of C2, amino and methyl ester groups, have a great impact in 
directing the bromide ions. The amine is an electron-donating group that significantly 
increases the activity of the aromatic ring at both ortho and para positions. The methyl 
ester substituent is electron-withdrawing, which in turn directs other substituents to 
the meta position of the aromatic ring. As a consequence, it can be envisioned that 
this reaction would be fast and drive the substitution to be on the C-2 and C-6 
positions and to be deactivating for the C-3 and C-5 positions (see scheme 2.7 for 
carbon atom positions). Noteworthy, the second introduction of bromide ion would 
likely be rather slower than the first one. That is because the bromide is an activating 
substituent, so it would deactivate the second substitution on the meta position. 
However, the impact would be minor due to presence of the other substituents.  
Electrons of the aromatic π system would attack one of the bromine atoms resulting 
in addition of a bromine atom, positively polarised, to the ortho position.  
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Scheme 2. 5: Mechanism of the synthesis of the dibrominated compound C3.  
Accordingly, the aromaticity of the ring would be restored when the other negatively 
charged bromine atom abstracts a proton. With another equivalent of bromine, the 
same mechanism would proceed for the second bromination. 
 
 
Scheme 2. 6: Atom numbering of the dibrominated compound C3. 
The dibrominated product was confirmed using 1H NMR spectroscopy (see scheme 
2.8 for atom numbering). It was noticeable that both doublets had disappeared as 
evidence that the proton substitution at aromatic C-2 and C-6 with bromine atoms 
was successful. The singlet at 8.07 ppm corresponds to the protons of C-3 and C-5. 
It was transformed from a doublet in C2 to a singlet in C3 due to the regioselective 
substitution of the protons at C-2 and C-6 with bromine atoms that removed the effect 
of the coupling between the two pairs of proton. The singlet position moved to a higher 
position characteristic of the added electron-withdrawing effect of bromide 
substituents that pull electrons away from the protons of C-3 and C-5 leaving them in 
more de-shielded situation. The chemical shift of the methyl group almost remained 
the same (3.87 ppm) due to its position distant from the changes to the compound. A 
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broad singlet peak can be recognised at 4.99 ppm corresponding to the two protons 
of the aniline group. 
During the scale up of this reaction, the product was washed with sodium thiosulfate 
to remove any bromine left. Consequently, a yellow precipitate of sulfur was formed, 
which was dissolved upon addition of 1M NaOH. This reaction was purified with flash 
chromatography giving an 82% yield of the product. 
2.2.3 Reduction of methyl ester to alcohol C4. 
In an attempt to shorten the pathway toward the required product, an alternative 
method was trialled to reduce the two subsequent steps, via reduction of the methyl 
ester C3 to an alcohol then re-oxidation of the alcohol to an aldehyde, to one step 
using DIBAL-H reagent to go directly to the aldehyde (Scheme 2.9). The ability  of the 
latter to reduce an ester to an aldehyde has been reported.(105) Thus, the ester was 
dissolved in toluene and added to a solution DIBAL-H at -70 °C. After 8 h, there was 
no apparent reaction. Due to the lack of the product this approach was not continued. 
 
Scheme 2. 7: The unsuccessful reduction of the methyl ester to the correspondent aldehyde 
using DIBAL-H. 
 
Scheme 2. 8: The reduction reaction of the methyl ester compound to alcohol C4 using LiAH4. 
Following Nicolaou’s approach, reduction of the ester compound with LiAlH4 in THF 
was carried out and afforded the alcohol compound C4 in a good yield of 90% 
(Scheme 2.10). The reaction required an excess of LiAlH4 to drive it to completion. 
Mechanistically, the reaction proceeds via a nucleophilic addition of two equivalents 
of hydride ion in two stages (Scheme 2.11). A hydride ion from LiAlH4 attacks the 
carbonyl of the methyl ester C3 of the substrate and the Li+ ion coordinates to the 
carbonyl oxygen forming a tetrahedral intermediate. This intermediate, rapidly 
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collapses and loses methoxide resulting in formation of an aldehyde intermediate. In 
the second stage of the reduction, another hydride ion attacks the aldehyde carbonyl 
while Li+ ion is coordinating to the oxygen. Then, upon work-up, aqueous ammonium 
chloride is added to protonate the alkoxide oxygen affording primary alcohol C4. 
 
 
Scheme 2. 9: Mechanism of the reduction reaction of the methyl ester C3 to the alcohol 
compound C4 using LiAH4. 
 
 
Scheme 2. 10: Atom numbering of the alcohol compound C4. 
The reduction reaction was confirmed using 1H NMR spectroscopy (see scheme 2.12 
for atom numbering). The singlet corresponding to the methyl group at 3.87 ppm in 
C3 has disappeared and a singlet of the two protons of the methylene C-7 appeared 
at 4.54 ppm. Moreover, the singlet of the aromatic protons at C-3 and C-5 moved to 
a lower position (from 8.07 to 7.40 ppm) due to loss of the de-shielding effect of the  
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ester carbonyl. The integration of the peak at 4.54 ppm was equivalent to 4, due to 
overlapping of the aniline-NH2 protons and methylene protons. 
In the larger scale synthesis, it was found that two equivalents of LiAlH4 were required 
to drive the reaction to the completion and maintain the optimum yield of 86%. 
2.2.4 Synthesis of the triazene derivative C5. 
 
Scheme 2. 11: Synthesis of the triazene-protected aniline C5 using NaNO2 and pyrrolidine. 
The triazene product C5 was afforded in a good yield of 93% after purification. Its 
synthesis consisted of two stages: 1) diazonium salt formation, by treatment with HCl 
and NaNO2, 2) triazene formation, by treatment of the diazonium salt with pyrrolidine 
and KOH (Scheme 2.13). Formation of the diazonium salt is called diazotisation and 
involves reaction of aniline with nitrous acid.  
The reaction starts when nitrous acid is formed by the reaction of NaNO2 with aqueous 
acid (Scheme 2.14). Following protonation and elimination of water, aqueous nitrous 
chloride is formed. The latter reacts with the amine through nucleophilic attack of the 
amine at the nitrogen. Following protonation, tautomerisation and elimination of 
water, the diazo salt is formed. Treatment of this salt, without isolation, with an excess 
of pyrrolidine and strong base then generates the product through direct nucleophilic 
attack of the pyrrolidine on the diazo compound followed by deprotonation by base. 
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Scheme 2. 12: Mechanism of the triazene derivative C5 formation using NaNO2 and 
pyrrolidine reagents. 
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Scheme 2. 13: Atom numbering of the triazene protected-aniline compound C5. 
1H NMR spectroscopy was used for characterization of the triazene product (Scheme 
2.15 for numbering). The two single broad peaks at 3.95 ppm and 3.73 ppm 
corresponded to the four protons of methylene C-8 and C-11 of the pyrrolidine; each 
of them integrates to two protons. The single broad peak at 2.08 ppm was assigned 
to the four protons of C-9 and C-10 of the pyrrolidine. The electron-withdrawing effect 
of the recently attached triazene group caused the singlets corresponding to the 
aromatic protons of C-5 and C-3 and methylene protons of C-7 to be moved to a more 
downfield position. 
2.2.5. Synthesis of the aldehyde compound C6. 
 
Scheme 2. 14: Oxidation reaction of the primary alcohol compound to the aldehyde C6 using 
PCC reagent. 
The aldehyde C6 was obtained via reaction of the primary alcohol with pyridinium 
chlorochromate (PCC) at room temperature for 2 h (Scheme 2.16). PCC is known for 
its toxic chromate by-product, which can make work up difficult giving rise to a lower 
yield (53%). This problem was solved by introducing silica into the reaction flask so 
that the chromate by-product adhered to the silica making the separation process 
easier. Florisil® (100-400 mesh) was used for the product filtration, which added 
another technique that improved the reaction yield up to 90%. 
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In terms of the mechanism of reaction, it is an oxidation reaction, in which the alcohol 
is oxidized to aldehyde and chromium(VI) is reduced to chromium(IV) (Scheme 2.17). 
A lone pair of the nucleophilic alcohol oxygen attacks chromium (VI), so a Cr-O bond 
forms. After the proton transfers from the positively charged OH to one of the two 
negatively charged chromium-oxygens, the other negatively charged chromium 
oxygen regenerates the Cr=O with expulsion of chloride ion. Intramolecular proton 
transfer occurs from the methylene group by the oxygen atom of Cr=O leading to 
aldehyde formation and removing the reduced chromium (IV) as a leaving group. 
 
 
Scheme 2. 15: Mechanism of oxidation reaction of the alcohol C5 to aldehyde C6 using PCC 
reagent. 
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Scheme 2. 16: Atom numbering of the aldehyde C6. 
The aldehyde product C6 formation was confirmed using 1H NMR spectroscopy 
(Scheme 2.18 for atom numbering). The aldehyde proton of C-7 produced a singlet 
at 9.84 ppm and the aromatic protons of C-3 and C-5 produced a singlet which was 
slightly deshielded compared with C5 (from 7.52 ppm to 8.02 ppm). This is because 
of the conjugation effect of the carbonyl group, reducing electron-density around the 
protons. The chemical shifts of the pyrrolidine protons remain at similar ppm shifts to 
C5 because of their distance from the newly formed aldehyde group.  
2.2.6 Synthesis of styrene C7. 
 
Scheme 2. 17: Synthesis of styrene compound C7 using n-BuLi through a Wittig reaction. 
The styrene C7 was formed in 60% yield using a Wittig reaction. n-BuLi was added 
to methyltriphenylphosphonium bromide at -20 °C under anhydrous conditions. After 
30 min, the aldehyde was added and furnished the alkene product after 3 h.  
The Wittig reaction was first demonstrated in 1953 by Wittig and Geissler.(106) It is of 
high significance for use in the synthesis of alkenes from aldehydes and ketones,(107) 
and is characterised by the production of a  C-C double bond via condensation of 
alkyl halides with carbonyl compounds by use of organophosphines.(108) The extent 
of the ylide stability plays a pivotal role in determination of the geometry of the 
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resulting olefin. Basically, non-stablised phosphonium ylides lead mainly to a cis 
alkene products (Z selectivity), whereas stabilised phosphonium ylides give rise to a 
trans alkene as a major product (E selectivity) (scheme 2.20).(109) 
 
Scheme 2. 18: Illustration of non-stabilised (a) and stabilised (b) ylide forms.(107) 
The ylide required is formed in an SN2 reaction. The lone pair of the polarised bond 
C-Li in n-BuLi attacks one of the three protons of the methyl group in methyltriphenyl 
phosphonium bromide leading to formation of the ylide. The latter would be in a 
resonance state between its polarized and double-bonded variants. Upon presence 
of the aldehyde compound the ylide would be added in 2+2 cycloaddition reaction 
forming an oxaphosphetane intermediate, which is a four-membered cyclic 
compound. This intermediate rapidly collapses to furnish the very stable triphenyl 
phosphine oxide and the styrene product (Scheme 2.21). An alternative proposal is 
that the reaction proceeds in a nucleophilic addition rather than 2+2 cycloaddition 
forming a betaine intermediate before transforming to the four-membered ring 
intermediate (Scheme 2.22).(110) 
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Scheme 2. 19: Illustartion of 2+2 cycloaddition mechanism of formation of styrene compound 
C7 through Wittig reaction. 
 
Scheme 2. 20: Nucleophilic addition proposal for styrene formation. 
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Scheme 2. 21: Atom numbering of the alkene product. 
The formation of the styrene product C7 was confirmed using 1H NMR spectroscopy 
(see scheme 2.23 for atom numbering). The two protons of the C-8 alkene furnished 
a doublet each. The first at 5.70 ppm, with coupling constant of 17.5 Hz characteristic 
of coupling to neighbouring trans-H of C-7, and the second at 5.26 ppm with constant 
coupling of 10.9 Hz, characteristic of coupling to the neighbouring cis-H on C-7. The 
proton of the alkene C-7 gave rise to doublet of doublets, at 6.55, with coupling 
constants of 17.5 Hz and 10.8 Hz. Disappearance of the aldehyde proton at 9.84 ppm 
and movement of the singlet peak of the aromatic protons (C-3 and C-5) to a lower 
chemical shift (from 8.04 to 7.57 ppm) gives further evidence of the formation of 
styrene group and disappearance of the carbonyl group. Again, the peaks of the 
pyrrolidine protons had similar shifts to C6 due to their distance away from the 
reaction site.  
 
2.2.7 Synthesis of the diol compound C8 using Sharpless AD. 
 
Scheme 2. 22: Synthesis of the diol compound C8 using AD-Mix-α through Sharpless AD 
reaction. 
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Treatment of styrene C7 with AD-mix-α furnished the diol C8. The styrene was stirred 
in t-BuOH/H2O for 8 h with AD-Mix-α. At the end of this time, C7 was still present, so 
the reaction was stirred for 24 h. After work-up, the diol C8 was obtained in 99% yield. 
This is an example of the Sharpless asymmetric dihydroxylation reaction (SAD). SAD 
involves the application of commercially available pre-mixed reagents, AD-Mix-α and 
AD-Mix-β, to generate diols in a stereoselective fashion. These premixes contain 
almost the same reagents except that they differ in the chiral ligand, AD-Mix-α 
contains a phthalazine adduct with dihydroquinine ((DHQ)2PHAL) and AD-Mix-β 
contains a phthalazine adduct with dihydroquinidine ((DHQD)2PHAL) (Figure 2.5). 
AD-Mix-β and AD-Mix-α are named so as they attack the olefin either at top face (β 
face) or at bottom face (α face) respectively (Scheme 2.25).(111) The other common 
reagents are: potassium osmate K2OsO2(OH)4 which acts as non-volatile source of 
the oxidant osmium tetraoxide, potassium ferricyanide K3Fe(CN)6, which is the 
reoxidant in the catalytic cycle, and potassium carbonate. These premixes are used 
for limited forms of olefins, which are terminal 1,1-disubstituted, 1,2-trans-substituted 
and tri-substituted olefins.(111) 
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Figure 2. 4: Chemical structure of the chiral ligands of AD-mix-α, (DHQ)2PHAL, and of AD-
mix-β, (DHQD)2PHAL.  
 
Scheme 2. 23: Illustrating how β- and α-diol results based on the attack orientation of AD-Mix-
β and AD-Mix-α. 
The importance of SAD is represented by its ability to produce pure cis-diol with great 
stereoselectivity.(112) Mechanistically, the reaction works by an asymmetric induction 
mechanism, via which a chiral ligand (catalyst) is used to convert optically inactive 
compounds to optically active (chiral) products.(113) There are two suggested 
mechanisms for SAD: a stepwise [2+2]-addition followed by rearrangement (Scheme 
2.26a), and a concerted cycloaddition [3+2] (Scheme 2.26b). The latter mechanism 
has a strong evidence base.(114) In the concept of a 3+2 mechanism, the presence of 
the ligand accelerates, to a significant extent, the catalytic reaction of AD due to its 
ability to transform OsO4 to 1,3-dipole over reaction with olefins.(115),(114) Therefore, 
depending on whether the double bond substituents of reacting olefin are electron-
donating or withdrawing, the 1,3 dipole renders the electron movement from olefin to 
the dipole and from the dipole to the olefin so slow that the stereoselectivity becomes 
much higher (see chapter 4 for full discussion of the mechanism). 
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Scheme 2. 24: Two different proposals for the Sharpless AD reaction mechanism: a) stepwise 
[2+2]-addition; b) concerted cycloaddition [3+2]. 
 
Scheme 2. 25: Atom numbering of the beta diol compound C8. 
The success of the reaction was confirmed using 1H NMR spectroscopy (Scheme 
2.27 for atom numbering). The proton of C-7 gave a doublet of doublets at 4.73 ppm 
with coupling constants of 8.04, 3.53 Hz, characteristic of coupling to neighbouring 
protons of C-8. Another two doublets of doublets peaks came out at 3.68 and 3.57 
ppm. Both corresponding to two protons of C-8 with coupling constants 11.1, 3.5 Hz 
and 11.1, 8.04 Hz respectively. These coupling constants are characteristic of 
coupling to each other and to the proton of C-7. There is a dramatic difference in 
chemical shift between the doublet corresponding to the proton on C-7 and the other 
two doublets for the protons on C-8. This is because of the presence of the secondary 
hydroxyl group attached to the same C-7 (two bonds away) in which the 
electronegativity pulls electron density away from the C-7 proton rendering it more 
deshielded. In addition, the presence of the C-7 proton close to the aromatic ring 
boosts the de-shielding effect. Polarimetric rotation was calculated at 22 °C: [α]= 
+82.05 (c=0.078 g/mL, CHCl3). The literature value at 22 °C is [α]=+79.4 (c=1.21, 
CHCl3).(99) It can be concluded that the compound C8 produced in this work is purer 
than the literature counterpart, i.e. has less the opposite enantiomere. 
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2.2.8. Synthesis of TBS-protected diol C9. 
 
 
Scheme 2. 26: TBS protection of the primary alcohol using TBSOTf. 
Compound C9 was obtained using TBSOTf with imidazole in DMF at 0 OC. Although, 
the reaction was successful, a low yield of 22% of product was obtained (Scheme 
2.28). The TBS group was introduced as it is more stable than other types of silyl 
ether protecting groups, for example, it is up to 104 times more stable to hydrolysis 
than a TMS group.(116),(117),(118) In addition, TBS is widely applied for primary and 
secondary alcohol protection due to its facile removal and compatibility with many 
chemical reactions.(119) TBS reacts very slowly with alcohols, so addition of imidazole 
or DMAP in DMF as a solvent increases its reactivity significantly.(117),(116) An initial trial 
followed the literature approach for alcohol protection. When TBSCl was used 
alongside imidazole as a base catalyst, the reaction gave no product (Scheme 2.29).  
 
 
Scheme 2. 27: The unsuccessful reaction of TBS protection of alcohol using TBS-Cl and 
imidazole. 
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Using highly reactive TBSOTf led to di-protected by-product in a yield of 32%. On 
TLC basis, the product and the TBS-diprotected by-product were recognised as two 
dense spots near the top of the plate. TBSOTf is characterized by its high reactivity  
even with more sterically hindered hydroxyl groups.(116) The TBS-diol was purified 
with flash column chromatography to be used later to regenerate the diol compound. 
This reaction was carried out using TBAF in THF as a reaction solvent giving to the 
product in 80% yield (Scheme 2.30). 
 
Scheme 2. 28: The TBS-deprotection of alcohol using TBAF reagent. 
Another trial was attempted using a different base catalyst, DMAP (0.1 equiv.) and 
anhydrous Et3N (1.5 equiv) (Scheme 2.31), alongside TBS-Cl in anhydrous DCM 
solvent. This was an attempt to avoid the di-protected by-product generated by 
TBSOTf. Interestingly, the reaction worked within 2 h and gave a 63% yield of the 
desired mono-protected compound. This approach was used for the scale-up of the 
reaction. Thus, a solution of diol and DMAP in dry DCM was cooled to 0 oC under N2. 
Dry Et3N and TBS-Cl were added sequentially and the mixture stirred for 2 h at room 
temperature. After purification with flash chromatography, the mono-protected diol 
was afforded as a yellow powder in a yield of 67%. 
 
 
Scheme 2. 29:The TBS-protection reaction of alcohol using TBS-Cl, Et3N and DMAP 
reagents. 
Herein, the mechanism of the reaction using TBSOTf is demonstrated as prototype 
of the other TBS-protection of alcohol reactions (Scheme 2.32). TBS protection of 
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alcohol C8 is a nucleophilic reaction. The lone pair on N-3 in imidazole attacks the 
polarised silicon atom in TBSOTf, displacing triflate ion as a leaving group. Since the 
intermediate is more activated, the terminal alcohol of the diol attacks the silicon atom 
expelling imidazole as a leaving group. The triflate ion deprotonates the oxonium ion 
furnishing the TBS-protected product. 
 
 
Scheme 2. 30: Mechanism of TBS-protection of primary alcohol. 
 
Scheme 2. 31: Atom numbering of the TBS-protected alcohol compound C9.  
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The TBS-protected structure was confirmed using 1H NMR spectroscopy (see 
scheme 2.33 for atom numbering). The most characteristic change is the emergence 
of two large single peaks at 0.94 and 0.07 ppm, which correspond to the nine protons 
of C-16, C-17, and C-18 and six protons of C-13 and C-14 respectively. The 
integration of the former was nine and for the later was six which indicated the tertiary 
butyl and dimethyl groups respectively. The polarimetric rotation value was observed 
at 22 °C: [α]=+18 (0.026 g/mL, CHCl3). The literature value was +22.8. (c=1.43, 
CHCl3).(99) Therefore, it can be inferred that the purity of compound C9 is slightly less  
than that of the literature compound, i.e. has more the ooposite enantimere. 
2.2.9. Synthesis of azide compound C10. 
 
Scheme 2. 32: Mitsunobu reaction for azide formation using Ph3P, DEAD, and DPPA 
reagents. 
The azide C10 was obtained using Ph3P, DPPA and DIAD (Scheme 2.34). Because 
of toxicity concerns DIAD reagent was used instead of DEAD.(120) The Mitsunobu 
reaction is one of the most useful reactions in organic synthesis for producing various 
acid derivatives such esters, imides, ethers, azides, and so on.(121) This reaction 
proceeds via dehydrative coupling of an alcohol with a suitable nucleophile. The most 
important characteristic feature of this reaction is the stereochemical inversion of the 
alcohol substrate.(122),(120) Three proposals have been made for the mechanism via 
which the first step of Mitsunobu reaction proceeds and leads to formation of the 
betaine intermediate (Scheme 2.35):  
1) Michael-type nucleophilic attack,  
2) Single electron transfer (SET), and  
3) [4+2] cycloaddition reaction followed by ring opening.  
Michael type reaction is the more accepted mechanism for the first step.(123) 
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1) 
 
 
2) 
 
3)  
 
Scheme 2. 33: The three proposals of the mechanism of the first step in Mitsunobu reaction 
for azide formation; 1) Michael addition, 2) Radical reaction, 3) Cycloaddition reaction. 
In general, the mechanism of Mitsunobu reaction involves three steps: 1) Adduct 
formation, in which a dialkylazodicarboxylate and Ph3P react with each other in a 
nucleophilic reaction to form a betaine intermediate. 
2) Alcohol activation, in which the alcohol is deprotonated to form oxyphosphonium 
ion. Formation of the oxyphsphonium ion relies mostly on basicity of the conjugate 
base of the adduct and reduced polarity of the solvent.  
3) Reaction of the nucleophile with the oxyphosphonium intermediate via SN2 
reaction, which is accompanied by complete inversion in stereochemistry.(124)  
Triphenyl phosphine (Ph3P) attacks diisopropylazodicarboxylate (DIAD) in a 
nucleophilic reaction (Michael-addition reaction) leading to formation of a betaine 
intermediate (Scheme 2.36). The latter deprotonates the alcohol substrate to form an 
ion pair of phosphonium and alkoxide ions, which carries out a nucleophilic attack on 
the phosphonium ion forming compounds 4 and 5. The compound 5 then attacks 
diisophenyl phosphorylazide releasing the azide anion. Then, the azide ion attacks 4 
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in SN2 nucleophilic reaction affording the azide compound C10 and triphenyl 
phosphine oxide. This addition of the azide is characterized by a complete inversion 
in stereochemistry of the original hydroxyl group. 
 
Scheme 2. 34: Mechanism of Mitsunobu reaction for azide product C10 formation.  
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Scheme 2. 35: Atom numbering of the azide product C10. 
In this case, 1H NMR gave little information about the formation of the azide 
compound. Therefore, the presence of azide group was confirmed with FT-IR as a 
peak was present at 2100 cm-1. On the NMR spectroscopy (see scheme 2.37 for the 
atom numbering) two peaks were present, a multiplet and doublet, at 5.5 and 1.6 ppm 
respectively. These peaks correspond to isopropanol, which was formed as a by-
product through the use of DIAD. The doublet of doublet peak corresponding to the 
proton of C-7 slightly shifted upfield (from 4.66-4.49 ppm), which is explained as the 
azide group is less electronegative than hydroxyl group, which makes the proton of 
C-7 less deshielded. The two doublets of doublets at 3.78 and 3.71 ppm which 
correspond to the two protons of C-8 are superimposed over the broad singlet that 
corresponds to the protons of either C-9 or C-12 of pyrrolidine. 
Although this reaction was successful on small scale synthesis (up to 0.5 g, 1.00 
mmol), on scale up to just twice this amount, the exact product was not identified 
(although starting material was consumed). As this was the case, the SM was divided 
into thirteen 0.5 g batches and the reactions were carried out in parallel on this scale. 
The presence of the side product isopropanol proved difficult to remove, making a 
yield difficult to quantify and so this material was used as crude form in the next 
reaction. The polarimetric rotation value was observed at 22 °C: [α]= - 102 (0.076 
g/mL, CHCl3). The literature value: - 43 (c=1.30, CHCl3).(99) Obviously, the rotation 
value of C10 is much more than that of the literature value, which indicates that the 
purity of C10 is much higher than the literature compound. 
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2.2.10. Synthesis of amine compound C11. 
 
Scheme 2. 36: Reaction of azide reduction to an amine product using Ph3P reagent. 
Reduction of azide to amine was carried out on crude C10 using Ph3P (Scheme 2.38). 
This reaction, a Staudinger reaction, mechanistically involves nucleophilic addition of 
Ph3P to the terminal nitrogen atom of azide forming a phosphazide intermediate, 
which rapidly loses a nitrogen molecule giving the iminophosphorane compound 
(Scheme 2.39). Upon addition of water, iminophosphorane is hydrolysed affording the 
amine C11 compound and the phosphine oxide by-product. 
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Scheme 2. 37: Mechanism of azide reduction to the amine C11 using Ph3P. 
 
 
Scheme 2. 38: Atom numbering of the amine compound C11. 
The amine product was confirmed using 1H NMR spectroscopy (see scheme 2.40 for 
atom numbering). A significant change in chemical shift was noticed for the doublet 
of doublets peak corresponding to the proton of C-7, where it was shifted upfield from 
4.5 to 3.93 ppm. That is explained as the azide reduced to amine which is less 
97 
 
electron-withdrawing so the proton of C-7 would become more shielded with electron 
density. Moreover, a broad singlet peak has emerged at 6.45 ppm, corresponding to 
the amine protons. In spite of repeated purification, the isopropanol peaks were still 
seen in the spectrum of the amine’s product. Again, the crude material was submitted 
to the next step. Reaching this point, formation of the amine, was a crucial step as it 
was the entrance to the Fmoc-protection, which is the cornerstone in the project plan. 
Also, it was only few steps from the final desired compound. The polarimetric rotation 
value was observed at 22 °C: [α]= - 10.7 (0.11 g/mL, CHCl3), and the literature’s value: 
-22.0 (c=1.53, CHCl3).(99) The big difference between the two values reflects the 
difference in the purity, i.e. C11 is less pure than the literature compound. 
2.2.11. Synthesis of Fmoc-protected compound C12. 
 
Scheme 2.39: Fmoc-protection reaction of the amine compound using Fmoc-Cl. 
Given the project objective is the synthesis of vancomycin using solid phase synthesis 
methods, Fmoc-protection of the amine was required. Therefore, treating the amine 
product with Fmoc-Cl afforded the Fmoc-protected as crude product due to the 
presence of isopropanol. This reaction was affected by dissolving the amine C11 in 
THF at 0 °C and adding aqueous NaHCO3 and Fmoc-Cl sequentially affording the 
Fmoc-protected compound C12 in 50% yield over the last three steps (Scheme 2.41). 
The mechanism of this reaction starts with the nucleophilic attack of the primary 
amine on the carbonyl atom and formation of a tetrahedral intermediate (Scheme 
2.42). The carbonyl group is reformed and chloride ion removed as a leaving group. 
Loss of a proton furnishes the Fmoc-protected amine and HCl.  
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Scheme 2. 40: Mechanism of Fmoc-protected amine compound C12. 
 
Scheme 2. 41: Atom numbering of the Fmoc-protected amine compound C12. 
The attachment of Fmoc group was confirmed using 1H NMR spectroscopy (Scheme 
2.43 for atom numbering). The spectrum peaks appeared broadened when 
chloroform solvent was used but in DMSO they were sharp enough for assignment. 
The Fmoc group emerged as six chemical shifts, four in the aromatic region at 7.92, 
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7.72, 7.44, and 7.35 ppm each of which integrates for two protons. The first two peaks 
at 7.92 and 7.72 ppm shifts are doublet and multiplet corresponding to protons of 
carbons (C-17, C-26) and (C-20, C-23) respectively. The protons of C-17, C-26 
experienced more de-shielding than the protons of carbon C-20, C-23 due to the 
closer position to the amide bond which is electron-withdrawing. In conclusion, the 
protons of carbons (C-20, C-23) are farther from the amide bond so their 
representative doublet (7.72 ppm) is slightly lower in the NMR spectrum. 
The peaks at 7.44 and 7.35 are multiplets corresponding to protons of carbons (C-
18, C-25) and (C-19, C-24) respectively. The other two of the six Fmoc group peaks 
are the doublet at 4.26 ppm and the triplet at 4.18 ppm, corresponding to the two 
protons of methylene C-14 and the proton of the tertiary C-15. Obviously, the latter 
two groups of protons are quite de-shielded because of the direct influence of the 
withdrawing effect of the amide bond. In addition, one of the quite prominent changes 
in the NMR spectrum for Fmoc-protected compound is the shift in the peak of the 
proton of C-7 to a higher chemical shift, 4.64 ppm, that is explained by its close 
position to the newly formed amide bond (two bonds distance). Moreover, it is 
noticeable that the multiplet for two methylene protons of C-8 has moved to a higher 
chemical shift, 3.72 ppm, also because of the influence of the amide bond. The 
polarimetric rotation value was observed at 22 °C: [α]= - 42.9 (0.067 g/mL, CHCl3). 
2.2.12. Deprotection of TBS group producing alcohol 
compound C13. 
 
Scheme 2. 42: Deprotection of TBS protection group forming the alcohol compound C13. 
As has been mentioned earlier in this chapter, use of TBS protecting groups has been 
of importance due to its facile installation and removal, stability, and suitability for 
many of reactions.(119),(125) Herein, a TBS-deprotection was carried out with 
tetrabutylammonium fluoride (TBAF) (Scheme 2.44). The mechanism involves a 
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nucleophilic attack of the fluoride ion of TBAF onto the silicon atom forming a very 
strong Si-F bond (Scheme 2.45). This strong bond would be the driving force of the 
cleavage. Thus, after forming a pentavalent intermediate, the alkoxy group acts as a 
leaving group so the bond between oxygen and silicon breaks forming an alkoxide 
ion which abstracts a proton from water affording the alcohol product C13. Since the 
presence of water in TBAF solution would generate a basic solution which strongly 
affects the protection of amine, the addition of acetic acid is very productive approach 
to neutralize that basic condition leading to a significant increase in the product yield 
(95%).(126) Therefore, addition of 3 equivalents of acetic acid was helpful and 
increased the amount of the product 2-fold. However, it also slowed the reaction rate 
down, so the reaction time increased from 2 h to 6 h. 
 
Scheme 2. 43: Mechanism of TBS-deprotection using Bu4NF. 
 
 
Scheme 2. 44: Atom numbering of the alcohol compound (TBS-deprotected) C13. 
TBS-deprotection was confirmed with 1H NMR (see scheme 4.46 form atom 
numbering). Obviously, the three peaks of TBS group at 0.85 ppm, 0.01 and at -0.02 
ppm in C-12 compound were no longer present in the NMR spectrum of the C13 
compound. In addition, a new triplet peak at 4.97 ppm which integrates to one proton, 
corresponds to the primary hydroxyl group, restored after TBS-deprotection. The 
multiplet peak at 3.63-3.52 ppm corresponded to the four protons of the C-8 
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(methylene) and C-12. Noticeably, the peak corresponding to the protons of C-8 
moved slightly to a lower position, comparing to the C-8 in the compound C12, to be 
overlapped with the signal of C-12 in the pyrrolidine moiety. That is because of a 
reduction in the electron-withdrawing influence of alcohol in comparison to the TBS 
protecting group. As has been mentioned earlier above, acetic acid was added to 
neutralise the basic by-product of TBAF reagent. Although addition of acetic acid 
increased the productivity significantly, the reaction lasted longer to completion (6 h 
rather than 2 h). A pinkish fluffy powder of alcohol was obtained from TBS 
deprotection step. The polarimetric rotation value was observed at 22 °C: [α]= - 32.4 
(0.056 g/mL, CHCl3). 
2.2.13. Oxidation of alcohol to carboxylic acid using TEMPO 
C14. 
 
Scheme 2. 45: Reaction of formation of the carboxylic compound C14 using TEMPO 
reagent. 
The alcohol was oxidised to a carboxylic acid by using the above reagents (scheme 
2.47). The product was afforded in 65% yield and the right molecular weight was 
confirmed with high resolution MS. The selective oxidation of alcohol to aldehyde or 
carboxylic acid that was described by Anelli et al, posed a breakthrough for an easy, 
fast and cheap type of oxidation.(127) The mechanism of this reaction proceeds on two 
oxidation stages: 1) conversion of alcohol to an aldehyde, 2) conversion of aldehyde 
to a carboxylic acid.  
 After formation of oxoammonium salt from oxidization of TEMPO radical with 
potassium bromide, it is attacked by the deprotonated alcohol substrate with the basic 
reagent, NaHCO3, forming an intermediate adduct (Scheme 2.48). This adduct 
undergoes either intramolecular or intermolecular proton abstraction leading to 
formation of hydroxylamine and aldehyde product.(127) In order for the oxidation 
process to further proceed to afford the required carboxylic acid, the oxoammonium 
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salt has to be regenerated. Therefore, sodium hypochlorite is added as a co-oxidant 
to accomplish this task by oxidizing bromide to hypobromite which functions as a 
secondary oxidant to regenerate the primary oxidant, oxoammonium salt (scheme 
2.49).(128) Thus, with the presence of water, aldehyde would be in equilibrium with its 
hydrated form which in turn undergoes the same fate of oxidation in presence of 
oxoammonium salt to end up with carboxylic acid (Scheme 2.50). 
 
Scheme 2. 46: Illustartion of formation of oxoammonium ion and its role in formation of the 
aldehyde intermediate. 
 
Scheme 2. 47:  Illustrates the role of KBr in oxidation of alcohols into corresponding carboxylic 
acid using TEMPO oxidizing reagent.(128) 
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Scheme 2. 48: The oxidation stage of aldehyde to the corresponding carboxylic acid with 
oxoammonium salt. 
It is important to illustrate some tips about TEMPO oxidation reaction in terms of 
conditions and reagents being used: 
1) It is more selective for primary alcohols than for secondary, as steric hindrance 
plays a role in this sense. 
2) To take the oxidation process further to the carboxylic acid formation, it is 
important to keep the reaction temperature as low as 0 oC in presence of 
water. The oxoammonium salt decomposes in aqueous medium at room 
temperature. 
3) The oxidation is accelerated at slightly basic pH, 8.6, which is provided by 
addition of NaHCO3. Whereas at very high pH the concentration of HOBr 
would be too low to oxidize hydroxylamine to oxoammonium slat which in turn 
oxidizes aldehyde to carboxylic acid. 
4) Biphasic solvent is of high importance if the alcohol oxidation is required to 
proceed to the carboxylic acid stage. Otherwise, the oxidation is more likely 
to stop at the aldehyde stage.(129) 
 
 
Scheme 2.49: Atom numbering of the carboxylic acid compound. 
The assignment for this amino acid C14 was confirmed using 1H NMR spectroscopy 
(see scheme 2.51 for atom numbering). The first sign that oxidation was affected 
successfully, the disappearance of the peak of protons of C-8 from the spectrum. 
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Secondly, the transfer of the doublet peak of the C-7 proton to a singlet peak and its 
movement to a higher ppm shift was another effective evidence that the oxidation was 
complete and the characteristic coupling to the neighbouring protons was lost. The 
polarimetric rotation value was calculated at 22 °C: [α]= - 28.4 (0.062 g/mL, MeOH). 
2.3. Summary. 
This chapter discusses the first successful synthesis of the central amino acid of 
vancomycin protected for Fmoc-synthesis and set up for the application of, for 
example, Ullman type coupling reactions to form cyclic ethers with neighbouring 
tyrosine analogues. Interestingly, the compound could also be incorporated into other 
peptides and used to introduce other functionality though, for example, cross coupling 
reactions. The synthesis is highly efficient, with several steps having high yields that 
are consistent in moving to scale-up reactions to produce the amounts required for 
solid phase synthesis. Only the Mitsunobu reaction proved intractable to scale-up and 
required multiple small-scale reactions. The reasons for this are not clear but it may 
be that for example, mixing was less efficient on a large scale and that is crucial for 
the reaction. In the next chapter, efforts to apply the compound to the solid phase will 
be described. 
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Chapter 3. 
Investigation of eligibility of the synthesised 
central amino acid to the solid phase synthesis. 
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3.1. Solid phase synthesis. 
Proteins and peptides have a significant position in all biological processes across all 
kinds of living organisms. Peptides in particular, have entered the therapeutic field 
and medicinal research as a starting structure for many pharmaceutical and 
therapeutic agents due to their small size.(130) Recently, the tendency towards the use 
of peptides in pharmaceutical industry has increased tremendously as there are more 
than 100 peptides in therapeutic use and more than 400 in clinical trials.(131) Solution 
phase synthesis and SPPS represent the main methods of chemical synthesis of 
peptides.(132) SPPS, in particular, has had a crucial role in the thriving peptide industry 
due to its efficiency, feasibility, and facile purification procedures.(131) It was first 
described by Merrifield in 1963 as a possible means for linking four amino acids to 
each other via an amide linkage making a tetrapeptide.(133) Although many bids to 
improve the implementation of SPPS or to discover more efficient methods have 
being trialled, SPPS remains as the method of choice for peptide synthesis over a 
broad spectrum of scales from milligrams to multi-kilograms.(134) 
The basic principle of the SPPS strategy largely relies on four fundamentals (Scheme 
3.1): i) using a solid support, to which the first amino acid is attached; ii) convenient 
protecting groups for N of amino acid and the side-chain functions; iii) coupling 
reagents for carboxylic acid activation; and iv) a suitable system for deprotection of 
the side chain-protecting group and final release of the peptide.(135),(136) The synthesis 
of peptides on solid phase progresses from the C-terminus rather than N-terminus. 
This is to minimize the racemisation problem that accompanies the formation of 
oxazolones. The latter is formed via activation of the C-terminus and leads to a large 
amount of racemisation under basic conditions.(137) Two common methods are used 
in SPPS; 
1) The Boc/Bz strategy, which uses acid labile tert-butyloxy carbonyl(80) for temporary 
amine protection and benzyl for side chain permanent protection.  
2) The Fmoc method, which adopts base labile 9-fluorenylmethoxy carbonyl (Fmoc) 
for the α-amine protection.  
The Boc method is less preferred nowadays than the Fmoc strategy due, mainly, to 
the requirements for a highly toxic and corrosive HF cleavage step to remove the 
peptide from the resin.(138) The base-lability of the Fmoc group has offered an 
orthogonal nature to other acid-labile side chain-protecting groups such as tert-butyl 
ester, ethers and carbamates. This has offered it more applicability in various 
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chemical syntheses.(139) In addition, its simplicity and efficiency have made it a most 
efficient method for obtaining active therapeutic peptides.(140) A TFA-based cleavage 
system is used in Fmoc chemistry for side chain deprotection and for the release of 
the peptide at the end of the synthesis.(136) 
In general, SPPS has several limitations: 1) aggregation of relatively long peptides at 
a certain point, which leads to difficult accessibility of reagents to the reactive sites; 
2) the use of excess solvents and reacting reagents, which can lead to increases in 
toxicity exposure and in the procedure cost, 3) the presence of secondary amines or 
bulky side-chain protecting groups could cause a decrease in reaction rate as a result 
of steric hindrance, and 4) long reaction times and repetitive steps.(141) 
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Scheme 3.1: The steps of solid phase synthesis process; 1) resin loading, 2) N-deprotection, 
3) coupling process, 4) cleavage process. NPG: N-protecting group, X: activator, SPG: side-
chain protecting group, Aa: amino acid. (Taken from reference (138)). 
The most common side chain protecting groups, solid supports, linkers and coupling 
reagents are outlined below. 
3.1.1. Side chain protecting groups. 
The main function of the side chain protecting group is the prevention of side reactions 
of the amino acids and the formation of branched peptides.(142) The nature of the side 
chain function of the amino acid determines the choice of the protecting group.(142) 
For example, 4-methoxy-2,3,6-trimethylbenzene sulphonyl (Mtr) is commonly used 
for protection of the guanidine group in Arg, and 2-chlorobenzyloxy carbonyl is used 
for side chain protection of Lys. Tert-butyl ethers are used for protection of the 
hydroxyl functionality of Ser, Thr and Tyr, as ethers confer more stability than other 
protecting groups for hydroxyl side chain.(139, 143) Tert-butyl esters are utilised for side 
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chain protection in Asp and Glu.(139) The combination of Fmoc/tBu is the most 
commonly used strategy in solid phase peptide synthesis.(144) The concentration of 
the acid used for the removal of the side chain protecting group is based on the lability 
of the protecting group itself. For example, t-butyl (tBu), is removed with high 
concentrations of TFA (90% TFA in DCM), while, 2-chlorotrityl (2-Cl-Trt) can be 
cleaved with only 1% TFA in DCM.(142)  
Allyloxy carbonyl (Alloc) protecting group strategies can be used as an alternative or 
alongside the Boc or Fmoc strategy, due to its removal orthogonality.(145) The 
possibility of deprotection of Alloc function under neutral conditions, catalysed by 
Pd(PPh3)4 and phenylsilane as scavenger, in DMF confers a high selectivity for 
deprotection in the presence of other protecting groups.(146, 147) The main use of the 
Alloc group is for the synthesis of cyclic and branched peptides in three-dimensional 
orthogonal protocols alongside Fmoc and tBu.(148) The amino-side chain function is 
more basic than α-amino group and hence their protecting groups are more difficult 
to remove.(142) Therefore, a more electron rich group (e.g. Mtt) is chosen for protection 
of an amino side chain (e.g. ω-amino group).(142) Table 3.1 illustrates the commonly 
used protecting groups in SPPS, their uses, and removal conditions. 
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Table 3.1: The commonly used protecting groups in SPPS, their uses, and their removal 
conditions. 
3.1.2. Solid support resin. 
The solid support is the essential element in SPPS, which its success, to a large 
extent, depends on. It should have several features to be competent for use in SPPS, 
which can be listed as follows:  
Protecting group Main Use Removal condition 
t-Butyl (tBu)  
α-carboxylic 
acid protection 
90% TFA-DCM (solid and 
solution phase) 
2-Chlorotrityl (2-Cl-Trt)  
α-Carboxylic 
acid protection 
1% TFA-DCM 
Trityl(Trt)  
α-Amino-group 
protection 
1% TFA-DCM 
9-Fluorenylmethoxycarbonyl (Fmoc) 
 
α-Amino-group 
protection 
20% Piperidne-DMF 
Allyloxycarbonyl (Alloc) 
 
α-Amino-group 
protection 
Pd(PPh3)4 cat., 
PhSiH3 scavenger 
t-butyloxycarbonyl (80) 
 
α-Amino-group 
protection 
25-50% TFA-DCM 
4-Methyltrityl (Mtt) 
 
ω-amino group 
protection 
1% TFA-DCM 
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1) Resistance to the various conditions used in SPPS, from basic to highly acidic.  
2) Good swelling properties in different solvents.  
3) Good accessibility for the different reagents used in the process.  
4) Mechanically stable.(80, 149)  
Accordingly, different solid supports have been developed (Figure 3.1). Polystyrene 
(PS) based resins are commonly used due to their mechanical and chemical stability, 
good swelling in organic solvents and they are cheap and easy to functionalise.(150) 
PS crossed-linked resins have more mechanical resistance and improved swelling 
properties, for example Merrifield resin (MR) is PS resin crossed linked to 2% with 
divinylbenzene (DVB).(149, 151) Other important types of resin used in SPPS are 
polyethylene glycol (PEG) resins, which have good swelling properties in both organic 
and aqueous solvents. However, their high hydrophilicity and ability to act as a Lewis 
acid sometimes limits their use.(149) PS cross-linked to PEG offers more swelling 
features in comparison to DVB-PS.(152) In 2000 Jandajel resin, a PS resin cross linked 
to tetrahydrofuran, was introduced as a resin that swells twice as well as MR.(153) To 
improve their compatibility with polar solvents, solid supports were incorporated with 
polar matrices like polyester, polyamide, and polysaccharides. However, these 
matrices contain a high chemically active species interfering with many reactions on 
solid phase that restrict their utility.(152) In conclusion, although it emerged back in the 
first evolution of SPPS, MR is still the support of choice for most syntheses on solid 
phase, mainly due to its compatibility with a lot of chemical reactions.(153) 
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Figure 3.1: The common used solid supports in SPPS. 
3.1.3. Linkers used in SPPS. 
The linker is a molecule that has two functionalised ends, the first end is attached to 
the solid support in a permanent way, while the second end is linked to the developing 
peptide chain in a temporary manner. Connection of the peptide to the solid support 
via a linker has the following advantages: 
1) It provides more flexibility for the use of a wider range of previously functionalised 
solid support. 
2) It reduces undesirable reactions, including racemisation, to the minimum.  
3) It facilitates the monitoring of yields of growing peptide at any step. 
4) The loading level can be determined and controlled easily with the use of linkers. 
 5) It can be adjusted to provide optimal yields in the attachment and cleavage 
steps.(154)  
In addition, the most important properties of the linker are that it should be inert during 
coupling and deprotection steps, attach efficiently to the first building unit, and the 
conditions used for peptide release should not influence the final products.(155) 
Acid labile linkers are most widely used in SPPS Fmoc/tBu strategy. The stability of 
the carbocation formed after treatment with acid, mostly TFA, specifies the acid lability 
of the linker. Thus, the more stable carbocation, the more acid labile the linker. For 
example, the carbocation of trityl compounds is more stable than other types of linker 
like benzhydryl and benzylic structures. In general, there are three chemical 
categories of linkers: 1) benzyl-based linkers like Sheppard and HAL linkers, 2) 
benzhydryl-based linkers, such as Rink acid and Rink chloride analogue, and 3) trityl-
based linkers, such as 2-chlorotrityl chloride linker (2-Cl-TC).(154, 155) The latter is 
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more commonly used due to the following: 1) It can be reused for another cycle of 
synthesis, 2) its use results in minimum formation of diketopiperazine side product 
due to steric hindrance effect of the trityl group, 3) the first amino acid attachment is 
accompanied by relatively low epimerization, and 4) it allows for peptides to be 
released under low acidic conditions.(154) The commonly used linkers are depicted in 
figure 3.2. 
 
 
Figure 3. 2: Commonly used linkers in SPPS. 
3.1.4. Coupling reagents. 
Formation of the amide linkage is not spontaneous and can occur directly only under 
high temperatures.(156) Therefore, the presence of coupling reagent for conversion of 
OH in the carboxylic acid into a good leaving group is necessary for the integrity of 
the reactants.(156) Coupling reagents can be defined as reagents used to link two 
amino acids by activation of the carbonyl group in the C-terminal part of the first amino 
acid to be attacked by the nucleophilic amine group from the other amino acid, 
forming the peptide bond (Scheme 3.2).(157) A typical procedure for peptide bond 
formation is by dehydrative coupling between a carboxylic acid and an amino 
group.(158) The ideal coupling reagent should have the following properties: 1) 
increase the coupling reaction rate, 2) keep side reaction production to a minimum, 
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and 3) effectively work through difficult steps, for example, when the peptide is 
aggregated where the access of the reagents become difficult to the active sites.(159) 
There are many coupling reagents that have been developed for activation of the 
carboxylic acid group. The main chemical categories of these reagents are 
carbodiimides such as DCC and DIC, phosphonium reagents such as BOP and 
PyBOP, aminium/uronium salts as HBTU and HATU.(157, 158) 
 
 
Scheme 3. 2: Coupling step mechanism of formation of peptide bond. 
 Mainly, there are three undesirable reactions intrinsically associated with coupling 
procedure (Scheme 3.3). Namely, N-carboxy-anhydride formation associated with 
carbamate-protected α-amine (Scheme 3.3a), formation of diketopiperazine which 
usually occurs after formation of a dipeptide (Scheme 3.3b), and formation of a 
guanidine by-product when aminium/uronium coupling reagents are used (scheme 
3.3 c). Guanidination occurs either by attack of the amino group on the coupling 
reagent and/or when the carboxylic acid is slowly activated by the reagent due to 
steric hindrance.(157, 160) In addition, racemisation of the amino acid is one of the 
challenging issues in SPPS that is associated mostly with activation of carboxylic acid 
terminus with carbodiimide forming an oxazolone (Scheme 3.4).(161) Therefore, 
addition of additives, for example HOBt, has been considered as one of the solutions 
to suppress or minimize this problem.(161) 
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Scheme 3. 3: Side reactions in the coupling step; a) formation of N-carboxyanhydride, b) 
formation of diketopiperazine, c) formation of guanidinated side product. 
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Scheme 3. 4:  Racemisation side reaction in SPPS during coupling step using carbodiimides. 
3.1.4.1. Carbodiimides. 
As has been mentioned earlier in this chapter, the typical examples of carbodiimides 
are DCC and DIC. Their efficiency and low cost are behind their extensive use in 
peptide synthesis. Due to its insoluble by-product, which can be separated easily, the 
use of DCC is encouraged in solution phase.(160) This property has been problematic 
in SPPS especially in the synthesis of long peptides. Therefore, use of DIC has been 
suggested as an alternative due to relative solubility of its by-product in DCM.(160) Use 
of carbodiimides leads to formation of a highly reactive intermediate called an O-
acylisourea (Scheme 3.5), which can undergo a rearrangement forming less active 
species.(161) Use of additives, has improved the activity of carbodiimides in terms of 
increasing the reaction rate and minimising the racemisation via conversion of O-
acylisourea to active esters.(161) The latter are characterised by less activity and 
more stability than O-acylisourea.(161) Therefore, these additives can prevent the 
conversion of the O-acylisourea intermediate to inactive N-acylurea or oxazolone, 
which can lead to racemization (Scheme 3.5).(162) HOBt is one of hydroxylamine 
additives which have been used in this regard. EDC/HOBt was applied by Boger in 
the synthesis of vancomycin for the closure of the AB ring system.(163)  
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Scheme 3. 5: Conversion of o-acylisourea into inactive species, N-acylures or O-acylisourea.  
3.1.4.2. Phosphonium reagents. 
These reagents do not contain a guanidinium moiety and hence do not generate 
guanidinated by-products.(156) The most common phosphonium salts are those of  
HOBt or HOAt based reagents.(156) BOP (Benzotriazol-1-yloxy) tris(dimethylamino) 
phosphonium hexafluorophosphate) is the typical example of phosphonium reagents 
associated with good yields and few and easily separable side-products.(164) It is an 
HOBt derivative, contains a dimethylamine moiety which was replaced with 
pyrrolidine in more recent reagents as PyBOP.(165) Pyrrolidine reacts with a carboxylic 
acid forming a pyrrolidide derivative.(165) PyBOP is also an HOBt analogue 
phosphonium  salt (Figure 3.3) and was one of set of reagents introduced to avoid 
the formation of the carcinogenic hexamethyl phosphoramide (HMPA)-side product 
that is generated with BOP reagent.(166) It is mainly useful in cyclisation steps, due its 
efficiency in activation of hindered amino acids, and as alternative to the uronium 
reagents when guanidination is a problem.(165)  
 
 
 
 
 
118 
 
 
Figure 3. 3: Chemical structure of phosphonium reagents, a) BOP, b) PyBOP. 
3.1.4.3. Aminium/uronium reagents. 
In general, these reagents are much more stable than corresponding phosphonium 
reagents and confer more efficient and rapid coupling process.(167, 168) Their use is 
associated with formation of toxic by-product, tetramethylurea.(168) HBTU is 
considered as the precursor of all other uronium reagents.(164) Structurally, it contains 
guanidine group and hexafluoro phosphate as a counter ion.(157) HATU is an HBTU 
analogue, which displays more stability and coupling efficiency.(164) Due to the 
reaction of the guanidine group with the free amine, these reagents can form 
guanidinated peptide side-product which results in blockage of peptide elongation.(167) 
Uronium reagents have a similar coupling mechanism to phosphonium reagents. So, 
the mechanism is based on formation of activated alkyl ester for carboxylic acid 
activation. In case of HATU, it reacts with the carboxylate forming HOAt ester and 
releasing tetramethylurea as side-product. The HOAt ester then reacts with available 
amine to afford the corresponding peptide, via formation of amide bond, and releasing 
HOAt as by-product (Scheme 3.6).(168)  
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Scheme 3. 6: Mechanism of activation of carboxylic acid of amino acid by HATU coupling 
reagent. 
In terms of solvents, DMF is the most convenient solvent for all coupling reagents in 
terms of stability and activity.(166) In addition, it has been found that the carboxylate 
anion is necessary for an efficient activation therefore presence of base, DIPEA, is 
crucial in this regard.(166, 169) 
3.2. The practical aspect of solid phase synthesis. 
With the analogue of the central residue C14 in hand, it was the time to demonstrate 
the eligibility of this residue to the solid phase. Therefore, this chapter discloses 
multiple trials of coupling of this amino acid to other amino acid analogues of 
vancomycin on the solid phase. Two issues had to be taken into the consideration, 1) 
the conditions used for the peptide cleavage should not be as highly acidic as it may 
deprotect the triazene moiety, the cleaving condition of triazene group is 50% 
TFA/DCM. So, the choice of the solid support (resin) had to be cleavable with low 
acidic condition. Therefore, the 2-chorotrityl chloride was the resin of choice for this 
task. Peptide loaded on the chlorotrityl resin can be released with 1% TFA in DCM. 
2) The amino acid analogues to be coupled to the central residue should be 
structurally convenient for the potential macrocyclisation. In other words, the coupled 
analogue, alongside the triazene residue, should be a suitable substrate for the 
reaction condition that will be used for the potential macrocyclisation step. 
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3.2.1. Attempted syntheses of a tetrapeptide containing the 
triazene-protected compound. 
For the first experiment, to be consistent with our initial proposal of using sensitive 
acid labile linker, the commercially available preloaded tyrosine 2-chlorotrityl resin (H-
Tyr(tBu)-2-ClTrt resin) was chosen (Figure 3.4). The amino acid is attached to the 
linker via an ester bond with a substitution level of 1.6 mmol/g. The latter is defined 
as an estimation of the amount of the first amino acid loaded on the resin.(170) 
   
 
Figure 3.4: Chemical structure of preloaded tyrosine 2-chlorotrityl resin. 
As discussed, peptides can be released from the 2-ClTrt linker with 1-5% TFA/DCM. 
Additives such as HOBt were not used in the coupling reaction as the acidic nature 
of the compound could lead to triazene deprotection.(171) A standard procedure in 
SPPS is resin swelling. This step is performed to facilitate access of the reagents to 
the active sites of the substrates attached to the resin by expanding the resin 
beads.(172) Thus, 3 ml of DMF was added to the resin in the peptide vessel reactor 
and allowed to shake for 10 min. This procedure was repeated three times, draining 
the solvent after each time period. The coupling step was performed using equimolar 
quantities (4 equiv.) of both the amino acid and the coupling reagent, HATU. As has 
been mentioned previously, reaction of HATU with a free amino group could result in 
a blocked-peptide, therefore, both the amino acid of free carboxylic group, and HATU 
were mixed separately in a minimum amount of DMF. DIPEA was added to the 
mixture in an excess (10 equiv.) to generate the carboxylate ion, which is necessary 
for the coupling reaction. The coupling mixture then was added immediately to the 
resin-bound N-deprotected amino acid and agitated for 30 min. HATU is used due to 
high yields and high efficiency, even for more sterically hindered coupling reactions. 
Although, its structure is similar to HBTU structure, it causes less epimerization.(173) 
After completion of the reaction, the solution was filtered and the resin washed five 
times with 5 ml of DMF. For the next step, the Fmoc-protected N-terminus of the resin-
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bound peptide was subject to deprotection. This step was carried out with 40% 
piperidine added to the peptide vessel, which was shaken for 10 min. Then, the 
solution was filtered followed by addition of 5% piperidine and shaken for 5 min. The 
last step was repeated twice. The solution was filtered and the resin washed with 
DMF. Monitoring of the coupling and deprotection steps used the Kaiser test. This 
test was first introduced in 1970 by E. Kaiser and co-workers for rapid detection of 
coupling reactions in SPPS.(174) It is a colour test based on formation of a 
chromophore compound called Ruhemann’s purple from reaction of ninhydrin with 
the amine group. (175) The Kaiser test is composed of three solutions, i) 0.5 g of 
ninhydrin/10 mL alcohol, ii) 0.8 g of phenol/20 mL alcohol, iii) 2 mL of KCN solution 
(0.001 M) diluted up to 100 mL of pyridine. In general, with the addition of 2-3 drops 
of each solution to an aliquot of the resin there are two colours that can be 
detected.(174) With a free amino group (deprotected), the beads and solution turn to a 
dark blue colour (positive result) after heating to 120 oC for at least 2 min. The beads 
would remain white and the solution turn either yellow or brown, after heating for 3-5 
min, if most of the amino group has reacted (coupled forming amide bond) giving a 
negative result.(174) 
The Kaiser test is useful mainly for detection of primary amines due to presence of 
the alpha proton, which is necessary for Schiff base formation.(176) The mechanism of 
the Kaiser test starts with nucleophilic displacement of the hydroxyl group of the 
ninhydrin, which exists in an equilibrium with indan-1,2,3-trione in the presence of 
water, by the amine moiety (Scheme 3.7).(176, 177) An imine (Schiff base 1) is formed 
after losing a second water molecule. A second form of imine (Schiff base 2) is formed 
as a result of deprotonation of the alpha proton. In the presence of water, the second 
imine is hydrolysed releasing the aldehyde and amine compounds. The latter reacts 
with another molecule of ninhydrin affording the Ruhemann’ purple.(176) 
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Scheme 3. 7: Kaiser test mechanism and formation of Ruhemann’s Purple. 
In this experiment, it was proposed to synthesise a tetrapeptide consisting of the 
following amino acids: Fmoc-Tyr(tBu)-OH, Fmoc-Tyr(OH)-OH, Fmoc-Ala-OH and the 
Fmoc-Tyr (triazene)-OH (Figure 3.5). 
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Figure 3.5: The chemical structure of the tetrapeptide: Tyr-Tyr-Ala-Gly. 
The first amino acid was commercially available, preloaded on the ClTrt resin.  As 
discussed, the deprotection of the butyl group needs a high acid concentration that 
was avoided to keep the triazene group on. The 2nd aa was chosen to act as a suitable 
substrate for the potential cyclisation (discussed earlier). The amino acids and the 
coupling reagent, HATU, were used in equimolar quantities (4 equivalents for each). 
The coupling of the last amino acid was left overnight as the Kaiser test displayed a 
negative result on the next day. Although the Fmoc-deprotection for the last aa was 
trialled three times, the Kaiser test was still giving negative result (brown beads 
colour). In spite of this, cleavage was performed with 1% TFA, and 10% TIPS in DCM. 
Following cleavage, the analytical HPLC showed two major peaks for the crude 
before purification with preparative HPLC (Figure 3.6). 
 
Figure 3. 6: HPLC analysis of the crude, before purification. 
After purification with prep. HPLC (Figures 3.7 and 3.8), both purified samples 
showed masses of m/z: 571 and 553 with MALDI analysis (Figures 3.9, and 3.10). 
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Noticeably, neither of these masses was relevant to the mass of the required 
tetrapeptide, m/z=859. 
 
Figure 3. 7: HPLC analysis of the first separated sample with prep. HPLC. 
 
 
Figure 3. 8: HPLC analysis of the second purified sample with prep. HPLC. 
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Figure 3. 9: MALDI results of the first sample showed mass m/z: 552.66 
 
Figure 3. 10: MALDI results of the second sample is showing mass m/z: 571.16. 
3.2.2. A model reaction to synthesise H2N-Ala-Tyr-Tyr(OtBu)-
COOH using HATU. 
To exclude any issues which might be caused by the synthesised triazene-protected 
central unit, it was decided to synthesise the tripeptide of Tyr-Tyr-Ala (Figure 3.11). 
As has been mentioned above, the three amino acids of this trimer were commercially 
provided. Therefore, the same experiment with the same conditions and reagents 
was repeated but without coupling the central unit (Figure 3.11). 
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Figure 3. 11: Chemical structure of the tripeptide; Tyr-Tyr-Ala. 
MALDI showed two major peaks m/z= (570, 499) (Figure 3.12). Noticeably, neither of 
these masses was the right mass of the required tripeptide, m/z=471.24. As 
mentioned earlier, the coupling reagent used, HATU, could have caused capping of 
resin-bound amino groups through formation of N-terminally guanidinated peptides. 
Based on the masses that were obtained with MALDI, 499 and 570, it was likely that 
they were a guanidinated dipeptide and tripeptide respectively (Figure 3.13). 
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Figure 3. 12: The MALDI results showing the masses of the guanidinated dipeptide and 
tripeptide. 
The tripeptide was suspected to be guanidinated at the hydroxyl group rather than on 
the amine moiety of Ala. That is because the deprotection of the Fmoc group of the 
terminal aa (Ala) occurred after the coupling reagents had been removed by filtration. 
Hydroxyl guanidination, could also have happened with the dipeptide. 
 
Figure 3.13: Chemical structures of the guanidinated side products. 
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3.2.3. A model reaction to synthesise H2N-Ala-Tyr-Tyr(OtBu)-
COOH using PyBOP. 
To confirm that the issue was caused with HATU, the use of a coupling reagent 
without guanidine, and hence not prone to cause the guanidination side reaction, was 
the advisable next step. The phosphonium derivative, PyBOP, was trialled for the 
synthesis of the same tripeptide sequence. Thus, the tripeptide was synthesized on 
100 mg of the 2-chlorotrityl resin. In this instance, analysis of the crude cleavage 
mixture with MALDI showed two masses of m/z 494 and 510 (Figure 3.14), which 
correspond to the [M+Na]+ and [M+K]+ peaks for the correct mass. This is very 
suggestive that it was, indeed, the use of excess HATU that led to guanidination, 
probably on the unprotected Tyr-OH. This suggested two further approaches-use of 
PyBOP to generate the target compound tetrapeptide or the use of a low excess of 
HATU for the same reaction. 
 
Figure 3. 14: MALDI result of the tripeptide model: Tyr-Tyr-Ala. 
3.2.4. Synthesis of a tetrapeptide compound using PyBOP. 
In the next experiment, the synthesis of the same sequence of the tetrapeptide in the 
1st experiment was explored using PyBOP. The tyrosine preloaded resin was used 
on 100 mg scale and PyBOP was used for the coupling reaction. Also, the last 
coupling was left overnight and the Kaiser test showed a negative result on the next 
day. The resin was divided into two halves. The first half was Fmoc-deprotected and 
cleaved from the resin. Upon deprotection of the terminal amine, which was repeated 
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three times, again the blue colour of the resin beads was not seen (remained negative 
with Kaiser test). Although the HPLC showed one major peak, MALDI did not display 
the expected mass, m/z= 859, and showed a mass of m/z= 714 instead (Figure 3.15). 
The second half of the peptide was cleaved with the Fmoc group of the last residue 
on. The required mass was not obtained with MALDI as well (Figure 3.16). 
 
Figure 3.15: MALDI result of the first part of the Fmoc-deprotected tripeptide. 
 
Figure 3.16: MALDI result of the Fmoc-protected tripeptide part. 
3.2.5. Synthesis of tripeptide of Tyr, Gly and triazene-protected 
compound using HATU for coupling and Wang resin as 
supporting solid. 
This synthesis was trialled using HATU as a coupling reagent but with only two 
equivalents rather than four. As discussed, that even the gentle acidic cleavage 
condition from the ClTrt resin can cleave the triazene group, it was decided to perform 
this reaction through use of Wang resin and apply an aggressive condition for 
cleavage (90% TFA). In this experiment, as the plan was to demonstrate the eligibility 
of the triazene-protected compound to the solid phase, so the synthesis of tripeptide 
was trialled rather than tetrapeptide. 
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This experiment was carried out on 100 mg of preloaded Fmoc-Tyr (tBu)-OH Wang 
resin. Attempting to avoid the guanidination issue of HATU, an excess of the amino 
acids was used compared to HATU. Thus, three equivalences of each amino acid 
were added. Upon dissolving the triazene in DMF the solution turned dark brown 
colour which may reflect the typical colour of azo dye. The coupling of the last unit, 
triazene derivative, was checked with Kaiser test three times after 45 min, 1.5 h, and 
2.5 h but the result was positive for each. Then, the coupling was repeated with fresh 
reagents and left overnight. On the next day, the Kaiser test showed a negative result, 
brown beads and solution. After Fmoc-deprotection of the last unit, the resin was 
cleaved with 95% TFA over 2 h. Mass spectrometry was performed with MALDI using 
freshly prepared cinnamic acid matrix. The mass of desired trimer could be 
recognized, m/z= 627 [M+H] (Figure 3.17). Another more prominent mass of 530 
[M+H]+ was recognized. The latter could be a fragmented trimer at the bond between 
the triazene and the aromatic ring (Figure 3.18). 
 
Figure 3.17: MALDI result of the tripeptide: Tyr-Gly-PhGly.  
 
 
Figure 3. 18: The chemical sturcture of the tripeptide (a) and its supposed fragment (b). 
The experiment was scaled up to 200 mg of the pre-loaded Wang resin and the same 
masses could be recognized as well with MALDI. After purification with prep. HPLC 
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three fractions were obtained, but none contained the expected masses. This 
suggests that the products of the reaction are unstable and are decomposed on 
purification. To test this, it was decided to try an alternative solution phase synthesis. 
3.3. Solution phase synthesis; 
3.3.1. The synthesis of Fmoc-protected dipeptide D1 using 
EDC/HOBt in DMF. 
These results suggested that the analogue of the central amino acid either cannot be 
coupled successfully and/or could not be characterised properly when it is reacted on 
the solid phase. Accordingly, it was important to try a solution phase method to prove 
that the right compound can be synthesised or to confirm it is not eligible for the solid 
phase. The first trial in this regard was to synthesise a tripeptide consisting of tyrosine, 
glycine, and the central amino acid. The tyrosine aa is protected at the carboxylic acid 
with methyl ester and with free amino moiety. The methyl ester of tyrosine and Fmoc-
protected glycine were reacted in DMF using HOBt/EDC as coupling system (Scheme 
3.8). EDC is a typical example of carbodiimides, which, mechanistically, reacts with 
the carboxylic acid in stoichiometric reaction giving O-acylisourea intermediate 
(Scheme 3.9).(178) As previously discussed, using HOBt, is essential to reduce 
racemisation, which is common with carbodiimides. It reacts in a catalytic reaction 
with the o-acylisourea forming an activated ester and releasing urea as side product. 
The activated ester, the HOBt ester, acts as the source of acylation of the amine 
compound to afford a peptide or amide bond and releasing HOBt. Thus, 100 mg of 
Fmoc-Gly-OH was dissolved in 1 mL DMF and 1 equivalent of each of HOBt, EDC, 
and Et3N was added sequentially. The reaction was monitored with TLC and after 1 
h of stirring some of SM was still present. A further 0.5 equiv of EDC was added and 
the reaction left overnight. On work up, the reaction had not worked. 
 
Scheme 3. 8: Reaction of dipeptide formation, Tyr-Gly, using EDC coupling reagent in DMF 
solvent. 
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Scheme 3. 9: Mechanism of peptide bond formation using EDC as a coupling reagent and 
HOBt as a racemisation suppressent. 
3.3.2. The synthesis of Fmoc-protected dipeptide D1 using 
EDC/HOBt in acetone. 
For the next experiment, the solvent was changed to acetone and the Tyr was 
dissolved first (Scheme 3.10).(179) The HOBt, Gly, and EDC were added sequentially 
with stirring. After 2 h the dipeptide precipitated as a colourless solid. The solvent was 
evaporated and the residue washed with diethyl ether then purified with flash 
chromatography. 
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Scheme 3. 10: Reaction of dipeptide formation, Tyr-Gly, using EDC coupling reagent in 
acetone solvent. 
 
 
Figure 3. 19: Atom numbering of the dipeptide. 
The product was confirmed using 1H NMR spectroscopy (see figure 3.19 for atom 
numbering). The presence of the signals of the Fmoc group is a prominent 
confirmation of the success of the reaction. As has been mentioned earlier there are 
five signals of the Fmoc group. Four of them are in the aromatic region, two doublets 
and two triplets. The two doublets are at chemical shifts 7.78 and 7.65 ppm with 
coupling value of 7.5 and 7.1 Hz respectively. The triplets are at chemical shifts 7.38 
and 7.30 ppm with coupling value 7.5 Hz for each. The doublet at 6.99 ppm 
corresponds to the aromatic protons of C-3 and C-5 and has coupling value of 8.4 
Hz. While, the protons of the C-2 and C-6 are represented by the doublet at 6.71 ppm. 
The reason that the latter doublet is at lower chemical shift than the former one is 
because of the electron-donating effect of the hydroxyl functionality (Scheme 3.11). 
This effect is concentrating the electron density at ortho and para positions of the 
aromatic ring so their shielding from the magnetic field would increase pushing the 
signals to a lower chemical shift upfield. 
 
Scheme 3. 11: Illustration of the resonance of the aromatic hydroxyl group. 
The multiplet at 4.65 ppm corresponds to the proton C-8. Another two signals belong 
to the Fmoc group at 4.34 and 4.20 ppm. The former is a doublet with J value of 6.5 
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Hz and latter is triplet of the same J value. The doublet at 3.78 ppm corresponds to 
the methylene protons of C-7. The methyl group is matched by the singlet at 3.37 
ppm. The multiplet at 3.05-2.87 ppm corresponds to two methylene protons of C-9. 
3.3.3. Deprotection of the Fmoc group; synthesis of the 
dipeptide D2. 
The next step was the deprotection of the Fmoc group. (20%) piperidine was used to 
accomplish this reaction and the solution was stirred for 20 min. The product was 
precipitated with hexane.  
1H NMR spectroscopy showed no methyl group. This suggests that under basic 
condition of the Fmoc deprotection, the free amine has undergone a cyclization 
reaction as shown in scheme 3.12. 
 
Scheme 3.12: Proposal of the cyclization of the free amine. 
3.3.4. Synthesis of dipeptide D3 using Boc-protected Gly. 
The next approach was to use Boc-protected glycine. That is because the 
deprotection of Boc group can be carried out under acidic conditions which in turn 
acidify the free amino group leading to lowering its reactivity (the protonated amino 
group is less nucleophilic). The coupling reaction was carried out at room temperature 
and left overnight (Scheme 3.13). After purification with flash chromatography, the 
product was characterized using 1H NMR spectroscopy which showed the right 
dipeptide terminally protected at the amine group.  
 
Scheme 3.13: Reaction formation of dipeptide using Boc-protected glycine at amine 
functionality. 
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Figure 3. 20: Atom numbering of the Boc-protected dipeptide 
This product was confirmed using 1H NMR spectroscopy (see figure 3.20 for atom 
numbering). Noticeably, the singlet 1.45 ppm signal corresponds to the nine protons 
of the Boc moiety and so is considered as an evident confirmation of the coupling. 
The two doublets at 7.00 and 6.72 ppm correspond to the aromatic protons. For the 
same reason mentioned earlier (see scheme 3.11) the protons of the C-6 and C-2 are 
represented by the doublet of the higher chemical shift, 7.00 ppm. The triplet at 4.65 
ppm corresponds to the proton of carbon C-8. The multiplet 3.72-3.69 ppm matches 
the five protons of C-7 and the methyl group. While, the two protons of C-11 are 
represented by the multiplet of 3.07-2.91. They are not identical although attached to 
the same carbon atom because of the enantiotopic effect. 
3.3.5. Deprotection of Boc group; synthesis of D4. 
The Boc deprotection reaction was carried out with 50% TFA/DCM. The product was 
purified with flash column chromatography.  
 
Scheme 3. 14: Reaction of Boc-deprotection with acidic conditions. 
 
 
Figure 3. 21: Atom numbering of the Boc-deprotected dipeptide. 
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The product structure of the Boc deprotection reaction was confirmed using 1H NMR 
spectroscopy (see figure 3.21 for atom numbering). It is recognizable that the singlet 
corresponding to the Boc group is no longer present. Each of the two protons of C-11 
can be recognized as a doublet of doublets at 3.01 and 2.85 ppm. The singlet at 3.31 
ppm corresponds the two protons of the amine group. 
3.3.6. Synthesis of the tripeptide D5; attachment of the 
central unit to the dipeptide.
 
Scheme 3. 15: Reaction of attachement of the synthesised triazene-protected unit to the 
dipeptide via a peptide bond. 
The last step in the solution synthesis involved coupling the central unit analogue to 
the dipeptide that was made earlier (Scheme 3.15). This experiment posed a critical 
step whether the analogue is eligible for the coupling with other amino acids in its 
Fmoc-protected form. The coupling reaction, the triazene derivative with the 
dipeptide, was carried out using the HOBt/EDC coupling system. After 2 h the product 
was purified with flash chromatography. The 1H NMR spectroscopy was carried out 
for it and showed the right tripeptide. In addition, LC-MS was used to confirm the right 
mass, which was (m/z=863), (Figure 3.22). 
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Figure 3. 22: The Mass spec. of the tripeptide showing the desired mass. 
 
Figure 3. 23: Atom numbering of the tripeptide. 
The tripeptide product was confirmed using 1H NMR spectroscopy (see figure 3.23 
for atom numbering). As always with the presence of the Fmoc moiety, six signals 
matching the protons of the Fmoc are recognisable. The four in the aromatic region 
are the doublet at 7.69 ppm, the broad singlet at 7.54 ppm, the triplet at 7.33 ppm, 
and the triplet 7.23 ppm. Each of them integrates to two protons and all of them belong 
to the aromatic part of the Fmoc group. The broad singlet at 7.63 ppm corresponds 
to the two aromatic protons of C-13 and C-15. The doublet of doublets at 6.84 ppm 
corresponds to the two aromatic protons at C-3 and C-5, while the triplet at 6.61 ppm 
corresponds to the two aromatic protons of C-4 and C-6. The multiplet at 4.77 ppm 
integrates to one proton and corresponds to the proton of C-8. The other two signals 
of the Fmoc protons are the broad singlet at 4.41 ppm which corresponds to the two 
protons of C-24 and the broad singlet at 4.19 which corresponds to the proton of C-
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25. There is another broad singlet at 3.93 ppm which corresponds to the two protons 
of C-23. The multiplet at 3.80-3.64 is a collection of different corresponding protons 
which involves the methyl protons, the methylene protons (C-7), and the two protons 
of C-20. The broad singlet at 2.08 ppm matches the four protons of C-21 and C-22. 
3.4. Conclusion 
This chapter displays the successful coupling of the synthesised Fmoc-protected 
central residue of vancomycin using solution phase synthesis methodology. However, 
the synthesis on the solid phase was not successful. The characterisation and 
purification operations that are followed in the solid phase may have a detrimental 
impact on the triazene-protected moiety. In the solid phase technique, the use of 
HATU in a reduced amount as a coupling reagent and Wang resin as a supporting 
solid were shown to generate a promising result, but it is evident that more work is 
required to successfully use solid phase methodology with this reagent. It may be that 
other central units, containing a different residue in place of the triazene protection 
would be more amenable to solid phase methods.  
In order to initiate studies of the other suitable units for peptide synthesis for 
vancomycin, the final chapter describes the synthesis of the amino acids 2 and 6 of 
the overall structure.   
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Chapter 4. 
Synthesis of the Fmoc-protected ester 
analogues of the amino acids 2 and 6 of 
vancomycin 
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4.1. The design of the tyrosine derivatives. 
This chapter focuses on the synthesis of the tyrosine units in the vancomycin structure 
amino acid 2 and amino acid 6 of the heptapeptide backbone. As with the design of 
the central residue, the aim of synthesis of each amino acid constituting the structure 
of vancomycin is to be Fmoc-protected at the amine functionality and have its 
carboxylic acid group unprotected, to comply with the criteria required for Fmoc 
chemistry. 
 
Figure 4. 1: Chemical structure design of the tyrosine derivative aa in vancomycin backbone. 
Moreover, finding a feasible way for having a phenol group to be a convenient 
substrate in the potential macrocyclization was another synthetic approach in the 
synthesis. Regarding chirality, this residue contains two chiral centres, therefore work 
on finding a way to introduce the chiral centres selectively and to maintain them 
through the steps of the synthesis was an important endeavour. As will be shown later 
in this chapter, Nicolaou’s approach has been followed to achieve the exact chirality 
using Sharpless AD. Using this approach, it was possible to complete the syntheses 
of the tyrosine analogues in Fmoc protected form of ethyl ester derivatives. 
4.2. Synthesis of the ethyl ester of the Fmoc-protected amino 
acid-2 (Tyrosine derivative). 
As mentioned above, the plan was to synthesise these units in their free carboxylic 
acid forms (Fmoc-protected amino acids) but for reasons discussed later in this 
chapter, the ethyl ester variants were successfully generated. Below, the full scheme 
of the synthesis of ethyl ester form of amino acid 2 is shown in scheme 4.1. 
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Scheme 4. 1: Synthetic route of the third aa in vancomycin peptidic backbone; Reagents and 
conditions: a) K2CO3 (1.5 equiv), BnBr (1.0 equiv), KI (0.1 equiv), DMF, 25 oC, 3 h, 86%; b) 
(EtO)2(O)PCH2-COOEt (1.1 equiv), KOH (1.5 equiv), THF, 25 oC, 3 h, 87%; c) AD-β, (1.4 
gmmol-1), MeSO2NH2 (1.0 equiv), t-BuOH/H2O (1:1), 25 oC, 12 h, 48% (92% ee); d) NosCl 
(1.0 equiv), Et3N (2.0 equiv), DMF, 0 oC, 24 h, 70%; e) NaN3 (1.5 equiv), DMF, 55 oC, 8 h, 
90%; f) SnCl2. H2O (2.0 equiv), MeOH, 25 oC, 3 h, 78%. 
 
4.2.1. Synthesis of the benzyl-protected phenol A2. 
 
Scheme 4. 2: Chemical reaction of the synthesis of the A2 using BnBr reagent. 
p-Hydroxyl benzaldehyde A1 was used as the SM to begin this synthesis. It is 
important to protect the phenol with a suitable group to withstand the different 
conditions of the subsequent steps of the reactions. Therefore, Nicolaou’s approach 
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using a benzyl protecting group was followed. Thus, p-hydroxybenzaldehyde was 
dissolved in DMF and K2CO3, KI, and BnBr added sequentially. Then, the mixture 
was stirred at room temperature for 3 h to furnish the product A2 in 86% yield following 
purification (Scheme 4.2). 
The mechanism of reaction proceeds according to Williamson ether synthesis which 
includes reaction of alkoxide with organohalide in an SN2 reaction furnishing the 
corresponding ether (Scheme 4.3). The presence of the base catalyst is important to 
deprotonate the alcohol to produce the alkoxide. The alkoxide intermediate 
approaches the polarised methylene carbon in benzyl bromide from the opposite site 
to the carbon bromide bond. As the bond between the oxygen and carbon starts to 
form, the carbon bromide bond starts to weaken. Whilst the bond strength between 
oxygen and carbon increases, the bond between carbon and bromide increasingly 
weakens until complete removal of bromide ion as leaving group occurs. It is known 
that a SN2 reaction is accompanied with complete inversion in the chirality of carbon 
group, although it is not applicable in this reaction as the carbon involved is achiral. 
A primary halide is more reactive than other types, secondary and tertiary. 
Furthermore, the solvent (DMF) has a clear influence in promoting the SN2 
mechanism for the reaction over other kind of mechanisms, i.e SN1, because it is a 
polar aprotic solvent which tends more to dissolve K+ cation, counterion of the 
intermediate, than the alkoxide ion (Figure 4.2).(180) Therefore, the alkoxide ion would 
have more electron density making it more reactive to attack the electrophilic carbon.  
 
 
Figure 4. 2: Illustrating the role of DMF in preferentially dissolving cations.(180) 
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Scheme 4.3: Mechanism of the synthesis of the A2. 
Accordingly, it is very unlikely the reaction proceeds via an SN1 mechanism due to 
following reasons: 
-Using primary halide, which is more reactive than secondary and tertiary 
counterparts.  
-Polar aprotic solvent. 
-Use of strong nucleophile, alkoxide. 
 
 
Scheme 4. 4: Atom numbering of the A2 compound. 
This product was confirmed using 1H NMR spectroscopty (see scheme 4.4 for atom 
numbering). It is noticeable that the singlet peak at 9.89 ppm corresponds to the 
aldehyde proton. The doublet peak, with coupling value 8.8 Hz, at 7.84 ppm 
corresponds to the two aromatic protons of C-5 and C-3. The position of the latter 
peak is downfield due to the electron-withdrawing effect of the aldehyde group which 
pulls the electrons away, reducing the electron density around the C-5 and C-3. The 
multiplet peak of the range of the chemical shift between 7.45 and 7.32 is due to the 
five aromatic protons of C-9, C-10, C-11, C-12, and C-13. Confirming the success of 
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the reaction is the singlet signal at 5.15 ppm matching the methylene protons (C-7). 
The doublet at 7.08 ppm corresponding is to the two aromatic protons of C-6 and C-
2. The mass was confirmed with high resolution-mass spectrometry; m/z: 213.0910. 
4.2.2. Synthesis of the cinnamate A3. 
 
Scheme 4.5: Chemical reaction of the synthesis of the A3 compound via Horner-Wadsworth 
Emmons reaction. 
This reaction was carried out under N2. The aldehyde was dissolved in THF then KOH 
and Horner-Wadsworth Emmons reagent were added sequentially. The mixture was 
stirred for 3 h to furnish the cinnamate product A3 in 87% yield after purification 
(Scheme 4.5). This reaction proceeds via the mechanism of the Horner-Wadswoth-
Emmons (181) reaction (Scheme 4.6). It is a modification of the Wittig reaction using 
phosphonate-stabilised carbanions for the generation of α, β unsaturated esters.(182) 
One of the acidic methylene protons in the phosphonate reagent is deprotonated with 
strong base producing the phosphonate anion. The resulting enol then attacks the 
carbonyl carbon leading to formation of two oxyanions as erythro and threo 
diastereomers. In both oxyanions, the lone pair on oxygen would attack the polarised 
phosphorus so the π bond between the latter and oxygen opens forming a four-
membered ring intermediate, oxaphosphetane. This intermediate would decompose 
to furnish olefins of two isomers, cis and trans. The HWE reaction preferentially gives 
rise to E-olefins (trans-isomer) as the pro(E)-oxyanion (threo adduct) is more 
thermodynamically stable than erythro adduct.(182-184) Unlike the Wittig reaction, the 
phosphate by-product is readily separable by washing only with water.(182) 
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Scheme 4. 5: Mechanism of the synthesis of the A3 compound. 
 
 
Scheme 4. 6: Atom numbering of the styrene compound. 
146 
 
The product was confirmed using 1H NMR spectroscopy (see scheme 4.7 for atom 
numbering). The apparent confirmation that the reaction has proceeded properly is 
the presence of the two doublets corresponding to the protons of the olefin carbons, 
C-7 and C-8. Hence, the two doublets at 7.63 and 6.30 ppm each with coupling value 
of 15.9 Hz correspond to the protons on C-7 and C-8 respectively. The large value of 
the coupling constant (15.9 Hz) indicates the two protons are in trans position. Due 
to the e-donating property of the benzyl oxygen, the aryl group would have a positive 
inductive effect that leads to increasing the electron density around the C-8 proton 
through the resonance effect, (Scheme 4.8). Although, the ethyl ester has an electron-
withdrawing effect, its impact of deshielding the C-8 proton is overwhelmed by the e-
donating effect of the substituted aryl ring. Therefore, the C-8 proton has emerged at 
a lower position than the C-7 proton. Further evidence of the success of the reaction 
is the appearance of the quartet and triplet peaks that belong to the ethyl group. The 
quartet peak at 4.25 ppm with coupling value 7.1 Hz, corresponds to the two protons 
of C-10. While the triplet at 1.33 ppm with coupling value 7.1 Hz belongs to the three 
protons of C-11. The absence of the aldehyde group has the impact of shifting the 
doublet corresponding to the aromatic protons at C-5 and C-3 to a lower position up-
field at 7.47 ppm. 
 
 
Scheme 4.7: Illustration of the inductive effect of the benzyl oxygen atom and its role in 
increasing the electron density around the C-8 through the resonance influence. 
4.2.3. Hydrolysis of the ethyl ester; synthesis of carboxylic 
acid A9. 
Before proceeding with the Sharpless AD, it was envisioned that hydrolysis of the 
ester in the final step in this synthesis might impact the potential Fmoc-protecting 
group. The hydrolysis of ethyl esters is often carried out using basic conditions, which, 
in turn, could deprotect the Fmoc group. Therefore, the suggestion was to replace the 
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ethyl ester with an acid labile ester to be consistent with standard conditions used in 
SPPS. t-Butyl ester was the choice of protecting group to accomplish this task. 
Therefore, the plan was to hydrolyse the ethyl ester using LiOH and incorporate the 
t-butyl group using t-BuOH. Initially, two equivalents of LiOH were used to perform 
hydrolysis in a biphasic solvent, THF/H2O (1:1), (Scheme 4.8). The reaction was set 
up at 0 oC for 1 h and then allowed to warm to rt. 
 
Scheme 4. 8: Unsuccessful reaction of the hydrolysis of the ethyle ester. 
The reaction was not successful. An alternative approach using three equivalents of 
LiOH and a solvent system consisting of three solvents, THF, MeOH, and water in 
ratio 3:1:1 respectively (Scheme 4.10), and the resulting mixture was left overnight 
until thereaction was shown to be complete by tlc. After work up, the product A9 was 
afforded in 85% yield without purification. 
 
 
Scheme 4. 9: Hydrolysis reaction of the ethyl moiety using LiOH in THF:MeOH:H2O solvent 
system. 
 
Scheme 4. 10: Atom numbering of the carboxylic compound. 
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The success of the hydrolysis reaction of the ethyl ester was confirmed using 1H NMR 
(see scheme 4.11 for atom numbering). The doublet that corresponds to the proton 
of C-7 has shifted from 7.63 ppm in the ethyl ester to 7.73 ppm in the carboxylic acid. 
It can be concluded, that the proton of the C-7 is in cis position to the carboxylic acid 
(Figure 4.3). This conclusion is based on the fact that the mutual coupling value 
between C-7 and C-8 protons is 16 Hz, which indicates they are in a trans position. 
As the carboxylic acid is geminal to the C-8 proton therefore it should be in a cis 
position to the C-7 proton. It is known that the cis proton is more influenced by the e-
withdrawing effect of the carboxylic acid than other type of protons, geminal and trans. 
This is an additional factor to the positive inductive effect of the substituted aryl ring, 
causing a more deshielding effect on the C-7 proton.(185) It is noticeable that both 
signals, quartet and triplet, corresponding to the ethyl group are not present in NMR 
spectrum of the carboxylic acid compound. This provides a confirmation of the 
success of the reaction. 
 
 
Figure 4. 3: Illustration of the cis position of the carboxylic acid to the proton across the alkene 
bond. 
4.2.4. Synthesis of the butyl ester A10. 
Initial attempts to form the t-Bu ester utilized a standard carbodiimide coupling 
approach (EDCl, t-BuOH, DMAP, anhydrous CH2Cl2) that was unsuccessful, 
(Scheme 4.12a). Treatment of the acid with oxalyl chloride at RT with catalytic DMF, 
to generate the more reactive acid chloride, was also unsuccessful, (Scheme 4.12b). 
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Scheme 4. 11: a) Unsuccessful reaction of the butyl ester formation using t-BuOH, DMAP and 
EDCl; b) unsuccessful reaction of production of acyl chloride using oxalyi-Cl. 
Fortunately, heating the acid to reflux with thionyl chloride using t-BuOH as solvent 
furnished the product A10 in 85% yield, (Scheme 4.13).  
 
Scheme 4. 12: Formation of the butyl ester A10 using SOCl2. 
 
 
Scheme 4. 13: Atom numbering of the butyl ester compound A10. 
The structure of the product was confirmed using 1H NMR spectroscopy (see scheme 
4.14 for atom numbering). The most prominent confirmation of the reaction is the 
emergence of the singlet signal corresponding to the nine butyl protons at 1.53 ppm. 
The doublet signal corresponding to the C-7 proton shifted from 7.73 ppm in the 
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carboxylic acid compound to 7.53 ppm in the butyl ester compound is due to the 
moderate electron-donating effect of the butyl ester. This in turn has increased the 
shielding impact to the protons leaving them less exposed to the magnetic field. For 
the same reason, the doublet corresponding to the C-8 proton has appeared at a 
lower chemical shift, 6.24 ppm, than its counterpart in the carboxylic acid compound, 
6.32 ppm.  
4.2.5. Synthesis of the diol A4. 
After the butyl ester was obtained, all attempts to oxidize the alkene failed (Scheme 
4.15). The Sharpless AD reaction was trialed in order to form the diol compound. The 
SM was suspended in t-BuOH/H2O solvent system, then AD-Mix-β and MeSO2NH2 
added sequentially. The mixture was stirred at room temperature and left overnight. 
TLC analysis showed only the SM. Another batch of the same reaction was set up 
with addition of NaHCO3 as it has been argued that is the buffer solution could prevent 
ester hydrolysis.(186) A solution of AD-Mix-β and MeSO2NH2 in a solvent system of 
t-BuOH/H2O containing NaHCO3 was made. The solution cooled to 0 °C and the SM 
added and the mixture stirred at that temperature. Then, the solution was allowed to 
warm up to rt. Again, this reaction did not work. Methods using less selective 
conditions, such as treatment with potassium permanganate or N-methylmorpholine-
N-oxide(151) and osmium tetra-oxide also returned starting material and were 
unsuccessful. The lack of success of formation of the diol was surprising. It is possible 
that the conjugated alkene was unreactive to these conditions, but results with the 
ethyl ester (see below) demonstrated that this was not the case. It would seem that 
the introduction of the more sterically demanding t-Bu in place of the ethyl ester was 
responsible for the lack of activity.  
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Scheme 4.14: Unsuccessful trials for oxidisation of the olefinic bond. 
Following these disappointments, it was decided to proceed with Nicolaou’s approach 
using the ethyl ester as the SM to carry out the Sharpless AD with AD-Mix-β. AD-Mix-
β was added to a stirred solution of the ethyl ester and methanesulfonamide 
tBuOH/H2O. After 48 h stirring at rt, the diol A4 was furnished as a yellow powder in 
82% yield after purification (Scheme 4.16). 
 
 
Scheme 4. 15: The synthesis reaction of the diol compoiund A4 from A3 using AD-Mix-β. 
The expense and high toxicity of osmium tetra-oxide had urged researchers to 
develop a way to reduce the amount that is used in diol formation. Therefore, addition 
of potassium ferricyanide was a significant advance as it acts as a reoxidant, 
regenerating osmium tetra-oxide in the reaction and hence the latter reagent can be 
used in catalytic amounts. The first step in the reaction mechanism is the 
complexation of osmium tetra-oxide with the ligand via N-Os bond (Figure 4.4). This 
complexation is considered as the determining step for the stereochemisty of the diol 
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product. So, the olefin substrate is held in an extremely constrained-position within 
the U-shaped binding pocket of the osmium-ligand complex. This minimal-motion lets 
the liganded OsO4 approach the alkene in a way that would allow concerted 
cycloaddition via a [3+2] mechanism to occur forming the pentacoordinated-osmate 
ester in the desired stereochemistry.(187) In the presence of water, the osmate ester is 
hydrolysed, giving rise to the diol, which escapes, alongside the ligand, into the 
organic phase and OsO2(OH)4-2 which goes into aqueous phase (Scheme 4.17).(188) 
The latter is re-oxidised with stoichiometric reagent potassium ferricyanide back to 
OsO4 to be involved in another catalytic cycle of AD reaction. The presence of 
methanesulfonamide is very important as a cosolvant agent, it acts on solvation of 
the biphasic solvent system leading to acceleration of the hydrolysis process of the 
osmate ester that is derived from nonterminal alkenes. This is because the osmate 
ester has a limited access to the aqueous phase due to its relative hydrophobicity. 
Noteworthy, methanesulfonamide has a reverse impact in the AD of terminal olefins 
where it leads to slowing down the reaction rate.  
The explanation of this is the osmate ester of terminal olefin is highly  hydrophilic and 
therefore resides in the aqueous pahse. The presence of methanesulfonamide can 
reduce the number of hydroxide ions, due to its solvation effect, needed for the 
hydrolysis step in aqueous phase leading to sluggishness in the hydrolysis. t-BuOH 
is a protic solvent and therefore can  trap hydroxide ions via hydrogen bonding and 
hence accelerate the hydrolysis step for nonterminal olefins in particular. Looking at 
the structure of the olefin,  it has  two functionally opposite substituents, an electron-
donating aromatic group and an electron-withdrawing ethyl ester group. While the 
aromatic moiety can decrease the electrophilicity of the osmate ester and hence slow 
down the reaction rate, the ethyl ester would increase its electrophilicty making it more 
reactive towards nucleophilic hydroxide ions. 
 
 
Figure 4. 4: Complexation of the osmium tetra-oxide within the chiral ligand via N-Os bond. 
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Scheme 4. 16: Mechanism of the diol formation via Sharpless AD reaction. 
 
 
Scheme 4.17: Atom numbering of the diol compound A4. 
 
1H NMR spectroscopy was used for assignment of the product of the SAD reaction 
(see scheme 4.18 for atom numbering). The appearance of the two doublets signals 
at 3.07 and 2.61 ppm corresponding to the both hydroxyl groups on C-8 and C-7 
respectively, is a noticeable confirmation of the success of the reaction. The former 
doublet has a coupling value of 5.9 Hz and the latter has a coupling value of 6.9 Hz. 
The two doublets of doublets at 4.93 and 4.31 pmm, which each integrate to 1 proton, 
correspond to the protons of C-7 and C-8 respectively. Both of them have a mutual J 
value of 3.1 Hz which confirms the reciprocal coupling. Another J value of the doublet 
of doublets at 4.93 is 6.9 Hz, which indicates the mutual coupling effect with the 
hydroxyl, of the same carbon C-7, that has the same J value. On the other hand, the 
additional J value for the doublet of doublets at 4.31 ppm is 5.9 Hz, which also 
indicates a spin-spin coupling with the other hydroxyl of the C-8. Noteworthy, the 
signals of the two protons and two hydroxyls of the carbon atoms C-7 and C-8 are 
recorded in the Nicoalou’s literature as broad singlets. The disappearence of the 
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alkene group has caused the doublet of the aromatic protons of C-5 and C-3 to move 
a slightly lower position upfield to be overlapped with the multiplet peak of five protons 
of the benzylic group. The polarimetric rotation value was calculated at 22 °C: [α]= -
11.0 (c=0.062 g/mL, MeOH). The literature value is -31.3 (c=1.15, CHCl3).(99) Noticebly, 
the solvent used in calculation of the polarimetric rotation value for compound A4, 
MeOH, is differnet to that used for the literature value, CHCl3, resulting in different 
values. In addition, A4 might have less purity than the literature value. 
4.2.6. Synthesis of the nosylated-diol A5. 
The nosylated diol was obtained via the reaction of 4-nitrobenzenesulfonyl chloride 
(1 equiv) and Et3N (2 equiv) with the diol in DMF at 0 oC (Scheme 4.19). The mixture, 
was stirred for 24 h to furnish nosyl-protected compound A5 in 70% yield. Formation 
of the nosylated-compound is a preparation step for the subsequent reaction involving 
azide substitution. Hydroxide is a strong base and hence acts as a poor leaving group 
in the substitution reactions. 
 
 
Scheme 4. 18: Reaction of the formation of the nosyl-protected diol using nosyl chloride. 
The  introduction of the nosyl group makes the substitution reaction easier and faster 
as the leaving nosylate ion is a weak nucleophile and would not react with 
nucleophiles. The reaction proceeds in SN2 mechanism where the alcohol attacks 
the electrophilic sulfur forming the pentavalent intermediate that loses chloride ion as 
leaving group (Scheme 4.20). The latter in turn deprotonates the positively charged 
alcohol producing HCl, which reacts with the Et3N and the nosylated compound. 
There are two factors reducing the opportunity of the other alcohol group, next to 
aromatic ring from being nosylated: 1) the aromatic moiety is more electron-
withdrawing than the ethyl ester group so the aromatic hydroxyl would be less 
nucleophilic than the ester hydroxyl, 2) the position of the bulky aromatic ring close to 
it would pose a kind of steric hindrance, which in turn can prevent the introduction of 
the bulky nosyl group, 3) using nosyl chloride in a stoichiometric amount would prefer 
its reaction with the relative more reactive  alcohol. 
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Scheme 4. 19: Mechanism of the nosyl-protected diol A6 using nosylchloride. 
 
 
Scheme 4. 20: Atom numbering of the nosylated compound A5. 
The nosylation reaction product was confirmed using 1H NMR spectroscopy (see 
scheme 4.21 for atom numbering). A clear confirmation, that the reaction was 
successflu is the two doublets at 8.24 and 7.87 ppm, which have coupling value 9.0 
Hz and correspondent to the four aromatic protons of the nosyl group. The former 
doublet corresponds to the two protons of C-13 and C-17 and the latter represents 
the two protons on C-14 and C-16. Both the nitro and sulfonate are strong electron 
withdrawing groups. A significant change in the chemical shift of the proton of the 
carbon C-8 is due to the direct attachment to the nosyl group. While it was a doublet 
of doublets at 4.31 ppm of the diol compound, it has emerged at higher chemical shift 
downfield at 5.15 ppm as a triplet in the nosylated compound, the shift being due to 
the electron-withdrawing sulfonate group. A doublet corresponding to the proton of 
C-7 has moved to a higher downfield position from 3.07 ppm in diol compound to the 
4.98 ppm in the nosylated compound due to the negative inductive effect of the nosyl 
group as well. Another noticeable change in the chemical shift is the movement of the 
doublet corresponding to the aromatic protons of C-3 and C-5 to a lower position at 
7.16 ppm. The polarimetric rotation value was calculated at 22 °C: [α]= - 46.2 (c=0.058 
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g/mL, CHCl3). The literature’s value is + 43.0.(99) Obviously, the nagative rotation value 
of A5, is opposite to the lietarture value, positive. In an RSC advances paper,(189) the 
optical rotation for the same compound (A5, 18 in the paper) is –40 (nagative sign).  
Therefore, it  confirms that the measured rotation of A5 in thesis is right and indicates 
that the older paper is wrong. 
4.2.7. Synthesis of the azide compound A6. 
 
Scheme 4.21: Synthesis of the azide compound A6 using NaN3. 
The azide compound A6 was furnished in 90% yield by reaction of the nosylated 
compound, with NaN3 in DMF at 55 oC for 8 h (Scheme 4.22). This reaction is a 
substitution reaction in which the azide replaces the nosylate group via an SN2 
mechanism (Scheme 4.23). The nucleophilic terminal nitrogen in NaN3 attacks the 
polarised carbon that is bonded to the nosylate. The latter is removed as a leaving 
group furnishing the azide compound. 
 
 
Scheme 4. 22: Mechanism of the azide compound A6 formation using NaN3. 
 
 
Scheme 4. 23: Atom numbering of the azide product A6. 
This structure of the product was confirmed usign 1H NMR spectroscopy (see scheme 
4.24 for atom numbering). A clear indication that the reaction was successful is that 
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the two doublets corresponding to the aromatic protons of the nosyl group are no 
longer present in the NMR spectrum of the azide compound. Since the electron-
withdrawing effect of the nosyl group was removed, the doublet peak of the proton of 
C-8 emerged at 4.08 ppm with a coupling value 7.1 Hz. In contrast to the nosylated 
compound, where the proton of the C-8 appeared as a triplet at a higher downfield 
position at 5.15 ppm. The two doublets  of the aromatic four protons of C-3 and C-5 
and C-6 and C-2 have moved a slightly to a higher position where the doublet that is 
corresponding to C-3 and C-5 has been overlaped with multiplet corresponding to the 
benzyl protons. IR was performed for the azide compound and the transmitance peak 
of the azide group was sharp and clear at 2113 cm-1 %T.  
The polarimetric rotation value was calculated at 22 °C: [α]= -1.3 (c=0.062 g/mL, CHCl3). 
The literature’s value is +3.09 (c=1.26, CHCl3).(99) In the same RSC paper,(189) the 
rotation value of the azide compound is positive, +63.8 (c=6.0, CHCl3), but much 
higher than that of the thesis’s and the Nicolauo’s values. This may suggest some 
racemisation has occurred in the synthesis. Also, the big difference in the magnitude 
between the RSC paper value and the Nicolaua’s literature value might be enough to 
suggest that there is some disagreement about the true value of the optical rotation.  
4.2.8. Synthesis of the amine A7. 
 
Scheme 4. 24: The synthesis reaction of the amine compound A7 via reduction of the azide 
A6 using hydrous tin chloride. 
The amine was obtained via reaction of azide with tin (II) chloride dihydrate in 
methanol at room temperature for 3 h. It was furnished in 78% yield after purification 
(Scheme 4.25). 
 
Scheme 4. 25: Atom numbering of the amine compound A7. 
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The reduction of the azide  to the amine was confirmed using 1H NMR (see scheme 
4.26 for atom numbering). In general, no significant changes in chemical shifts of the 
proton signals influenced by the reduction step have been noticed. All the relavant 
peaks have shifted slightly to a lower position upfield as a result of introduction of the 
amine. Consequently, these protons become more shielded in the amine product 
compared to the azide compound. For example, the doublet corresponding to the 
proton of the C-8, has changed from a 4.08 ppm in the azide compound to a 3.77 
ppm, with a coupling value 5.9 Hz, in the. A well recognised doublet corresponding to 
the two aromatic protons of C-3 and C-5 appears at 7.22 ppm with a coupling value 
8.8 Hz.  
 
4.2.9. Synthesis of the Fmoc-protected amine A8. 
As it has been mentioned earlier in this chapter it was expected that basic hydrolysis 
to the ethyl ester would be likely to deprotect the Fmoc-protecting group. Therefore, 
as a bid to avoid that potential, it was decided to protect the amine functionality with 
a suitable protecting group that can withstand basic conditions. The Boc protecting 
group was the choice to protect the amine functionality temporarly so after hydrolysis 
of the ethyl ester, the Fmoc group can be attached following Boc deprotection.  
 
 
 
Scheme 4. 26: Unsuccessful reaction to protect the amine with Boc protecting group. 
The above reaction (Scheme 4.27) was trialled to attach Boc group on the amine but 
did not work. The reaction was repeated with DMAP used instead of Et3N. Also, 
nothing obtained relevant to the product. In view of this, it was decided to proceed to 
produce the Fmoc protected compound and to investigate approaches to ester 
hydrolysis that would not deprotect the amine. 
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Scheme 4. 27: Fmoc-protection reaction of the amine compound using Fmoc-Cl. 
The Fmoc-protected A8 compound was obtained by reaction of the SM with Fmoc-Cl 
and NaHCO3 in THF at 0 oC (Scheme 4.28). The mixture was stirred for 1 h to afford 
the compound A8 in 95% yield after purification. 
 
 
 
 
Scheme 4. 28: Atom numbering of the Fmoc-protected compound A8. 
The assignment of the Fmoc protected amine using 1H NMR is discussed here (see 
scheme 4.29 for atom numbering). The first confirmation of success of the reaction is 
the presence of all the peaks related to the protons of the attached Fmoc group. Two 
peaks, doublet and triplet, both with coupling value 7.4 Hz are present at 7.77 and 
7.57 ppm repectively. The doublet peak is due to the protons of C-15 and C-21, which 
are chemically equivalent. Meanwhile, the triplet peak is relevent to the protons on 
the C-16 and C-22 carbons. Another two peaks matching the protons of the Fmoc 
group on C-17, C-18, C-23 and C-24 overlap with the multiplet of the five protons of 
the benzyl group over the chemical shitf range 7.44-7.29 ppm. As a result, this range 
integrates to nine protons, matching the benzylic five protons added to the four 
protons of the Fmoc relevant carbons. Additional peaks related to the Fmoc group 
are the two doublets of doublets at 4.51 and 4.37 which correspond to the two protons 
of the methylene carbon (C-12). Although the two protons of the C-12 are attached to 
the same carbon atom, they are not chemically equivalent. This is attributed to their 
enantiotopic properties. The last noticeable peak of Fmoc protons is the one 
corresponding to the proton of C-13 which overlaps with the signal corresponding to 
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the two protons of C-10 carbon of the ethyl group. This overlap results in a multiplet 
signal which integrates for three protons and extends over the chemical shift range 
4.24-4.10 ppm. An interesting change in the peaks matching the protons of C-7 and 
C-8 carbons was noticed on the NMR spectrum of Fmoc-protected amine compound 
compared to the spectrum of the amine compound. Both peaks have moved 
significantly to a higher chemical shift downfield. The doublet corresponding to the 
proton of C-7 has shifted from 4.90 ppm in the amine to 5.52 ppm, with coupling value 
8 Hz, in the Fmoc-protected amine. Meanwhile, the doublet of doublets, with coupling 
values 4 and 8 Hz, and matching the proton of the C-8 carbon has shifted from 3.77 
ppm in the amine, to 4.74 ppm in the product.  
Another doublet with coupling value 4 Hz at 5.17 ppm, matches the carbamate amide 
proton. To exclude any confusion that might have been seen over the latter three 
peaks for C-8, C-7 and carbamate proton, a 1H Cosy NMR was used (Figure 4.5). It 
is noticed that the amide proton has a spin-spin coupling with J value 4 Hz with the 
proton of C-8 carbon. In addition, a spin-spin coupling with J value 8 Hz is recognised 
between the protons of C-7 and C-8. There is no coupling effect between the 
carbamate proton and the C-7 proton. Noteworthy, it has been recognised that the 
chemical shift of the of C-8 proton in last three compounds, azide, amine and Fmoc-
protected is lower than that of the C-7, whereas, it is higher than the C-7 proton in the 
nosylated compound. That can be explained by the fact that the sulfonate group in 
the nosylated compound is a strong electron-withdrawing group. So, it pulls the 
electron density away from the proton of the carbon C-7, leaving it unshielded and 
ultimately the corresponding peak would present at a higher chemical shift. In 
contrast, the azide, amine, and the carbamate are positively activating groups, 
donating electrons, so the proton of C-8 would be shielded from the magnetic field. 
Therefore, the chemical shift of the C-8 proton would be at a lower position than that 
of C-7 proton. 
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Figure 4. 5: 1H Cosy NMR of the Fmoc-protected compound A8. 
 
The polarimetric rotation value was calculated at 22 °C: [α]= - 29.8 (c=0.063 g/mL, 
CHCl3). 
4.2.10. Hydrolysis of the ethyl ester. 
 
 
 
Scheme 4. 29: The chemical reaction of hydrolysis of ethyl ester using LiOH. 
This step was considered to be last step in the synthesis of the 2nd building unit and 
crucial in the course of the work. The above reaction (Scheme 4.30) was trialled using 
LiOH to hydrolyse the ethyl ester. TLC analysis showed no SM was left, NMR showed 
neither ethyl nor Fmoc groups however. 
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Scheme 4.30: The chemical reaction of acid hydrolysis of the ethyl ester. 
Alternatively, acid hydrolysis was trialled to avoid removal of the Fmoc group 
(Scheme 4.31). Upon tlc, a highly polar product was formed that was proved to be 
intractable to isolation and identification. A protonation of the side-chain hydroxyl 
under acidic condition might have occurred, and can potentially lead to elimination, in 
addition to the ester hydrolysis (Scheme 4.32). 
 
 
Scheme 4. 31: Illustration of the elimination of H2O molecule because of protonation of 
hydroxyl group. 
4.3. Synthesis of the Fmoc-protected ethyl ester, B5, 
analogue of the amino acid-6 (α-enantiomer). 
In parallel to the successful synthesis of ethyl ester A8, the opposite enantiomer was 
also generated using a similar approach. This is detailed briefly in the following 
section (Scheme 4.33). 
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Scheme 4. 32: The synthetic route of the ethyl ester compound B5. Reagents and conditions: 
a) AD-α, (1.4 gmmol-1), MeSO2NH2 (1.0 equiv), t-BuOH/H2O (1:1), 25 oC, 12 h; b) NsCl (1.0 
equiv), Et3N (2.0 equiv), DMF, 0 oC, 5 h, 44%; c) NaN3 (1.5 equiv), DMF, 55 oC, 12 h; d) SnCl2. 
H2O (2.0 equiv), MeOH, 25 oC, 2 h; e) Fmoc-Cl (1.1 equiv), NaHCO3 (2 equiv), THF, H2O, 0 
oC ,3 h. 
4.3.1. Synthesis of the diol B1 (α-enantiomer). 
The synthesis process was started with the cinnamate intermediate A3. The latter 
was subjected to SAD reaction using AD-Mix-α and methanesulfonamide to furnish 
the diol B1 in 70% yield as a white amorphous solid (Scheme 4.34). 
 
 
Scheme 4. 33: The reaction of production of the diol compound B1 through SAD using AD-
Mix-α. 
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The polarimetric rotation value was calculated at 22 °C: [α]= +16.16 (c= 0.049, 
EtOAc). 
4.3.2. Synthesis of the nosylated diol B2. 
As it was shown with the β-diol, the hydroxyl group was needed to be more reactive 
to act as a leaving group in a preparation step for the subsequent azide reaction. The 
reaction proceeded for 5 hours to give the product B2 in 44% after purification with 
flash chromatography (Scheme 4.35). 
 
 
Scheme 4. 34: Synthetic reaction of the nosylated compound B2. 
The polarimetric rotation value was calculated at 22 °C: [α]= +65.2 (c= 0.0065, 
EtOAc). 
4.3.3. Synthesis of the azide compound B3. 
This reaction was left overnight to furnish the product B3 in 68% after purification with 
flash chromatography (Scheme 4.36). 
 
 
Scheme 4.35: The chemical reaction of production of the azide compound B3. 
The polarimetric rotation value was calculated at 22 °C: [α]= -2.2 (c= 0.054, CHCl3). 
4.3.4. Synthesis of the amine compound B4. 
The reduction was carried out using SnCl2 in MeOH at room temperature. After 2 hour 
of stirring the product B4 was furnished in 84% (Scheme 4.37). 
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Scheme 4.36: The reduction reaction of the azide compound to produce the amine compound 
B4. 
4.3.5. Synthesis of the Fmoc-protected amine B5. 
The reaction of the Fmoc protection was proceeded for 1 h (Scheme 4.38). The  
Fmoc-protected compound B5 was given in 80% after purification with flash   
chromatography. 
 
 
Scheme 4.37: The reaction of formation of the Fmoc-protected compound B5 using Fmoc-
Cl. 
The polarimetric rotation value was calculated at 22 °C: [α]= +30.0 (c= 0.058, CHCl3). 
4.4. Synthesis of the TBS-protected compound B6. 
 
 
Scheme 4. 38: Reaction of production of the TBS-protected hydroxyl compound B6. 
In order to investigate the effects of the β-OH group on the hydrolysis reaction, and 
also as a potential protecting group for solid phase synthesis, we briefly investigated 
introducing a TBS group. TBSOTf was used as a source of TBS group and 2,6-lutidine 
as a catalyst base (Scheme 4.39). The SM was dissolved in DCM and the TBSOTf 
and 2,6-lutidine were added sequencially. The mixture was stirred for 1 h. After 
purification, the product B6 was furnished in 89% as a transparent oil. 
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Scheme 4. 39: Atom numbering of the TBS-protected compound B6. 
The TBS-protection product was confirmed using 1H NMR spectroscopy (see scheme 
4.40 for atom numbering). As the SM was fully assigned previously, the main change 
in the NMR spectrum for the product is the emergence of three signals related to the 
TBS group. The singlet at 0.92 ppm corresponds to the nine protons of the three 
methyl group attached to the C-25 carbon. The other two singlet signals at 0.07 ppm 
and -0.01 ppm correspond to the protons of both methyl groups attached to the silicon 
atom. Each of these singlets integrates to three protons. The doublet signal that 
corresponds to the amine proton has shifted slightly to a lower chemical shift at 5.07 
ppm. Unlike the Fmoc-protected amine, the signal that corresponds to the acidic 
proton of the Fmoc group (C-13) is appeared as a prominent triplet at 4.22 ppm.  
4.4.1. Hydrolysis of the ethyl ester compound B6. 
Hydrolysis of the TBS protected ethyl ester was attempted under neutral conditions, 
using methyltrichlorosilane and sodium iodide, however this led to preferential 
removal of the TBS group (Scheme 4.41). After two hour of stirring, the reaction 
mixture was worked up and purified with flash chromatography. NMR showed no TBS 
group while the ethyl group was still attached. Due to time constrains, further attempts 
to hydrolyse the ester function were not made. 
 
 
Scheme 4. 40: Unsuccessful reaction for hydrolysis of the ethyl ester. 
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4.5. Summary 
In summary, this chapter discusses the synthesis of two Fmoc-protected 
stereoisomers, which following the identification of appropriate methods of the 
removal of the ethyl ester group, are suitable for solid phase synthesis. The synthetic 
route, based on the the Nicolauo’s approach, involved the successful use of the 
Sharpless AD reaction to set the stereochemistry of the two compounds. The failure 
of the t-Bu protected compound to undergo sharpless AD or dihydroxylation under 
harsh conditions was surprising and led to complications later in the synthesis due to 
the presence of the ethyl ester groups. Both basic and acidic conditions for the 
hydrolysis of the ethyl ester were unsuccessful, at least in initial trials. A hydrolysis 
method using neutral conditions, methyltrichlorosilane and sodium iodide, was also 
briefly investigated but without a productive result.  
The recommendation to resolve this problem is hydrolysis of the ethyl ester before 
attachment of Fmoc group and the resulting zwitterionic compound can be isolated 
using preparative-HPLC. Another approach is via the use of a buffer system to 
precisely adjusting the pH of the zwitterion solution until neutral pH is reached and 
hence the amino acid would be precipitated and isolated. 
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Chapter 5. Summary 
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5.1. The Synthesis of the central unit C14 of vancomycin.  
Due to the demanding nature of the solution phase synthesis of a complex natural 
product like vancomycin, which requires multiple protection and deprotection steps 
and purification at every stage, a solid phase synthesis approach was an attractive 
aim. The feasibility of SPPS, which requires less purification steps and could 
potentially generate analogues in a rapid timeframe, was not clear for this complex 
molecule, therefore, the synthesis of the amino acid components of vancomycin in 
Fmoc-protected forms was the central idea in the project plan.  
The synthesis of the central unit of vancomycin was successfully carried out following 
a variation of the approach developed by Nicoloau and co-workers but which required 
some modification in order to generate the correctly substituted Fmoc protected 
amino acid suitable for SPPS. The synthesis started with p-amino benzoic acid C1, 
which was esterified to the methyl ester C2 using methanol. The C1 was converted 
to the more reactive intermediate, acyl chloride, via the use of thionyl chloride. 
Dibromination was carried out to the C2 producing C3 by using liquid bromine and 
alcohol as solvent. The methyl ester moiety of C3, was reduced to the primary alcohol 
using LiAlH4 in THF at 0 °C, furnishing C4, which was protected at the aniline function 
by triazene group using nitrous oxide and pyrrolidine in AcOH/H2O solvent system at 
0 °C affording C5. The latter, was subjected to an oxidation reaction using PCC in 
DCM at room temperature giving the aldehyde C6. A Wittig reaction was implemented 
to convert the C6 to the cinnamate C7, which was converted to the diol C8 via 
Sharpless AD reaction using AD-mix-α in t-BuOH/H2O solvent system. The primary 
hydroxyl group of C8 was protected by TBS group using TBSOTf in DMF at 0 °C 
giving C9. Then, through a Mitsunobu reaction, the secondary hydroxyl group was 
displaced by azide function via a nucleophilic reaction using Ph3P, DPPA and DIAD 
to furnish azide compound C10. The latter was reduced to the amine compound C11 
using Ph3P. The Fmoc protection reaction was carried out to the amine C11, using 
Fmoc-Cl in THF at 0 °C, affording Fmoc-protected C12. The TBS-deprotection 
reaction was performed using TBAF in THF at 0 °C converting the C12 to the alcohol 
C13. Finally, via an oxidation reaction using TEMPO the desired amino acid C14 with 
free carboxylic acid and Fmoc-protected amine was afforded. This multi-step 
synthesis demonstrates that, while the target compound was relatively simple, the 
oxygenated structure and the requirement for suitable substitution on the aromatic 
ring to aid eventual ring forming reactions, leads to a complex route to synthesis. In 
retrospect, the incorporation of the triazene group to both direct ring closing reactions  
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and to act as a protecting group may have been ambitious in the context of SPPS 
and led to complications with cleavage from the resin and identification of the final 
product. 
5.2. Solid phase synthesis incorporating C14. 
The central unit C14 was taken through several trials of solid phase synthesis. In the 
first trial, a model of tetrapeptide was proposed consisting of the following amino 
acids: Fmoc-Tyr(tBu)-OH, Fmoc-Tyr(OH)-OH, Fmoc-Ala-OH and the Fmoc-
Tyr(tirazene)-OH. Using the ClTrt resin as a supporting solid and HATU as a coupling 
reagent, this trial ended unsuccessful. In the 2nd trial, the central unit was removed 
from the above model to exclude any potential issue might be caused by the triazene 
group. Using the same reagents and conditions, we also failed to obtain the required 
tripeptide, which was shown to be guanidinated due to the use of the HATU reagent. 
This is promising in that the peptide was present but undergoing a side reaction due 
to the use of excess HATU that was not predicted.  In the 3rd trial, PyBOP was used 
as a coupling reagent instead of HATU and the result was successful in the synthesis 
of the tripeptide model. Including the central residue C14, the earlier model of 
tetrapeptide was trialled using PyBOP as a coupling reagent but the target 
tetrapeptide was not obtained. This suggests that the Fmoc protected amino acid, as 
the triazene derivative, may well be unsuitable as a reagent in the synthesis of 
vancomycin analogues on the solid phase. It may be that the triazene unit is not stable 
enough to be applied to these conditions. In the last trial, the supporting solid was 
changed to Wang resin and a model of tripeptide of Tyr, Gly, and the triazene 
derivative C14 was trialled but also no positive result was reached. 
5.3. Solution phase synthesis using C14. 
After the unsuccessful trials of the solid phase synthesis of the central residue C14, 
it was taken through a solution phase synthesis model to explore its compatibility to 
this type of chemistry (i.e. peptide coupling). A model of tripeptide of methyl ester of 
tyrosine, Fmoc-protected glycine and the central unit C14 was proposed. The methyl 
ester of tyrosine and the Fmoc-protected glycine were reacted in acetone using 
HOBt/EDC as a coupling system producing the Fmoc-protected dipeptide D1. The 
latter, was then deprotected by 20% piperidine furnishing the Fmoc-deprotected 
dipeptide D2. As 1H NMR result showed no methyl group was present, this suggested 
that under basic condition of the Fmoc deprotection, the free amine has undergone a 
cyclization reaction. Therefore, the Fmoc-protected glycine was replaced by Boc-
protected glycine and the coupling proceeded using the same reagents and 
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conditions, affording the Boc-protected dipeptide D3. Then, the Boc deprotection 
reaction of the latter was carried out with 50% TFA/DCM to give the Boc-deprotected 
dipeptide D4. The final step in the solution phase synthesis, involved the attachment 
of the triazene derivative to the D4 in acetone and that culminated successfully in 
production of the desired tripeptide D5 including the compound C14. This 
demonstrates that, under peptide coupling conditions, it is possible to generate the 
desired peptides, at least under solution phase conditions. Further work needs to be 
carried out to optimise the conditions to be able to use C14 as a reagent for solid 
phase synthesis.  
5.4. The Synthesis of A8. 
To continue towards the aim of the project, for the synthesis of all the amino acid 
components of the vancomycin structure in their Fmoc-protected forms, the synthesis 
of tyrosine derivatives, amino acids 2 and 6, was trialled. The ethyl esters of the latter 
amino acids protected by Fmoc group at the α-amine, compounds A8 and B5 
respectively, were obtained. 
The synthesis of A8 started with the benzylation of p-hydroxybenzaldehyde A1 using 
BnBr in DMF producing the A2 compound. The latter, was then taken through a 
Horner-Wadworth-Emmons reaction to afford the styrene A3. Using AD-Mix-β, the 
styrene A3 was oxidised to the diol A4 via a Sharpless AD reaction. The diol then 
was protected using NoSCl in DMF giving the nosylated compound A5. The latter, 
was subjected to a SN2 reaction by NaN3 in DMF affording the aizde derivative A6. 
The amine A7 was produced by reacting SnCl2 with A6 in MeOH. Finally, the Fmoc-
protected ethyl ester A8 was furnished via the reaction of A7 with Fmoc-Cl in THF. 
5.5. The synthesis of B5. 
The opposite enantiomer of the A8 compound, compound B5, was obtained 
successfully using the same approach, which started with the A3 intermediate. The 
latter was subjected to the Sharpless AD reaction using AD-Mix-α and 
methanesulfonamide to furnish the diol B1. The nosylated compound B2 was 
afforded via the reaction of the B1 with NoSCl in DMF. The B2 was reacted with NaN3 
in DMF to give the azide B3. The latter was subjected to SnCl2 in MeOH affording the 
amine B4. The Fmoc-protected compound B5 was obtained by the reaction of the B4 
with Fmoc-Cl in THF. 
Several procedures were trialed to hydrolyse the ethyl ester of both A8 and B5 but 
without successful results. The hydrolysis with LiOH led, predictably, to deprotection 
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of the Fmoc group, while the hydrolysis under acidic conditions using HCl and under 
neutral conditions using CH3SiCl3 did not generate the products. There are potential 
alternative approaches to generate the free acid, Fmoc protected derivatives. 
Notably, deprotection of the ester through hydrolysis prior to Fmoc protection could 
be carried out. Time constraints meant that this approach was pursued. 
5.6. Conclusions. 
The first goal of this project was partially accomplished in that, the synthesis of the 
Fmoc-protected forms of the amino acid components of vancomycin was successfully 
carried out, albeit with two of the compounds still in Me ester protected form. The 
synthesis of C14 was efficient, with several steps having high yields that are 
consistent in moving to scale-up reactions to produce the amounts required for solid 
phase synthesis. The successful routes to the synthesis of the Fmoc-protected forms 
of the ethyl esters of the tyrosine derivatives, A8 and B5 were also disclosed, 
although the hydrolysis of the ethyl ester was not successfully demonstrated.  
The successful coupling of the synthesised Fmoc-protected central residue C14 of 
vancomycin using solution phase synthesis methodology was disclosed. However, to 
date, the application of the synthesis to the solid phase has not been successful. The 
synthesis utilising the triazene moiety is likely to be having a detrimental effect on the 
solid phase route and, in future work, it would probably be reasonable to replace this 
moiety with other groups.  
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Chapter 6. Experimental 
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6.1.General experimental 
Sigma Aldrich was the main source of purchasing most of the chemicals as reganet 
grade. Also, some of chemicals were purchased from Novabiochem, Fluorochem, or 
Fisher Scientific. All solvents were bought as anhydrous and supposed to comply the 
manofactureeres’ standards. Distilled water was used for all specified experiments. 
Peptide grade DMF was used for the solid phase peptide synthesis. All solvents for 
HPLC mobile phases solvents were purchased as HPLC grade.  
1H and 13C-NMR spectrometry with Fourier Transform mode on a Bruker B-ACS 60 
Ultrashield 400 plus spectrometer, operating at a nominal 1H NMR frequency of 400 
MHz, was used for the chemical structure assignments of the reaction products. All 
specified spolvents for NMR were used as deuterated. Topspin 3.0 software was used 
for spectra processing. The peaks of both 1H and 13C-spectra were reported as 
chemical shifts in ppm and the chemical shift of the specified residual solvent peak 
was assigned as a reference. The peaks of NMR spectra are described as 
multipulities as follows: s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q 
= quartet, m = multiplet and br = broad. The coupling constants, J, are recorded in 
Hz. EPSRC National Mass Spectrometry Service Centre, Swansea, was used for 
accurate recorded-mass spectra. A Perkin-Elmer Spectrum BX FT-IR was used for 
recording Infrared spectra, which were manipulated using Spectrum v5.3 Software. 
Thin layer chromatography (TLC) was carried out using Merck aluminium plates, 
coated with 0.2 mm silica gel-60 F254, as a stationary phase, which after elution were 
visualised under UV light.  
Both normal and automated flash chromatography were used for crude compound 
purification as specified. The normal flash chromatography was carried out using 
glass columns filled with silica gel (particle size 60 µm) for column chromatography 
and the application of positive pressure was performed using hand bellows. The 
automated flash chromatography was performed on a Biotage Isolera 4, using as 
specified a pre-packed Biotage SNAP column. 
RP-HPLC was carried out as specified on an Agilent 1200 using an Agilent eclipse 
XDB-C18 column, 4.6 x 150mm, 5 µm and a flow rate of 1 mL/min. Solvent A = H2O 
+ 0.05% TFA and Solvent B = MeOH + 0.05% TFA. Gradient 5% B  95% B over 15 
minutes 95% B  5 % B over 5 mins. Detection wavelength 254 nm.  
Preparative RP-HPLC was performed as spacified on an Agilent 1260 infinity using 
an Agilent eclipse XDB-C18 column, 21.2 x 150 mm, 5 µm and a flow rate of 20 
175 
 
mL/min. Solvent A = 95% H2O + 5% MeOH + 0.05% TFA and Solvent B = 95 % 
MeOH + 5 % H2O + 0.05% TFA. Gradient 0 % B  100 % B over 15 minutes, 100 % 
B  0 % B over 5 mins. Detection wavelength 254 nm. 
 
6.2. Organic synthesis. 
6.2.1. Synthesis of C14. 
 
 
C2(99): thionyl chloride (10.6 mL, 146 mmol) was added slowly to a solution of C1 (20 
g, 146 mmol) in MeOH (200 mL). The resulting solution was heated at reflux for 15 h 
until the reaction was shown to be complete by tlc. The solvent was removed under 
reduced pressure and the residue was dissolved in saturated aqueous NaHCO3 
solution (150 mL) and extracted with EtOAc (3 x 120 mL). The combined extracts 
were washed with H2O (150 mL), brine (150 mL), dried (Na2SO4), filtered and the 
solvent was removed under reduced pressure to give C2 as a light yellow amorphous 
solid in a 97% yield without purification. mp 114-122 °C; 1H NMR (400 MHz, CDCl3): 
ppm=7.85 (d, J=8.8 Hz, 2H, ArH), 6.64, (d, J=8.8, 2H, ArH), 3.85 (s, 3H, CH3); 13C 
NMR (400 MHz, CDCl3): ppm=167.17, 150.82, 131.61, 119.75, 113.80, 51.61; IR: 
3463, 3368, 1678, 1593, 1567, 1520, 1434, 1313, 1286, 1180, 1167, 1121 cm-1; 
HRMS calculated for C8H10NO2 152.0706 [M+H]+ observed 152.0703. 
 
 
C3(99): bromine (2.7 mL, 52.8 mmol) was added slowly to a solution of C2 (4 g, 26.4 
mmol) in ethanol (50 mL). The resulting mixture was stirred for 30 min at rt until until 
the reaction was shown to be complete by tlc. The solvent was removed under 
reduced pressure, and the residue triturated with 10% aqueous of solution sodium 
thiosulfate (20 mL) and extracted with EtOAc (3 x 20 mL). 1M NaOH (25 mL) was 
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added to remove the sulfur precipitate that formed during the extraction process. The 
organic layers were washed with H2O (20 mL), brine (20 mL), dried (Na2SO4), filtered 
and concentrated under reduced pressure. The crude was purified by flash 
chromatography to give 71% yield of the product as a white amorphous solid. On the 
large scale (21.5 g, 142 mmol), the precipitated product after 30 min of stirring was 
only filtered under reduced pressure and triturated with ethanol to give the 
dibrominated product C3 in 82% yield without purification. mp 133-137 °C; 1H NMR 
(400 MHz, CDCl3): ppm=8.07(s, 2H, ArH), 4.99 (br. s, 2H, NH2), 3.87(s, 3H, CH3); 13C 
NMR (400 MHz, CDCl3): ppm=164.99, 145.76, 133.40, 120.93, 107.40, 52.15; IR: 
3423, 3320, 1720, 1606, 1547, 1430, 1300, 1255 cm-1; HRMS calculated for 
C8H7Br2NO2 309.8902 [M+H]+ observed 309.8901. 
 
 
C4(99): a solution of C3 (2.83 g, 9.2 mmol) in 30 mL anhydrous THF was added 
dropwise, to a cooled suspension at 0 °C of LiAlH4 (0.7 g, 18.4 mmol) in 15 mL 
anhydrous THF. The resulting mixture was stirred at this temperature for 3 h until the 
reaction was shown to be complete by tlc. The mixture then quenched with slow 
addition of NH4Cl (15 mL), filtered and extracted with EtOAc (20 mL x 3). The 
combined organic extracts were washed with H2O (20 mL), brine (20 mL), dried 
(Na2SO4) and the solvent was removed under reduced pressure. Purification was 
carried out with column flash chromatography giving the product, as a dark yellow 
amorphous solid, in 87% yield. The largescale reaction (20.1 g, 65.00 mmol) reached 
to completion after 1 h of stirring, furnishing the product in 86% yield without 
purification. mp 127-130 °C; 1H NMR (400 MHz, CDCl3): ppm=7.40(s, 2H, ArH), 4.54 
(s, 2H, CH2), 4.54 (br. s, 2H, NH2); 13C NMR (400 MHz, CDCl3): ppm=141.44, 132.29, 
130.75, 108.68, 63.95. IR: 3419, 3308, 2916, 2865, 1612, 1580, 1544, 1509, 1476, 
1405, 1350, 1282, 1199, 1024 cm-1; HRMS calculated for C7H6Br2NO 279.8801 [M-
H]- observed 279.8802. 
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C5(99): 6 M HCl (7.5 mL) and NaNO2 (736 mg, 10.7 mmol) were added sequentially to 
a suspention of C4 (2.5 g, 8.9 mmol) in acetic acid/H2O (30 mL, 1:1) at 0 oC and the 
resulting mixture was stirred at this temperature for 45 min. The resulting solution was 
transferred slowly to another flask containing KOH (15 g, 267 mmol) and pyrrolidine 
(1.1 mL, 13.35 mmol) in an 80 mL of water. Upon the addition, a brown sticky solid 
was precipitated. The mixture was extracted with EtOAc (100 mL × 3) and washed 
with H2O (100 mL) and brine (100 mL). Without purification, the product was afforded 
as a brown amorphous solid in 85% yield. The SM’s spot turned to yellow while the 
product’s spot turned to grey. This reaction was scaled up on two stages, first C4 was 
used in 8 g (28.5 mmol) to give 9.56 g (93% yield). In the 2nd stage, 24.5 g of C4 (87.1 
mmol) was used and gave to 15.5 g of a brown amorphous solid (50% yield) after 
purification with column flash chromatography. EtoAc/n-hexane was used as a mobile 
phase in a gradient elution, 15-30%. On the large-scale reactions, the crude product 
was filtered under vacuum rather than extracted. mp 106-115 °C ; 1H NMR (400 MHz, 
CDCl3): ppm=7.52 (s, 2H, ArH),4.61(s, 2H CH2OH), 3.95 (br s, 2H, NCH2), 3.73(br s, 
2H, NCH2), 2.08 (br. s, 4H, NCH2CH2, NCH2CH2); 13C NMR(400 MHz, CDCl3): 
ppm=145.96, 140.86, 130.03, 117.78, 62.99, 51.46, 46.81, 23.92, 23.72; IR: 3324, 
2947, 2874, 1539, 1405, 1339, 1309, 1260, 1191, 1048 cm-1; HRMS calculated for 
C11H13Br2 N3OH 363.9478 [M+H]+ observed 363.9480. 
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C6(99): PCC (2.3 g, 12.45 mmol) was mixed with 2 g silica and added to a stirring 
solution of C5 (3 g, 8.3 mmol) in DCM (40 mL). The resulting mixture was stirred for 
5 h until the reaction was shown to be complete by tlc. The mixture was filtered 
through Florisil® (60-100) (in the literature, celite was reported(99)) and washed with 
H2O (15 mL), brine (15 mL), dried (Na2SO4) and the solvent was removed under 
reduced pressure to give the aldehyde C6 in 90% yield as a dark brown solid (2.7 g) 
without purification. This reaction was scaled up to 15.5 g (4.2 mmol) of C5 and the 
product was filtered through silica under reduced pressure instead of Florisil® to give 
the aldehyde in 91% yield (13.82 g). mp 105-112 °C; 1H NMR (400 MHz, CDCl3): 
ppm= 9.84 (s, 1H, CHO), 8.04(s, 2H, ArH), 3.99(s, 2H, NCH2), 3.75(s, 2H, NCH2), 
2.11 (br. s, 4H, NCH2CH2CH2); 13C NMR(400 MHz, CDCl3): ppm=188.88, 152.80, 
134.11, 133.63, 118.51, 51.44, 46.94, 24.01, 23.54; IR: 3359, 3048, 2971, 2871, 
2834, 1688(C=O, aldehyde), 1579, 1536, 1407, 1337, 1307, 1260, 1222, 1191, 1103, 
1026 cm-1; HRMS calculated for C12H12Br2N2OH 360.9369 [M+H]+ observed 
361.9325. 
 
 
C7(99): n-BuLi (12.12 ml) was handled under inert conditions (N2) and added 
dropewise to a suspension of methyltriphenylphosphonium bromide (7.43 g) in 40 mL 
anhydrous THF, at -20 oC. The resulting mixture was stirred under N2 for 0.5 h. A 
solution of C6 (5 g, 13.85 mmol) in 30 mL anhydrous THF was added to the resulting 
suspension at that temperature and the resulting mixture was left overnight for stirring 
under N2 untile the reaction was shown to be complete by tlc. The resulting mixture 
was quenched with H2O (50 mL), extracted with EtOAc (50 mL × 4), washed with of 
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H2O (2 x 50 mL), brine (50 mL), and dried (Na2SO4). The crude was purified by flash 
chromatography using ether/n-Hexane system as a mobile phase, which was run in 
a linear gradient 4-8%.  The product was furnished in a 58% yield as a yellow/brown 
oil. This reaction was scaled up to 13.5 g of C6 and the same above procedure was 
followed to give the product in 55% yield (7.5 g). 1H NMR (400 MHz, CDCl3): 
ppm=7.57 (s, 2H, ArH), 6.55 (dd, J=17.5, 10.9 Hz, 1H, ArCH), 5.70 (d, J=17.5 Hz, 1H, 
ArCH=CHH), 5.26 (d, J=10.9 Hz, 1H, ArCH=CHH), 3.96 (br. s, 2H,NCH2), 3.73(br. s, 
2H, NC 2), 2.08 (br. s, 4H, NCH2CH2CH2); 13C NMR(400 MHz, CDCl3): ppm=147.34, 
136.49, 134.22, 130.17, 118.01, 115.39, 51.31, 46.73, 24.12, 23.77; IR: 2976, 2946, 
2873, 1520, 1446, 1402, 1380, 1353, 1337, 1305, 1256, 1223, 1194 cm-1; HRMS 
calculated for C12H13Br2N3 359.9529 [M + H]+ observed 359.9529. 
 
 
C8(99): AD-Mix-α (30.22 g) powder was added to a stirring suspension of C7 (7.75 g, 
216 mmol) in 200 mL t-BuOH/H2O (1:1) at rt, and the resulting mixture was stirred for 
48 h until the reaction was shown to be complete by tlc. Then, Sodium sulfite (32.4 g) 
was added to the suspension and the resulting mixture was stirred for 1 h and 
extracted with EtOAc (100 mL × 3) and the combined extracts were washed with H2O 
(100 mL) and brine (100 mL). Without purification, the product was furnished in 97% 
yield (8.28 g) as a yellow amorphous solid. mp= 120-130 °C;  1H NMR (400 MHz, 
CDCl3): ppm=7.50 (s, 2H, ArH), 4.73 (dd, J=8.04, 3.53 Hz, 1H, ArCH), 3.95 (br. s, 2H, 
NCH2), 3.71(br. s, 2H, NCH2), 3.68 (dd, J=11.1, 3.5 Hz, 1H, CHHOH), 3.57 (dd, 
J=11.1, 8.04 Hz, 1H, CHHOH), 2.09 (br s, 4H, NCH2CH2CH2); 13C NMR(400 MHz, 
CDCl3): ppm=146.35, 140.75, 129.86, 117.98, 72.94, 67.71, 51.57, 46.86, 23.90, 
23.74; IR: 3548, 3274, 2960, 2874, 1540, 1405, 1309, 1262, 1209, 1083, 1029 cm-1; 
HRMS calculated for C12H14Br2N3O2 393.9583 [M+H]+ observed 393.9583; 
polarimetric rotation was calculated at 22 °C: [α] =+82.05 (c=0.078 g/mL, CHCl3). 
 
 
180 
 
 
 
 
C9(99): anhydrous Et3N (1.37 mL) and TBS-Cl (1.5 g, 9.81 mmol) were added 
sequentially to a solution of C8 (2.57 mg, 6.54 mmol) and DMAP (79.8 mg) in DCM 
(50 mL) at 0 °C and under inert atmosphere (N2), The resulting mixture was stirred at 
that temperature for 2 h before quenching with saturated aqueous solution of NH4Cl 
(20 mL). The organic layer was separated, and the aqueous layer was extracted with 
DCM (30 mL × 3).  The combined organic extracts were washed with H2O (30 mL) 
brine (30 mL), dried with sodium sulfate and concentrated under reduced pressure. 
Purification was carried out with an automated flash chromatography system. The 
crude was dry loaded on 100 g SNAP Ultra preloaded column, and a mobile phase 
system of EtOAc/n-Hexan was run in a linear gradient 10-30%. The TBS-protected 
diol C9 was furnished in a 63% yield as a yellow oil. This reaction was scaled up to 
8.9 g of C8 using the same conditions and reagents, and the product was purified 
with the automated flash chromatography in a similar way to that of the small scale to 
give the TBS-protected diol C9 in 67% yield. 1H NMR (400 MHz, CDCl3): ppm=7.54 
(s, 2H, ArH), 4.66 (dd, J=8.2, 3.6, 1H, ArCH), 3.85 (br. s, 4H, NCH2), 3.73 (dd, J=10.1, 
3.6, 1H, CHHOSi), 3.49 (dd, J=10.1, 8.2 Hz, 1H, CHHOSi), 2.08 (br. s, 4H, 
NCH2CH2CH2), 0.91 (s, 9H, tBuSi), 0.07 (s, 3H, CH3Si), 0.06(s, 3H, CH3Si); 13C 
NMR(400 MHz, CDCl3): δ=146.84, 140.25, 130.08, 117.61,72.83, 68.45, 51.29, 
46.69, 25.89, 23.97, 23.69, 18.29, -5.36. IR: 3361, 3300, 2926, 2856, 1541, 1417, 
1360, 1328, 1314, 1253, 1225, 1111 cm-1; HRMS calculated for C18H29Br2N3O2Si 
508.0449 [M+H]+ observed 508.0441; polarimetric rotation value was observed at 22 
°C: [α]=+18 (0.026 g/mL, CHCl3). 
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C10(99): Triphenylphosphine (780 mg, 3 mmol), diisopropylazo dicarboxylate (DIAD) 
(590.4 µl, 3 mmol) and diphenylphosphoryl azide (DPPA) (640 µl, 3 mmol) were 
added sequentially to a solution C9 (600 mg, 1.2 mmol) in an anhydrous THF (3 mL) 
at 0 °C under inert atmosphere (N2). The resulting mixture was stirred at this 
temperature for 2 h until the reaction was shown to be complete by tlc. The solvent 
was removed under reduced pressure and the residue was purified with the 
automated flash chromatography as a mobile phase of ether/n-hexane was run in a 
linear gradient 5-10%.  450 mg of the crude (still contained isopropanol) was obtained 
as a yellow oil. As mentioned in chapter 2, all attempts to scale up this reaction more 
than 700 mg of the SM failed to give the right azide compound. However, the amount 
of the crude azide product was obtained from the reaction of alcohol C9 (9.00 g, 17.75 
mmol), was 6.8 g.  1H NMR (400 MHz, CDCl3): δ=7.49 (s, 2H, ArH), 4.49 (dd, J=7.7, 
4.4 Hz, 1H, ArCH), 3.92 (br. s, 2H, NCH2), 3.76 (br. s, 2H, NCH2) 3.78 (dd, J=10.6, 
4.4 Hz, 1H,CHHOSi), 3.71(dd, J=10.6, 7.7 Hz, 1H, CHHOSi), 2.08 (br. s, 4H, 
NCH2CH2), 0.90 (s, 9H, tBuSi), 0.07 (s, 3H, CH3Si), 0.06 (s, 3H, CH3Si); 13C NMR 
(400 MHz, CDCl3): ppm=148.05, 135.81, 131.10, 117.95, 67.92, 65.67, 51.33, 46.72, 
25.89, 24.12, 23.75, 18.35, -5.39, -5.44; IR: 2983, 2929, 2857,  2100, 1773, 1416, 
1315, 1239 cm-1; HRMS calculated for C18H28Br2N6OSi 533.0514 [M+H]+ observed 
533.0506; polarimetric rotation value was observed at 22 °C: [α]= - 102 (0.076 g/mL, 
CHCl3). 
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C11(99): Triphenyl phosphane (400 mg, 1.52 mmol) and H2O (93 µl, 5 mmol) were 
added sequentially to a solution of C10 (270 mg, 0.507 mmol) in an anhydrous THF 
(5 mL). The the resulting mixture was heated to 60 °C and stirred for 2 h untile the 
reaction was showen to be complete by tlc. The resulting solution was cooled down 
to rt, the solvent was removed under reduced pressure and the residue was purified 
using the automated flash chromatography. The crude was dry loaded on 25g SNAP 
Ultra preloaded column and a mobile phase system of EtOAc/n-hexane was run in a 
linear gradient 10-30%. The crude was furnished in a 200-mg weight as a light-yellow 
oil. On the large-scale reaction, 4.64 g of C10 was used, furnishing 4 g of the crude 
after purification with normal column flash chromatography as a mobile phase system 
of EtOAc/n-Hexane was used in a 30-40% gradient. 1H NMR (400 MHz, CDCl3): 
ppm=7.55 (s, 2H, ArH), 3.98 (dd, J=7.5, 4.0 Hz, 1H, ArCH), 3.93 (br. s, 2H, NCH2), 
3.70 (br. s, 2H, NCH2), 3.67 (dd, J=9.7, 4.0 Hz, 1H, CHHOSi), 3.47 (dd, J=9.7, 7.5 
Hz, 1H, CHHOSi), 2.06 (br. s, 4H, NCH2CH2, NCH2CH2 ), 0.89 (s, 9H, tBu-Si), 0.02 
(s, 6H, (CH3)2-Si); 13C NMR (400 MHz, CDCl3): ppm=147.06, 141.85, 130.90, 117.58, 
68.94,56.34, 51.17, 46.58, 25.90, 23.90, 23.70, 18.27, -5.40, -5.42; IR: 3208, 2927, 
2855, 1711,1534, 1590,1467, 1414, 1313, 1251, 1223, 1179, 1112 cm-1; HRMS 
calculated for C18H30Br2N4OSi 507.0609 [M + H]+ observed 507.0602; the 
polarimetric rotation value was observed at 22 °C: [α]= - 10.7 (0.11 g/mL, CHCl3). 
 
 
C12: An aqueous solution of NaHCO3 (66.6 mg, 0.8 mmol, 1 mL H2O) was added to 
a solution of C11 (200 mg, 0.4 mmol) in THF (3 mL) at 0 oC, and the resulting mixture 
was stirred. Then, a cooled solution at 0 °C, of Fmoc-Cl (153.3 mg, 0.6 mmol) in THF 
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(2 mL) was added dropwise to the stirring mixture and the resulting mixture was 
stirred for 3 h untile the reaction was showen to be complete by tlc. The THF solvent 
was removed under reduced pressure and the emaining aqueous residue was 
extracted with EtoAc (2 mL × 3). The combined organic extracts were washed with 
H2O (3 mL), brine (3 mL), dried with sodium sulfate and concentrated under reduced 
pressure. The purification was performed with the automated flash chromatography 
as the crude was dry loaded on 25 g SNAP Ultra preloaded column and EtoAc/n-
Hexane mobile phase was run in a linear gradient, 5-20%. A 240mg weight of the 
pure product was obtained as a yellow fluffy solid. On the scale up steps, the average 
yield over the last four reactions, bigning with C9 (9.00 g, 17.75 mmol) and ending up 
with C12 (6.5 g, 9.00 mmol), was 50% and the the Fmoc-protected product C12 was 
purified with normal column flash chromatography (gradient elution, 10-20% EtOAc/n-
Hexane). mp 70-85 °C; 1H NMR (400 MHz, CDCl3): ppm=7.92(d, J=7.4 Hz, 2H, Ar-
Fmoc), 7.72(m, 2H, Ar-Fmoc), 7.67( s, 2H, ArH), 7.44(m, 2H, Ar-Fmoc), 7.35 (m, 2H, 
Ar-Fmoc), 4.64(m, 2H, CHNH), 4.34(d, J=7 Hz, 2H, CH2-Fmoc), 4.26(t, J=7 Hz, 1H, 
Ar-Fmoc), 3.91(br. s, 2H, NCH2), 3.72(br. s, 2H, CH2OH), 3.60(br. s, 2H, NCH2), 
2.03(m, 4H, NCH2CH2), 0.85(s, 9H, (CH3)3-TBS), 0.01(s, 3H, CH3, TBS), -0.02(s, 3H, 
CH3, TBS); 13C NMR (400 MHz, CDCl3): ppm=155.86, 147.39, 143.92, 141.39, 
139.35, 130.99, 127.79, 127.19, 125.13, 120.05, 117.78, 67.08, 66.01, 55.21, 51.30, 
47.27, 46.65, 25.91, 24.04, 23.81, 18.33, -5.52; IR: 2950, 1706, 1501, 1414, 1315, 
1253, 1104 cm-1; HRMS calculated for C33H40Br2N4O3Si 729.1292 [M + H]+ observed 
729.1290; the polarimetric rotation value was observed at 22 °C: [α]= - 42.9 (0.067 
g/mL, CHCl3). 
 
 
C13: AcOH (44 µl, 0.9 mmol) and TBAF (0.35 ml, 0.36 mmol) were added sequentially 
to a solution of C12 (220 mg, 0.3 mmol) in THF (3 mL) at 0 °C. The resulting solution 
was stirred at that temp for 6 h untile the reaction was showen to be complete by tlc. 
The rsulting solution was quenched with saturated aqueous solution of NH4Cl (2 mL) 
and extracted with EtoAc (3 mL × 3). The combined organic extracts were washed 
with H2O (4 mL), brine (4 mL) and concentrated under reduced pressure. The residue 
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was purified using automated flash chromatography, so it dry loaded on 25 g SNAP 
Ultar preloaded column. A mobile phase system of EtOAc/n-Hexane was run in a 
linear gradient, 20-50%, affording the alcohol C13 in 92% yield as an orange 
amorphous solid. This reaction was scaled up using 6.0 g of C12 and purified with 
normal column flash chromatography to afford the product in 98% yield (5.00 g). A 
mobile phase system of EtoAc/n-Hexane was run in a gradient elution 30-60%. mp 
85-125 °C; 1H NMR (400 MHz, DMSO-D6): ppm=7.92 (d, J=7.4 Hz, 2H, Ar-Fmoc), 
7.74(d J=7.4 hz, 2H, Ar-Fmoc), 7.62 ( s, 2H, ArH), 7.44(m, 2H, Ar-Fmoc), 7.36 (m, 
2H, Ar-Fmoc), 4.97(t, J=5.5, 1H, OH), 4.58 (m, 1H, CHNH), 4.37-4.23(m, 3H, 
CH2ArH-Fmoc), 3.91(br. s, 2H, NCH2), 3.63-3.52 (m, 4H, NCH2, CH2OH), 2.11-
1.95(m, 4H, NCH2CH2CH2); 13C NMR (400 MHz, CDCl3): ppm=156.28, 147.61, 
143.84, 141.39, 138.52, 130.52, 127.82, 127.22, 125.11, 120.05, 118.22, 67.03, 
65.77, 55.74, 51.34, 47.27, 46.73, 24.07, 23.77; IR: 3400, 3309, 2947, 2873,  1696, 
1535, 1448, 1411, 1333, 1313, 1257, 1222, 1052 cm-1; HRMS calculated for 
C27H26Br2N4O3 615.0426 [M+H]+ observed 615.0417; the polarimetric rotation value 
was observed at 22 °C: [α]= - 32.4 (0.056 g/mL, CHCl3). 
 
 
C14: The small scale was performed on 50 mg (0.1 mmol) of C13, which was 
dissolved in 1 mL acetone at 0 °C. 5% aqueous solution of NaHCO3 (1 mL) was added 
to the solution of C13 and the resulting mixture was stirred vigorously at that 
temperature. KBr (0.244 mg) and TEMPO (15.85 mg) were added sequentially to the 
stirring mixture before addition of NaOCl (0.4 mL) dropwise. The resulting mixture 
was stirred at 0 °C for 1 h until the reaction was showen to be complete by tlc. H2O 
(5 mL) and EtOAc (5 mL) were added sequentionally the resulting solution. The 
organic layer was separated and the aqueous layer was extracted with EtOAc (3 mL 
× 3). The combined organic extracts were washed with H2O (7 mL), brine (7 mL), 
dried with sodium sulfate and concentrated under reduced pressure. The residue was 
purified with automated flash chromatography using preloaded 10 g SNAP Ultra 
column and a mobile phase system of MeOH/DCM was run in a linear gradient, 5-
20%. The acid C14 was obtained in a 47% yield as a yellow/brown amorphous solid. 
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The reaction was scaled up to 4.5 g of C13 and purified with automated flash 
chromatography device as the crude was dry loaded on 50 g SNAP Ultra pre-loaded 
column and a mobile phase of MeOH/DCM was run in a linear gradient, 5-10% to 
give the acid product C14 in 61% yield (2.82 g). mp 105-135 °C1H; NMR (400 MHz, 
DMSO): ppm=7.93(d, J=7.4 Hz, 2H, Ar-Fmoc), 7.76(d J=7.4 Hz, 2H, Ar-Fmoc), 7.70 
( s, 2H, ArH),7.48-7.41(m, 2H, Ar-Fmoc), 7.40-7.32 (m, 2H, Ar-Fmoc), 5.05 (br. s, 1H, 
CHNH), 4.34-4.23 (m, CH2ArH-Fmoc), 3.91(br. s, 2H, NCH2), 3.61(m, 2H, NCH2), 
2.12-1.96(m, 4H, NCH2CH2CH2); 13C NMR (400 MHz, CDCl3): ppm=155.55, 147.86, 
143.90, 141.34, 137.10, 131.32, 127.78, 127.23, 125.21, 120.01, 118.07, 67.23, 
56.42, 51.26, 47.21, 45.31, 24.07, 23.77; IR: 3383, 2957, 1693, 1608, 1448, 1409, 
1312, 1260, 1223, 1048 cm-1; HRMS calculated for C27H23Br2N4O4 627.0073 [M-H]- 
observed 627.0071; the polarimetric rotation value was calculated at 22 °C: [α]= - 
28.4 (0.062 g/mL, MeOH). 
6.2.2. Synthesis of A8. 
 
 
A2(99): K2CO3 (8.49 g, 61.5 mmol) and KI (0.7 g, 4.1 mmol) were added sequentially 
to a solution of 4-hydroxybenzaldehyde (5 g, 41 mmol) in DMF (50 mL). The resulting 
mixture was stirred at rt, then BnBr (7.00 g, 41 mmol) was added dropwise. The 
resulting mixture was stirred for 2 h until the reaction was shown to be complete by 
tlc. The solution was extracted with EtOAc (40 mL × 5), washed with H2O (50 mL) 
and brine (50 mL), dried with MgSO4 and concentrated under reduced pressure. The 
4-benzylbenzaldehyde was obtained as an orange powder in 70% yield, without 
purification. mp 69-72 °C; 1H NMR(400 MHz, CDCl3): ppm= 9.89(s, 1H, CHO), 7.84 
(d, J=8.8, 2H, ArH), 7.45-7.32 (m, 5H, ArH), 7.08 (d, J=8.8, 2H, ArH), 5.15(s, 2H, 
OCH2Ph); 13C NMR (400 MHz, CDCl3): ppm= 190.81, 163.76, 135.99, 32.03, 130.15, 
128.76, 128.36, 127.53, 115.1, 70.28; IR: 2828, 2744, 1685, 1598, 1573, 1508, 1453, 
1424, 1393, 1300, 1255, 1162, 1017. 1685, 1598, 1573, 1508, 1453, 1424, 1393, 
1300, 1255, 1162, 1017 cm-1; HRMS calculated for C14H12O2 213.0910 [M+H]+ 
observed 213.0910. 
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A3(99): KOH (1.00 g, 17.7 mmol) and (EtO)2(O)PCH2COOEt (2.6 mL,13.00 mmol) 
were added sequentially to a solution of A2 (2.5 g, 11.8 mmol) in an anhydrous THF 
(30 mL) at rt. The resulting mixture was stirred at rt for 3 h until the reaction was 
shown to be complete by tlc. The solvent was removed under reduced pressure and 
the solvent was removed under reduced pressure, and the residue dissolved in DCM 
(30mL) and washed with H2O (10 mL ×3) and brine (15 mL). The cinnamate 
compound A3 was obtained in 87% yield as a white amorphous solid without 
purification. mp= 75-81 °C; 1H NMR (400 MHz, CDCl3): ppm=7.63 (d, J=15.9Hz, 1H, 
CH=CHCO2Et), 7.47(d, J=8.8Hz, 2H, ArH), 7.44-7.30 (m, 5H, ArH), 6.97 (d, J=8.8 Hz, 
2H, ArH),6.30 (d, J=15.9 Hz, 1H, CH=CHCO2Et),5.10 (s, 2H, OCH2Ph), 4.25 (q, J=7.1 
Hz, 2H, CH2CH3), 1.33 (t, J=7.1 Hz, 3H, CH2CH3);  13C NMR (400MHz, CDCl3): ppm= 
167.32, 160.53, 144.20, 136.51, 129.73, 128.69, 128.17, 127.48, 127.46, 115.93, 
115.22, 70.08, 60.35, 14.40; IR: 2988, 2941, 2859, 1709, 1631, 1601, 1572, 1508, 
1460, 1420, 1378, 1300, 1283, 1247, 1204, 1160, 1010, 982 cm-1; HRMS calculated 
for C18H18O3 283.1329 [M+H]+ observed 283.1328. 
 
 
A4(99): methanesulfonamide (0.7 g, 7.4 mmol) and AD-Mix-β (10.36 g, 1.4 gmol-1) 
were added sequentially to a stirring suspension of A3 (2.00 g, 7.4 mmol) in t-
BuOH/H2O (40 mL, 1:1) at rt. The mixture was stirred for 48 h until the reaction 
completion was confirmed by tlc. The solution was extracted with EtOAc (25 mL × 3) 
and washed with H2O (30 mL) and brine (30 mL). Purification was performed using 
column flash chromatography in a 10-40% gradient elution of mobile phase of 
EtoAc/n-Hexane. The diol product A4 was obtained in 82% yield as a white 
amorphous powder. mp 100-106 °C; 1H NMR (400 MHz, CDCl3): ppm=7.44-7.31(m, 
7H, ArH), 6.97(d, J= 8.8 Hz, 2H, ArH), 5.07(s, 2H,  OCH2Ph), 4.93 (dd, J=3.1, 6.9 Hz, 
1H, ArCHOH),4.31(dd, J=3.2, 5.9  Hz, 1H, CHCOOEt), 4.26 (q, J=7.1 Hz, 
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2H=CH2CH3), 3.07 (d, J=5.9 Hz, 1H, OH), 2.61( d, J=6.9 Hz, 1H, OH), 1.26 (t, J=7.1 
Hz, 3H, CH2CH3); 13C NMR (400 MHz, CDCl3): ppm= 172.86, 158.67, 137.01, 132.49, 
128.67, 120.06, 127.76, 127.52, 114.84, 74.91, 74.34, 70.09, 62.15, 14.17. IR: 3452, 
2907, 1720, 1700, 1611, 1585, 1512, 1454, 1385, 1300, 1238, 1175, 1095, 1054, 
1018 cm-1; HRMS calculated for C18H20O5 334.1649 [M+NH4]+ observed  334.1651; 
polarimetric rotation value was calculated at 22 °C: [α]= - 11.0 (c=0.062 g/mL, MeOH). 
 
 
 
A5(99): NsCl (2.73 g, 12.33 mmol) and Et3N (o.9 mL, 6.32 mmol) were added 
sequentially to a solution of diol A4 (3.9 g, 12.33 mmol) in DCM (60 mL) at 0 °C. The 
resulting mixture was stirred at this temperature for 4 h before quenching with 
aqueous saturated NH4Cl (20 mL). The organic layer was separated and washed with 
1 N HCl (20 mL), H2O (20 mL), and brine (20 mL), and concentrated under reduced 
pressure. The purification was carried out using column flash chromatography with a 
gradient elution (10-40%) using EtOAc/n-Hexane as a mobile phase. The nosylated 
compound A5 was obtained as a dark brown powder in 60% yield. mp 114-124 °C; 
1H NMR (400 MHz, CDCl3): 8.24 (d, J=9.0 Hz, 2H=ArH), 7.87 (d, J=9.0 Hz, 2H, ArH), 
7.45-7.31 (m, 5H, ArH), 7.16 (d, J=8.6 Hz, 2H, ArH), 6.83 (d, J=8.7 Hz, 2H, ArH), 5.15 
(t, J=4.3 1H, CHCOOEt), 5.01 (s, 2H, CH2Ph), 4.98 (d, J=4.2 Hz, 1H, CHOH), 4.16 
(q, J=7.2 Hz, 2H, OCH2CH3), 2.42 (d, J=5.1 Hz, 1H, OH), 1.18 (t, J=7.1 Hz, 3H, 
OCH2CH3); 13C NMR (400 MHz, CDCl3): ppm=166.57,158.96, 150.52, 141.45, 
136.50, 129.74, 129.15, 128.64, 128.15, 127.59, 127.50, 124.10, 114.74, 82.60, 
73.06, 70.00, 62.51, 13.89; IR: 3517, 3106,  2978, 2876, 1763, 1714, 1607, 1584, 
1530, 1510, 1457, 1389, 1348, 1308, 1244, 1204, 1178, 1091, 1024 cm-1; HRMS 
calculated for C24H23NO9S [M+NH4]+ observed 520.1439; polarimetric rotation value 
was calculated at 22 °C: [α]= - 46.2 (c=0.058 g/mL, MeOH). 
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A6(99): NaN3 (585 mg, 9 mmol) was added to a solution of A5 (3 g, 6 mmol) in DMF 
(30 mL) at rt. The resulting mixture was heated to 55 °C, and left overnight for stirring 
until the completion was confirmed by tlc. The resulting solution was diluted with H2O 
(60 mL), extracted with EtOAc (50 mL × 4), washed with H2O (60 mL) and brine (60 
mL), dried with MgSO4 and concentrated under reduced pressure. The purification 
was carried out with the automated flash chromatography system using a pre-loaded 
10 g SNAP Ultra column. A mobile phase system of EtOAc/n-Hexane was run in a 
linear gradient 10-40%. The azide product A6 was obtained in an 81% yield as a 
yellow oily solid. mp 83-93 °C; 1H NMR (400 MHz, CDCl3): ppm=7.45-7.30 (m, 7H, 
ArH), 6.98 (d, J=8.8 Hz, 2H, ArH), 5.07 (s, 2H, CH2Ph), 4.97 (dd, J=4.5 Hz, 7.1 Hz, 
1H, CHOH), 4.25 (q, J=7.1 Hz, 2H, OCH2CH3), 4.08 (d, J=7.1 Hz, 1H, CHCOOEt), 
2.80 ( d, J=4.5, 1H, OH), 1.27(t, J=7.1 Hz, 3H, OCH2CH3); 13C NMR (400 MHz, 
CDCl3): ppm=169.08, 159.17, 136.88, 131.47, 128.70, 128.12, 128.08, 127.56, 
115.04, 73.79, 70.12, 66.95, 62.24, 14.18; IR: 3436, 2981, 2911, 2126, 2114, 1725, 
1608, 1513, 1463, 1454, 1368, 1245, 1208. HRMS calculated for C18H19N3O4 [M 
+NH4]+ 359.1714 found 359.1715; polarimetric rotation value was calculated at 22 °C: 
[α]= -1.3 (c=0.062 g/mL, CHCl3). 
 
 
A7(99): A hydrous tin chloride (SnCl2) (2 g, 9 mmol) was added to a solution of A6 (1.5 
g, 4.5 mmol) in MeOH (30 mL). The resulting mixture was stirred at rt for 2 h until the 
reaction was confirmed to be complet by tlc. The solvent was removed under reduced 
pressure and the residue was dissolved in EtOAc (30 mL) and washed with 3 N NaOH 
(15 mL ×3), H2O (15 mL) and brine (15 mL). The solvent was removed under reduced 
pressure to give the amine A7 as a yellow oil in a 78% yield. 1H NMR (500 MHz, 
CDCl3): ppm=7.45 -7.30 (m, 5H, ArH), 7.22 (d, J=8.8 Hz, 2H, ArH), 6.94 (d, J=8.8 Hz, 
2H, ArH), 5.05 (s, 2H, CH2Ph), 4.90 (d, J=5.8 Hz, 1H, CHOH), 4.18-4.10 (m, 2H, 
OCH2CH3), 3.77 (d, J=5.9 Hz, 1H, CHCOOEt), 3.48(s, 1H, OH), 1.24 (t, J=7.1Hz, 3H, 
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OCH2CH3); 13C NMR (400 MHz, CDCl3): ppm=172.27, 158.56, 136.90, 131.93, 
128.58, 127.98, 127.58, 127.47,114.64, 73.58, 69.98, 61.32, 59.93, 14.04; IR: 3034, 
2977, 2922, 2109, 1716, 1645, 1604, 1510, 1454, 1380, 1300, 1238, 1218, 1171, 
1111, 1037, 1023;  HRMS calculated for C18H21NO4 316.1543 [M + H]+ observed 
316.1544. 
 
 
 
 
 
 
A8: An aqueous solution of NaHCO3 (600 mg) was added to a solution of A7 (750 
mg, 2.38 mmol) in 10 mL THF (10 mL) at 0 °C. A cooled solution of Fmoc-Cl (677.5 
mg) to 0 °C was added dropwise to the resuling solution. The resulting mixture was 
stirred at this temperature for 1 h until the reaction was shown to be complete by tlc. 
The solvent was removed under reduced pressure and the residue was purified using 
column chromatography with a linear gradient (10-30%, EtOAc/n-Hexane) to give an 
80% yield of the Fmoc-protected product A8 as a yellow powder. mp 135-143 °C; 1H 
NMR (500 MHz, CDCl3): ppm=7.77  (d, J=7.5 Hz 2H, ArH-Fmoc), 7.57 (t, J=7.5 Hz, 
2H, ArH-Fmoc), 7.44-7.29 (m, 9H, ArH), 7.18 (d, J=8.4 Hz, 2H, ArH), 6.93 (d, J=8.58 
Hz, 2H, ArH), 5.52 (d, J=8 Hz, 1H,CHOH), 5.17 (d, J=4 Hz, 1H, NH), 5.04(s, 2H, 
PhCH2), 4.74 (dd, J=4, 8 Hz, 1H, CHN), 4.51 (dd, J=6.9 Hz, 10.5 Hz, 1H, CHH-Fmoc), 
4.37 (dd, J=6.9, 10.5 Hz, 1H, CHH-Fmoc), 4.24-4.10 (m, 3H, CH-Fmoc+CH2CH3), 
2.95 (br. s, 1H, OH), 1.21 (t, J=7.1 Hz, 3H, CH2CH3); 13C NMR (400 MHz, CDCl3): 
ppm=169.81, 158.77, 156.79, 143.75, 141.42, 136.94, 131.34, 128.68, 127.86, 
127.55, 127.44, 127.19, 125.24, 125.12, 120.12, 114.79, 74.59, 70.08, 67.36, 61.92, 
60.00, 47.22, 14.12; IR: 3402, 3038, 2972, 1727, 1609, 1511, 1447, 1370, 1347, 
1228, 1196, 1010 cm-1, HRMS calculated for C33H31NO6 555.2490 [M +NH4]+ 
observed 555.2482; polarimetric rotation value was calculated at 22 °C: [α]= - 29.8 
(c=0.063 g/mL, CHCl3). 
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6.2.3. Synthesis of A9. 
 
A9: LiOH.H2O (9.00 mg, 21.3 mmol) was added to a solution of A3 (2.00 g, 7.1 mmol) 
in a solvent system of THF, MeOH, and H2O (70 mL, 3:1:1) at rt. The resulting mixture 
was stirred for overnight until the reaction was shown to be complete by tlc. The 
resulting solution was quenched with 1 M HCl (20 mL) and extracted was with EtOAc 
(40 mL × 3), washed with H2O (20 mL), and brine (20 mL), dried with Na2SO4 and 
concentrated under reduced pressure. The acid product A9 was obtained as a white 
amorphous solid in an 85% without purification. mp 193-200 °C; 1H NMR (400 MHz, 
CDCl3): ppm=7.73 (d, J=16, 1H, CHCHCOOH), 7.5 (d, J=8.8 Hz, 2H, ArH), 7.45-
7.31(m, 5H, ArH), 6.99(d, J=8.8, 2H, ArH), 6.32(d, J=16, 1H, CHCOOH), 5.11 (s, 1H, 
PhCH2); 13C NMR (400 MHz, CDCl3): ppm=168.64,160.36, 143.80, 137.187, 130.28, 
128.92, 128.38, 128.18, 127.59, 117.51, 115.64, 69.78; IR: 3328, 2576, 1660, 1622, 
1599, 1572, 1510, 1452, 1429, 1385, 1308, 1284, 1245, 1171, 1078, 1017, 980 cm-
1; HRMS calculated for C16H14O3 255.1016 [M+H]+ observed 255.1017. 
 
6.2.4. Synthesis of A10. 
 
A10: A mixture of 20 mL SOCl2 and A9 (2.00 g, 7.87 mmol) were shacked thoroughly, 
heated at reflux and stirred for 1 h until the reaction completion was confirmed by tlc. 
The mixture was cooled down to rt, SOCl2 was removed under reduced pressure and 
the residue was washed with DCM (15 mL × 2) and concentrated under reduced 
pressure (to co-evaporate SOCl2 with DCM). Excess t-BuOH (25 mL) was added to 
the residue and the resulting mixture was stirred for 30 min at rt before addition of 
aqueous saturated NaHCO3 (20 mL) (to remove any remaining residue of the A9). 
The butyl ester product A10 was obtained as a white amorphous solid in 78% yield 
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after purification with normal column chromatography using EtoAc/n-Hexane system 
as a mobile phase in a gradient elution 1-5%. mp 90-95 °C; 1H NMR (400 MHz, 
CDCl3): ppm=7.53 (d, J=16, 1H, CHCHOOtBu), 7.47-7.33 (m, 7H, ArH), 6.96 (d, 
J=8.8, 2H, ArH), 6.24(d, J=16, 1H, CHCOOtBu), 5.09 (s, 2H, PhCH2), 1.53(s, 9H, 
COOtBu); 13C NMR (400 MHz, CDCl3): ppm=166.68, 160.33, 143.18, 136.56, 129.60, 
128.68, 128.15, 127.66, 127.50, 117.89, 115.17, 80.25, 70.07, 28.28; IR: 2971, 1708, 
1692, 1631, 1600, 1509, 1453, 1422, 1366, 1326, 1252, 1141 cm-1; HRMS calculated 
for C20H22O3 311.1642 [M+H]+ observed 311.1644. 
 
 
 
6.2.5. Synthesis of B6. 
 
 
B1: Methanesulfonamide (1.35, 14.2 mmol) and AD-Mix-α (19.9 g, 1.4 g mmol-1) were 
added sequentially to a stirring suspension of A3 (4.00 g, 14.2 mmol) in t-BuOH/H2O 
(150 mL, 1:1) at rt. The resulting mixture was stirred for 48 h, before addition a 21.3 
g of sodium sulphite (1.5 g mmol-1) and stirred for further 1 h. The mixture was 
extracted with EtOAc (100 mL × 3) and washed with H2O (100 mL) and brine (100 
mL) and the solvent was removed under reduced pressure to give the diol product B1 
in an 89% yield as a yellow amorphous solid without purification. mp 81-93°C;  1H 
NMR (400 MHz, CDCl3): ppm=7.45-7.31(m, 7H= ArH), 6.97(d, J= 8.8 Hz, 2H=ArH), 
5.07(s, 2H,  OCH2Ph), 4.93 (dd, J=3.1, 6.9 Hz, 1H, ArCHOH), 4.31(dd, J=3.2, 5.9  Hz, 
1H, CHCOOEt), 4.26(q, J=7.1 Hz, 2H, CH2CH3), 3.07 (d, J=5.9 Hz, 1H, OH), 2.61( d, 
J=6.9 Hz, 1H, OH), 1.26(t, J=7.1 Hz, 3H, CH2CH3); 13C NMR (400MHz, CDCl3): ppm= 
172.79, 158.63, 136.91, 132.37, 128.60, 127.99, 127.66, 127.44, 114.80, 74.73, 
74.23, 70.0281, 62.1532, 14.1008; IR: 3327, 3252, 2923, 1713, 1610, 1581, 1512, 
1467, 1380, 1300, 1246, 1162, 1097, 1012, 986; HRMS calculated for C18H20O5NH4 
334.1649 [M+NH4]+ observed 334.1652; polarimetric rotation value was calculated at 
22 °C: [α]= +16.16 (c= 0.049, EtOAc). 
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B2: NoSCl (3.1g, 12.6 mmol) and Et3N (3.5 ml, 23.2 mmol) were added sequentially 
to a solution of diol B1 (4 g, 12.6 mmol) in DCM (50 mL) at 0 °C, The resulting mixture 
was stirred at this temperature for 5 h before quenching with aqueous saturated 
NH4Cl (20 ml). The organic layer was separated and washed with 1 N HCl (15 mL), 
H2O (15 mL), brine (15 mL) and concentrated under reduced pressure. The 
purification was carried out using the automated flash chromatography. The crude 
was dry loaded on a 340 g SNAP Ultra preloaded column and a mobile phase system 
of EtOAc/n-Hexane was run in a linear gradient 20-50%. The nosylated product B2 
was furnished in a 44% yield as a black/brown amorphous solid. mp-109-115 °C; 1H 
NMR (400 MHz, CDCl3): ppm= 8.24 (d, J=9.0 Hz, 2H, ArH), 7.87 (d, J=9.0 Hz, 2H, 
ArH), 7.45-7.31 (m, 5H, ArH), 7.16 (d, J=8.6 Hz, 2H, ArH), 6.83 (d, J=8.7 Hz, 2H, 
ArH), 5.15 (t, J=4.3 1H, CHCOOEt), 5.01 (s, 2H, CH2Ph), 4.98 (d, J=4.2 Hz, 1H, 
CHOH), 4.16 (q, J=7.2 Hz, 2H, OCH2CH3), 2.39 (d, J=5.1 Hz, 1H, OH), 1.18 (t, J=7.1 
Hz, 3H, OCH2CH3); 13C NMR (400 MHz, CDCl3): ppm=166.42, 159.08, 150.57, 
141.55, 136.47, 129.53, 129.17, 128.66, 128.16, 127.56, 127.48, 124.09,114.83, 
82.39, 73.19, 70.03, 62.51, 13.90; IR: 3518, 3106, 1763, 1607, 1530, 1511, 1454, 
1348, 1243, 1177, 1091, 1025; HRMS calculated for C24H23NO9S 519.1432 [M+NH4]+ 
observed 519.1420; polarimetric rotation value was calculated at 22 °C: [α]= +65.2 
(c= 0.0065, EtoAc). 
 
 
B3: NaN3 (780 mg, 12 mmol) was added to a solution of B2 (4 g, 8 mmol) in DMF (50 
mL) at rt. The resulting mixture was heated to 55 °C, and stirred for 15 h until the 
reaction was confirmed to be complete by tlc. The mixture was diluted with H2O (100 
mL), extracted with diethylether (100 mL × 4), washed with H2O (100 mL), brine (100 
mL), dried with MgSO4 and concentrated under reduced pressure. The purification 
was performed using automated flash chromatography as the crude was dry loaded 
on a 50 g SNAP Ultra preloaded column and a mobile phase of EtOAc/n-hexane was 
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run in a linear gradient 5-20%. The azide product was obtained in a 72% yield as 
yellow oily solid. mp 85-94 °C; 1H NMR (400 MHz, CDCl3): ppm= 7.45-7.30 (m, 7H, 
ArH), 6.98 (d, J=8.8 Hz, 2H, ArH), 5.07 (s, 2H, CH2Ph), 4.97 (dd, J=4.5 Hz, 7.1 Hz, 
1H, CHOH), 4.25 (q, J=7.1 Hz, 2H, OCH2CH3), 4.08 (d, J=7.1 Hz, 1H, CHCOOEt), 
2.74 ( d, J=4.5, 1H, OH), 1.27 (t, J=7.1 Hz, 3H,OCH2CH3); 13C NMR (400 MHz, 
CDCl3): ppm=168.99, 159.10, 136.80, 131.38, 128.62, 128.04, 127.99, 127.48, 
114.96, 73.71, 70.04, 66.85, 62.16, 14.10; IR: 3434, 2981, 2902, 2113, 1725, 1610, 
1588, 1512, 1454, 1384, 1305, 1245, 1206, 1168, 1072, 1009 cm-1; HRMS calculated 
for C18H19N3O4 359.1719 [M+NH4]+ observed 359.1710; polarimetric rotation value 
was calculated at 22 °C: [α]= -2.2 (c= 0.054, CHCl3). 
 
B4: SnCl2.H2O (675 mg, 2.29 mmol) was added to a solution of B3 (500 mg, 1.46 
mmol) in MeOH (10 mL). The mixture was stirred at rt for 2 h until the reaction was 
shown to be complete by tlc. The solvent was removed under reduced pressure and 
the residue dissolved in EtOAc (10 mL) and the resulting solution was washed with 3 
N NaOH (5 mL ×3), H2O (5 mL) and brine (5 mL). The solvent was removed under 
reduced pressure to give the amine product B4 as a yellow oil in an 87% yield without 
purification. 1H NMR (400 MHz, CDCl3): ppm= 7.45 -7.30 (m, 5H, ArH), 7.22 (d, J=8.8 
Hz, 2H, ArH), 6.94 (d, J=8.8 Hz, 2H, ArH), 5.05 (s, 2H, CH2Ph), 4.90 (d, J=5.8 Hz, 
1H, CHOH), 4.18-4.10 (m, 2H, OCH2CH3), 3.77 (d, J=5.9 Hz, 1H, CHCOOEt), 3.48 
(s, 1H, OH), 1.24 (t, J=7.1Hz, 3H, OCH2CH3); IR: 2983,  2932, 2871, 1737, 1646, 
1604, 1510, 1454, 1422, 1378, 1300, 1251, 1225, 1190, 1160, 1066, 1007 cm-1; 
HRMS calculated for C18H21NO4 338.1363 [M+Na]+ observed 338.1363. 
 
 
B5: an aqueous solution of NaHCO3 (400 mg, 4.74 mmol) was added to a solution of 
B4 (500 mg, 1.58 mmol) in THF (10 mL) at 0 °C. Then, a cooled solution of Fmoc-Cl 
(450 mg) at 0 °C was added dropwise to the resulting solution. The resulting mixture 
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was stirred at this temperature for 1 h until the reaction completion was confirmed by 
tlc. The solvent was removed under reduced pressure and the residue was purified 
by automated flash chromatography using a 25 g SNAP Ultra preloaded column and 
a mobile phase of EtOAc/n-Hexane in a linear gradient, 10-50%. The Fmoc-protected 
B5 was obtained in an 80% yield as a white amorphous solid. mp 130-14 °C; 1H NMR 
(400 MHz, CDCl3): ppm=7.77 (d, J=7.5 Hz 2H, ArH-Fmoc), 7.57 (t, J=7.5 Hz, 2H, ArH-
Fmoc), 7.44-7.29 (m, 9H, ArH), 7.17 (d, J=8.4 Hz, 2H, ArH), 6.92 (d, J=8.58 Hz, 2H, 
ArH), 5.48 (d, J=8 Hz, 1H, CHOH), 5.17 (s, 1H, NH), 5.04 (s, 2H, PhCH2), 4.74 (dd, 
J=4, 8 Hz, 1H, CHN), 4.51 (dd, J=6.9 Hz, 10.5 Hz, 1H, CHH-Fmoc), 4.37 (dd, J=6.9, 
10.5 Hz, Hz, 1H, CHH-Fmoc), 4.24-4.10 (m, 3H, CH-Fmoc+CH2CH3), 3.37(d, J=5.4 
Hz, 1H, OH), 1.21 (t, J=7.1 Hz, 3H, CH2CH3); 13C NMR (400 MHz, CDCl3): 
ppm=169.66, 158.71, 156.72, 143.70, 141.34, 136.86, 131.21, 128.60, 128.01, 
127.78, 127.47, 127.34, 127.11, 125.15, 120.04, 114.72, 74.58, 70.01, 67.27, 61.87, 
59.90, 47.15, 14.05; IR: 3396, 2902, 1723, 1706, 1610, 1511, 1449, 1380, 1226, 
1196, 1174, 1016 cm-1; HRMS calculated for C33H31NO6 560.2044 [M+Na]+ observed 
560.2033; polarimetric rotation value was calculated at 22 °C: [α]= +30.0 (c= 0.058, 
CHCl3). 
 
B6: 2,6-Lutidine (162.5 µl, 1.4 mmol) and TBSoTf (225 µl, 1.023 mmol) were added 
sequentially to a solution of B5 (500 g, 0.93 mmol) in DCM (7 mL) at 0 °C. The 
resulting mixture was stirred at this temperature for 30 min before quenching with 
aqueous saturated solution of NaHCO3 (4 mL). The organic layer was separated and 
extracted with DCM (3 mL × 3). The combined organic extracts were washed with 
NaHCO3 (5 mL), H2O (5 mL), and brine (5 mL), dried with Na2SO4 and concentrated 
under reduced pressure. The TBS-protected B6 was obtained in an 89% yield as a 
transparent oil after purification with the automated flash chromatography as the 
crude was dry loaded on a 50 g SNAP Ultar pre-loaded column and a mobile phase 
of EtoAc/n-Hexane was run in a linear gradient 15-30%. 1H NMR (500 MHz, CDCl3): 
ppm=7.78  (d, J=7.5 Hz 2H, ArH-Fmoc), 7.59 (t, J=8.3 Hz, 2H, ArH-Fmoc), 7.44-7.28 
(m, 11H, ArH, benzyl-H, Fmoc-4H), 6.95 (d, J=8.5 Hz, 2H, ArH), 5.48 (d, J=8.8 Hz, 
1H, ArCH), 5.07 (d, J=4.2 Hz, 1H,NH), 5.04 (s, 2H, PhCH2), 4.60 (dd, J=4.2, 8.6 
Hz,1H, CHN), 4.42-4.30 (m, 2H, CH2-Fmoc), 4.22 (t, J=7.3 1H, CH-Fmoc), 4.12 (q, 
J=7.4, 2H, CH2CH3), 1.18(t, J=7.3 Hz, 3H, CH2CH3), 0.92 (s, 9H, TBS), 0.07(s, 3H, 
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TBS), -0.01(s, 3H, TBS); 13C NMR (400 MHz, CDCl3): ppm=169.91,158.57, 
155.66,143.97, 141.40,137.04, 132.70,128.67, 128.08,127.80, 127.65, 127.61, 
127.15, 125.26, 120.09, 114.50, 75.30, 70.11, 67.23, 61.38, 61.23,47.21, 
25.81,18.24,14.14, -4.67, -5.16; IR: 3342, 2929, 2855, 1718, 1610, 1508, 1450, 1371, 
1344, 1242, 1090, 1029 cm-1; HRMS calculated for C39H45NO6SiNH4 669.3354 [M + 
NH4]+ observed 669.3348. 
 
 
 
6.2.6. Synthesis of D4. 
 
 
D1: HOBt (157 mg, 1.02 mmol), Fmoc-Gly-OH (333.58 mg, 1.12 mmol) and EDC.HCl 
(215 mg, 1.12 mmol) were added sequentially to a solution of MeOH-Tyr-NH2 (200 
mg, 1.02 mmol) in 4 mL acetone. The equivalences in this reaction were calculated 
based on the equivalence of the amino acid with free terminal amine, tyrosine. The 
resulting mixture was stirred at rt for 2 h until the reaction was confirmed to be 
complete by tlc. The solvent was removed under reduced pressure and the residue 
was purified with automated flash chromatography using 25 g SNAP Ultra preloaded 
column and EtOAc/n-Hexane system as a mobile phase system in a linear gradient, 
30-70%, giving the the dipeptide D1 as a white amorphous solid in 60% yield. 1H NMR 
(400 MHz, CDCl3): ppm= 7.78 (d, J=7.5 Hz, 2H, Fmoc), 7.65 (d, J=7.1 Hz, 2H, Fmoc), 
7.38 (t, J=7.5 Hz, 2H, Fmoc), 7.30 (t, J=7.5 Hz, 2H, Fmoc), 6.99 (d, J=8.4 Hz, 2H, 
ArH), 6.71 (d, J=8.4 Hz, 2H, ArH), 4.65 (m, 1H, CHNH2), 4.34 (d, J=6.7 Hz, 2H, Fmoc), 
4.20 (t, J=6.7 Hz, 1H, Fmoc), 3.78 (d, J=5.4 Hz, 2H, ArCH2),3.67 (s, 3H, COOCH3), 
3.37 (s, 1H, NHFmoc), 3.05-2.87 (m, 2H, CH2NHFmoc); 13C NMR (400 MHz, CDCl3): 
ppm= 171.60, 168.712, 156.17, 144.11, 141.13, 130.22, 127.58, 127.17, 127.01, 
125.23, 119.84, 115.05, 66.43, 54.49, 53.59, 51.31, 47.02, 43.64, 41.86, 36.57; IR: 
3318, 2926, 2481, 1693, 1661, 1613, 1514, 1445, 1358, 1247, 1201; HRMS 
calculated for C27H26N2O6 475.1864 [M+H]+ observed 475.1861. 
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D2: HOBt (234.24 mg, 1.53 mmol), Fmoc-Gly-OH (333.58 mg, 1.68 mmol) and 
EDC.HCl (300 µl, 1.68 mmol) were added sequentially to a solution of MeOH-Tyr-
NH2 (300 mg, 1.53 mmol) in 10 mL acetone. The equivalences in this reaction were 
calculated based on the equivalence of the amino acid with free terminal amine, 
tyrosine. The resulting mixture was stirred at rt and left overnight until the reaction 
was confirmed to be complete by tlc. The solvent was removed under reduced 
pressure and the crude residue was purified by automated flash chromatography. The 
crude was dry loaded on 100 g snap Ultra preloaded column using a mobile phase of 
EtoAc/n-Hexane in a linear gradient, 30-60%, to give the Boc-protected dipeptide D2 
as a colourless oil in 61% yield. 1H NMR (400 MHz, MeOH-D4): ppm=7.00 (d, J=8.5 
Hz, 2H, ArH), 6.72 (d, J=8.5 Hz, 2H, ArH), 4.65 (t, J=6.5 Hz, 1H, CHNH2), 3.72-3.69 
(m, 5H, Ar-CH2, -CH3), 3.07-2.91 (m, 2H, CH2NH), 1.45 (s, 9H, Boc); 13C NMR (400 
MHz, MeOH-D4): ppm=173.34, 172.20, 158.32, 157.61, 131.25, 128.24, 116.37, 
80.74, 55.25, 52.66, 44.39, 37.68, 28.68; IR: 3319, 2977, 1738, 1662, 1613, 1595, 
1514, 1444, 1365, 1391, 1246, 1216, 1161; MRMS calculated for C17H24N2O6 
353.1707 [M+H]+ observed 353.1710. 
 
 
D3: A 50% TFA in DCM (5 mL) was added to a 200 mg of D2 and the resulting mixture 
was stirred for 2 h until the reaction was shown to be complete by tlc. The solvent 
was removed under reduced pressure and the residue was purified by automated 
flash chromatography as the crude was wet loaded on a 50-g preloaded column, and 
a mobile phase of MeOH/DCM was used in a linear gradient 10-30% to give the 
deprotected-dipeptide D3 as a white/yellow oil in a 90% yield. 1H NMR (400 MHz, 
MeOH-D4): ppm=6.97 (d, J=8.5 Hz, 2H, ArH), 6.68 (d, J=8.5 Hz, 2H, ArH), 4.64 (m, 
1H, CHNH2), 3.72-3.60 (m, 5H, Ar-CH2, CH3), 3.31 (s, 2H,, NH2), 3.01(dd, J=5.6, 14 
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Hz, 1H, CHHNH2), 2.85 (dd, J=8.4, 14 Hz, 1H, CHHNH2); 13C NMR (400 MHz, MeOH-
D4): ppm= 173.25, 167.20, 157.54, 131.20, 128.40, 116.32,55.67, 52.77, 41.33, 
37.70; IR: 3027, 1731,1665, 1614,1554, 1515, 437, 1355, 1181, 1123 cm-1; HRMS 
calculated for C12H16N2O4 253.1183 [M + H]+ observed 253.1185. 
 
 
 
 
 
 
D4: HOBt (78.1 mg, 0.51 mmol), C14 (320 mg, 1.68 mmol) and EDC.HCl (100 µl) 
were added sequentially to a solution of D3 (130 mg, 0.51 mmol) in acetone (5 mL). 
The equivalences in this reaction were calculated based on the equivalence of the 
amino acid with free terminal amine, tyrosine. The resulting mixture was stirred at rt 
and left overnight until the reaction was shown to be complete by tlc. The solvent was 
removed under reduced pressure and the residue was purified by automated flash 
chromatography as the crude was dry loaded on a 50-g preloaded column and a 
mobile phase system of EtoAc/n-Hexane was used in a linear gradient, 15-60%, 
giving the tripeptide D3 as a yellow amorphous solid. 1H NMR(400 MHz, CDCl3): 
δ=7.69 (d, J=7.5 Hz, 2H, Fmoc), 7.63 (br. s, 2H, ArH), 7.54 (br. s, 2H, Fmoc), 7.33 (t, 
J=7.5 Hz, 2H, Fmoc), 7.23 (t, J=7.5 Hz, 2H, Fmoc), 5.29 (s, 1H, CHNHFmoc), 6.84 
(dd, J=8.3, 11.5 Hz, 2H, ArH), 6.61(t, J=7.5 Hz, 2H, ArH), 4.77(m, 1H, CHNHCO), 
4.41(br. s, 2H, Fmoc), 4.19(br. s, 1H, Fmoc), 3.93 (br. s, 2H, NCH2), 3.8-3.64 (m, 7H, 
CH3, ArCH2, NCH2), 2.08 (br. s, 4H, NCH2CH2CH2); 13C NMR (400 MHz, CDCl3): 
ppm=171.95, 168.52,155.93, 155.44, 148.12,143.58, 141.22, 136.34, 
131.19,130.32,127.72, 127.11, 125.13, 119.92, 118.38, 115.61, 67.46, 57.26, 53.77, 
52.51, 50.72, 47.01, 46.73,43.28, 37.10, 23.61; IR: 3280, 2951, 1638, 1514, 1445, 
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1413, 1356, 1311, 1223, 1104, 1042, 907 cm-1; HRMS calculated for C39H38Br2N6O7 
863.1225 [M+H]+ observed 863.1204. 
 
 
 
 
 
 
6.2.7. Synthesis of D5. 
 
D5: a 100 mg of Fmoc-Tyr-Wang Resin was swelled in DMF (5 mL) for a 30 min of 
shaking. The Fmoc-protecting group was removed using a 40% piperidine (5 mL) for 
10 min shaking, then 20% piperidine (5 mL × 2) for 5 min shaking. The deprotection 
was confirmed by a Kaiser test. A solution of Fmoc-Gly-OH (76.1 mg), HATU (48.6 
mg), and DIPEA (111.2 µl) in a least dissolving amount of DMF, was added to the 
resin and was shacked for 1 h until the reaction was shown to be complete by with a 
Kaiser test (negative result). The solution was filtered and the resin was washed with 
DMF (5 mL × 5). Then, a solution of triazene protected residue (80 mg), HATU (48.6 
mg) and DIPEA (111.2 µl) was added to the resin, and left for shaking. A Kaiser test 
was carried out and indicated a positive result (still blue) after 45 min and 2.5 h of the 
shaking. The solution was filtered, and the resin washed with DMF (5 mL × 5), then 
the coupling process was repeated with fresh reagents. The resin was left overnight 
for shaking, until a Kaiser test indicated a negative result (brown beads). The solution 
was filtered and the resin was washed with DMF (5 mL × 5). The Fmoc deprotection 
was performed using of 40% piperidine (5 mL) for 10 min shaking, 20% piperidine (5 
mL × 2) for 5 min shaking and monitored with a Kaiser test. The solution was drained 
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and the resin was washed with DMF (5 mL × 5). Cleavage step was carried out with 
5 mL TFA/TIPS/H2O (95:2.5:2.5) by shaking for 2 h and the TFA was removed under 
reduced pressure, and the peptide was precipitated with a cold diethylether. Mass 
spectrometry was carried out for the peptide which showed the desired MW, [M+H]+= 
626.6. 
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